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ABSTRACT 
 
Bacterial exotoxins are amongst the principal virulence factors of pathogenic 
bacteria and usually contribute for the majority of symptoms and lesions caused by 
infection. The AIP56 toxin (apoptosis-inducing protein of 56 kDa) is a major virulence 
factor of Photobacterium damselae piscicida (Phdp), a Gram-negative bacterium 
causing a septicaemic infection that is one of the most threatening diseases in 
mariculture. During infection, the toxin is secreted by Phdp and is systemically 
disseminated, triggering apoptosis of macrophages and neutrophils. The destruction of 
both professional phagocytes of the host allows bacterial evasion from phagocytosis, 
promoting bacterial septicaemic spread. This process culminates in cell lysis by 
secondary necrosis with release of the phagocyte’s cytotoxic contents, thus 
contributing to the necrotic lesions observed in the diseased animals.  
Despite the toxic effects of AIP56 and their contribution to the pathology of 
Phdp infections are well known, knowledge about the toxin’s structure-function 
relationships and the molecular determinants beyond its biologic activity was still 
missing.  
The work herein presented shows that AIP56 is a zinc-metalloprotease that 
cleaves NF-κB p65 at Cys39, an evolutionarily conserved residue of the Rel homology 
domain, removing crucial residues involved in DNA interaction and compromising the 
NF-κB activity. Cleavage was observed upon incubation of sea bass cell lysates or 
recombinant p65 Rel homology domain with AIP56 and was dependent on the 
metalloprotease signature of the toxin. Furthermore, the proteolytic activity towards NF-
κB p65 was found to be essential for toxicity, since mutations within the toxin’s 
metalloprotease signature completely abolished its apoptogenic activity. Given the 
central role of the NF-κB family of transcription factors in the host responses to 
microbial pathogen invasion (particularly regulating the expression of inflammatory and 
anti-apoptotic genes) it is not surprising that depletion of NF-κB p65 is involved in the 
disseminated apoptosis observed in Phdp infections.  
Bacterial toxins acting on intracellular targets enter cells through a multistep 
process involving specific binding to the cell surface, internalization via receptor-
mediated endocytosis and translocation into the cytosol from an intracellular 
compartment. The structure of those toxins is adapted to their entry mechanisms and, 
to this end, these toxins are organized in a so-called AB-type structure consisting of a 
catalytic A subunit bound to a cell interacting B subunit(s) that mediate toxin binding to 
a cell receptor and delivery of the catalytic A subunit into the cytosol. Homology 
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analysis of AIP56 primary structure provided the first evidences of a two-
domain/subunit structural organization. By performing limited proteolysis assays 
together with in silico secondary structure analysis we confirmed that AIP56 is 
organized in two structural protease-resistant domains held together by an 
unstructured flexible region containing two cysteine residues, involved in a disulphide 
bond. Furthermore, by using truncated versions of the toxin, designed based on the 
chymotrypsin cleavage site, we disclosed the role played by the two identified structural 
domains in AIP56’s intoxication mechanism. The recombinant AIP56 N-terminal 
portion, containing the zinc-binding signature, exhibited proteolytic activity in vitro 
towards NF-κB p65. In addition, delivery of the N-terminal region into the cell cytosol 
using the Bacillus anthracis PA/LF system reproduced the proteolytic and apoptogenic 
activities of the full length toxin, attributing to the N-terminal region the catalytic role. In 
contrast, the C-terminal portion of AIP56 exhibited no proteolytic activity in vivo or in 
vitro but, when used as a competitor, it efficiently prevented AIP56 toxic effects, 
demonstrating the involvement of the C-terminal region in toxin binding/entry into target 
cells. 
Despite for AIP56 the boundaries of the A and B domains were not yet defined, 
its structural architecture adds the toxin to the family of the AB toxins alongside with 
diphtheria toxin, botulinum and tetanus neurotoxins and Pseudomonas exotoxin A. 
However, we found that AIP56 differs from those toxins in some structural features 
required for cell intoxication. AIP56 does not require proteolytic or any other kind of 
activation to display enzymatic activity in vitro. In addition, integrity of the region 
between the two cysteine residues (Cys278 and Cys314), linking the two functional 
subunits, appears to be a requirement for toxicity since nicking of AIP56 at this region 
rendered the toxin inactive. These findings suggest that this region plays a role in the 
translocation of the toxin into the cell’s cytosol and may be part of the yet unidentified 
translocation domain.  
The catalytic region of AIP56 has homology with NleC, a type III secreted 
effector of enteropathogenic bacteria that has also been shown to target NF-κB p65. 
Using CD spectroscopy and in silico secondary structure predictions we showed that 
these proteins are highly similar in terms of secondary structure. Still, even though 
AIP56 and NleC share structural and functional homology, AIP56 N-terminal region and 
NleC were found not to be cross compatible since substitution of AIP56’s N-terminus 
by NleC resulted in a non-toxic chimera and the Bacillus anthracis PA/LF system also 
failed to deliver NleC into the cytoplasm of cells. Differential scanning fluorimetry 
analysis revealed that AIP56 catalytic region and NleC have different unfolding 
properties in response to pH, likely explaining their distinct behaviour.  
XVI 
 
The intrinsic abilities of AB toxins to enter target cells make these proteins 
attractive not only as tools in cell biology, to study cellular processes, but also as 
systems to deliver protein cargos inside targeted cells. This, associated to the 
extensive involvement of NF-κB transcription factors in inflammation and cancer 
diseases establishes AIP56 has a promising therapeutic/biotechnological tool. 
Nevertheless, in depth knowledge on the toxin’s structural features, intracellular 
pathways and molecular mechanisms of action are crucial before considering the use 
of AIP56 to these ends. 
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RESUMO 
 
As exotoxinas bacterianas estão entre os principais factores de virulência das 
bactérias patogénicas e, frequentemente, são responsáveis pela maioria dos sintomas 
e lesões decorrentes da infecção.  
A exotoxina AIP56 é um factor de virulência fundamental da Photobacterium 
damselae piscicida (Phdp), uma bactéria Gram-negativa causadora de uma septicemia 
que afecta várias espécies de peixes marinhos economicamente importantes. A toxina 
é secretada pela Phdp durante a infecção, dissemina-se sistemicamente e induz a 
apoptose de macrófagos e neutrófilos. A destruição simultânea dos dois tipos de 
fagócitos, induzida pela toxina, compromete a defesa imunológica do hospedeiro, 
promovendo a proliferação e distribuição sistémica da bactéria. Para além disso, a 
destruição dos macrófagos tem como consequência a eliminação ineficaz das células 
em apoptose, o que, por sua vez, resulta na lise dos fagócitos por necrose secundária, 
com libertação de moléculas citotóxicas que contribuem para a génese das lesões 
necróticas características da infeção pela Phdp. 
Apesar dos efeitos tóxicos da AIP56 já serem conhecidos, e de estar bem 
documentada a sua participação na patologia associada às infecções pela Phdp, as 
relações entre a estrutura e a função da toxina e os determinantes moleculares que 
estão na base da sua actividade tóxica permanecem por identificar. 
Trabalhos desenvolvidos no âmbito desta tese revelaram que a AIP56 é uma 
metaloprotease dependente de zinco que corta a subunidade p65 do NF-κB no seu 
domínio Rel, mais concretamente na cisteína 39. A clivagem neste resíduo remove 
uma região do p65 essencial para a sua interacção com o DNA, desta forma 
comprometendo a sua atividade. O corte do p65 foi observado após incubação da 
AIP56 com extractos totais de leucócitos de robalo ou com o domínio Rel do p65 
produzido in vitro e mostrou ser dependente da assinatura de metaloprotease presente 
na AIP56. Além do mais, a clivagem foi demonstrada ser essencial para a actividade 
tóxica da AIP56, uma vez que mutantes da toxina desprovidos de actividade catalítica 
revelaram-se não tóxicos. Tendo em conta a importância do NF-κB na resposta do 
hospedeiro contra invasões microbianas, regulando a expressão de genes 
inflamatórios e anti-apoptóticos, é espectável que a depleção do NF-κB esteja 
envolvida na apoptose disseminada observada durante as infeções pela Phdp. 
As toxinas bacterianas que têm alvos intracelulares entram nas células por um 
processo que envolve a ligação específica a recetores celulares seguido de 
internalização e translocação para o citosol a partir de um compartimento organelar. 
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As estruturas dessas toxinas estão adaptadas aos seus mecanismos de entrada, 
possuindo uma organização do tipo AB, com uma subunidade A, que é responsável 
pela actividade enzimática, ligada a uma sub-unidade B, que leva a cabo a ligação e 
entrada da toxina nas células. 
A existência de dois domínios na AIP56 foi inicialmente sugerida pelo resultado 
da análise comparativa da sua estrutura primária com a de proteínas semelhantes 
obtidas a partir de bases de dados. Durante o presente trabalho, através de ensaios 
de proteólise limitada e da análise in silico da estrutura secundária da AIP56, 
detectamos a existência de dois domínios unidos entre si por uma região desordenada 
e uma ponte dissulfureto. Usando versões truncadas da toxina, produzidas com base 
nos resultados da proteólise limitada, foi possível estabelecer o papel que os dois 
domínios estruturais da AIP56 desempenham no mecanismo de intoxicação. A porção 
amino-terminal recombinante, que contém a assinatura de metaloprotease, revelou ter 
actividade proteolítica contra o p65 do NF-κB in vitro e quando introduzida no citosol 
das células alvo, usando o sistema LF/PA (lethal factor/protective antigen) do Bacillus 
anthracis, reproduziu as atividades proteolítica e apoptogénica da toxina. Estes 
resultados permitiram atribuir à porção amino-terminal da AIP56 a função catalítica. 
Pelo contrário, a porção carboxi-terminal da toxina não apresentou actividade catalítica 
in vivo nem in vitro. No entanto, quando usada como competidor, preveniu os efeitos 
tóxicos da AIP56, demonstrando que desempenha um papel importante na ligação e 
entrada da toxina nas células. 
Apesar das fronteiras dos domínios A e B da AIP56 não estarem ainda bem 
definidas, os resultados obtidos permitiram incluir a AIP56 na família das toxinas do 
tipo AB, da qual fazem parte as toxinas da difteria, botulismo e tétano, e a exotoxina A 
da Pseudomonas, entre outras. No entanto, os nossos resultados também revelaram 
que, quando comparada com as outras toxinas do tipo AB, a AIP56 possui algumas 
diferenças no que respeita aos requisitos estruturais necessários para a intoxicação. 
Contrariamente a outras toxinas AB, a AIP56 não necessita de activação proteolítica 
ou qualquer outro tipo de activação para ser enzimaticamente activa in vitro. Não 
obstante, parece necessitar que a região de ligação entre as duas cisteínas (C262 a 
C298) esteja intacta, uma vez que uma incisão nesta região tornou a toxina inativa. 
Estas observações sugerem que a região de ligação entre as duas cisteínas participa 
na translocação da toxina para o citosol e poderá fazer parte do ainda não definido 
domínio de translocação.  
A porção catalítica da AIP56 apresenta uma grande semelhança com o NleC, 
um efetor de tipo III de bactérias entéricas patogénicas que também tem como alvo a 
subunidade p65 do NF-κB. Resultados de dicroísmo circular e previsões in silico 
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revelaram que as duas proteínas são muito semelhantes em termos de estruturas 
secundárias. No entanto, apesar de a AIP56 e o NleC partilharem homologia estrutural 
e funcional, a região catalítica da AIP56 não é permutável pelo NleC, uma vez que a 
substituição da porção amino-terminal da AIP56 pelo NleC originou uma quimera sem 
toxicidade. Igualmente, não foi possível introduzir o NleC no citoplasma das células 
alvo usando o sistema LF/PA do Bacillus anthracis (que no entanto se mostrou eficaz 
na introdução do domínio catalítico da AIP56). De facto, resultados de fluorimetria 
diferencial de varrimento mostraram que a região catalítica da AIP56 e o NleC têm 
propriedades diferentes relativamente à sua desnaturação em resposta à acidificação, 
podendo estes resultados justificar as diferenças acima mencionadas. 
A capacidade intrínseca das toxinas AB para entrarem nas células alvo torna-
as atractivas não só como ferramentas para estudos de processos/mecanismos 
celulares mas também como mecanismos de transporte de diferentes cargas para o 
interior de células. Isto, associado envolvimento do NF-κB em situações patológicas 
graves, incluindo doenças inflamatórias e cancerígenas, confere à AIP56 um enorme 
potencial como ferramenta para fins terapêuticos e/ou biotecnológicos. Todavia, a 
futura utilização da AIP56 nestes contextos, implica a detenção de um conhecimento 
profundo das características estruturais da toxina, das suas vias intracelulares e dos 
detalhes moleculares que estão na base da sua toxicidade. 
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CHAPTER I- INTRODUCTION 
 
A. Bacterial exotoxins 
1. Overview 
The word toxin derives from the Greek τοξικον (“toxikon”) that translates as “poison”. 
The concept that pathogenic bacteria might induce harm and cause disease through the 
production of “poisons”, is almost as old as the notion of pathogenic bacteria itself (Alouf, 
2006). However, it was not until the 1880’s that the term toxin was introduced; according to 
Carl Lamanna (Lamanna, 1990), first by E. Ray Lankester, in 1886, to name “poisons for 
animals produced by pathogenic bacteria” and two years later by Roux and Yersin (Roux & 
Yersin, 1888) to describe the “diphtherial poison” currently known as diphtheria toxin (Alouf, 
2006). The discovery of this first bacterial protein toxin prompted outstanding discoveries not 
only in microbiology and infection but also in biological and medical sciences. The study of 
the biological effects of bacterial toxins at subcellular and molecular levels, revealed the high 
complexity and implications of these molecules in a variety of physiological and metabolic 
processes that ultimately lead to pathogenesis (Alouf, 2006). 
Bacterial exotoxins are amongst the principal virulence factors of pathogenic bacteria 
and usually contribute for the majority of symptoms and lesions caused by infection (Balfanz 
et al, 1996; Menestrina et al, 1994). These toxins, typically of protein nature, act at a distance 
from the infectious site and can diffuse throughout the organism. Through diverse and 
sophisticated mechanisms, toxins manipulate host cell functions and attack crucial events in 
vital processes of living organisms in favour of microbial infection. This is often achieved by 
the recognition of specific cell surface receptors that, in addition to cell-specificity, provide 
anchoring to the cell surface, lower the diffusion space and consequently lead to an increase 
in toxin concentration. Upon binding to their cell receptor, these toxins can unleash their toxic 
program at the cell membrane level or can enter the cells and recognize and modify specific 
intracellular targets (Balfanz et al, 1996; Popoff, 2005).  
 
2. Exotoxins acting at the plasma membrane  
Three levels of action can be established among those toxins acting at the plasma 
membrane: (i) interference with signal transduction pathways, (ii) enzymatic activities 
towards membrane components and (iii) pore formation (Popoff, 2005). 
2.1. Toxins interfering with signal transduction pathways 
The Heat-stable toxins (STs) secreted by some enteropathogenic bacteria and the 
superantigen toxins (SAgs), secreted by many Gram-positive bacteria, such as 
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Staphylococcus aureus, Clostridium perfringens and Streptococcus pyogenes, and by the 
Gram-negative bacteria Yersínia pseudotuberculosis (Brosnahan & Schlievert, 2011; Muller-
Alouf et al, 2001), are examples of bacterial toxins that act at the plasma membrane and 
interfere with signalling pathways through binding to a specific cell surface receptor (Popoff, 
2005).  
STs are produced by a variety of enteric pathogenic organisms, including 
diarrheagenic Escherichia coli, Vibrio cholerae, Vibrio mimicus, Yersinia enterocolitica, 
Citrobacter freundii, and Klebsiella pneumonia and are known to interfere with intestinal fluid 
homeostasis and induce diarrhea (Lin et al, 2010). These toxins are small peptides that fall 
into two families: STa (or ST-I) and STb (or ST-II) toxins, which differ on their 
physicochemical and biological characteristics (Lin et al, 2010). The STa members bind and 
activate guanylate cyclase C (de Sauvage et al, 1991; Schulz et al, 1990), a membrane 
protein receptor primarily expressed in intestinal mucosal cells involved in regulation of fluid 
and ion secretion, colon cell proliferation, and the gut immune system (Arshad & 
Visweswariah, 2012; Lucas et al, 2000). Activation of guanylate cyclase C by STa results in 
an increase in intracellular levels of cyclic guanosine monophosphate (cGMP) leading to the 
activation of protein kinase G (PKG) and protein kinase A (PKA), which in turn induce 
phosphorylation of chloride ion-channels on the apical membrane of intestinal cells causing 
water and chloride ions efflux resulting in watery diarrhea. In addition, cGMP-dependent PKA 
activation also leads to inhibition of the re-absorption of sodium by the Na+/H+-exchanger 
(Figure 1.1) (Hasegawa & Shimonishi, 2005; Weiglmeier et al, 2010).  
 
Figure 1.1. Heat-stable toxin a (STa) mechanism of action. Over-activation of guanylate cyclase C through binding of STa 
leads to an increase in intracellular levels of cyclic GMP (cGMP). This initiates a signalling cascade that ultimately results in 
secretion of electrolytes into the intestinal lumen. PDE3: cGMP-inhibitable phosphodiesterase 3; PKG: protein kinase G PKA: 
protein kinase A (Adapted from (Weiglmeier et al, 2010)). 
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SAgs are a particular class of bacterial toxins that share the ability to induce a 
powerful inflammatory response within the host (Muller-Alouf et al, 2001; Proft & Fraser, 
2003). These enterotoxins hijack T-cell antigen recognition through binding to invariable 
regions of major histocompatibility complex class II (MHC-II), outside the antigen-binding 
groove, and to the vβ domain of T-cell receptors (TCR) at the surface of antigen presenting 
cells (APCs), causing a non-specific activation of the targeted-lymphocytes (Fraser, 2011; Li 
et al, 1999) (Figure 1.2). By crosslinking MHC-II and TCR, SAgs bridge T-cells and APCs, 
bringing co-stimulatory molecules closer to their ligands, which results in a more efficient 
interaction and signal transduction (Muller-Alouf et al, 2001; Proft & Fraser, 2003). As a 
consequence, both APC and T-cells are stimulated to release massive amounts of cytokines, 
overpowering the host regulatory network and causing tissue damage (Krakauer, 1999; 
Muller-Alouf et al, 2001; Proft & Fraser, 2003). Additionally, these toxins have also been 
described to bind to epithelial cells and equally stimulate the production of pro-inflammatory 
cytokines by these cells (Kushnaryov et al, 1984a; Kushnaryov et al, 1984b). This 
phenomenon, termed outside-in signalling, acts to recruit adaptive immune cells to the 
submucosa, initiating cytokine cascades that lead to toxic shock syndrome (Brosnahan & 
Schlievert, 2011). Established members of the SAgs family are several staphylococcal 
enterotoxins, which are among the leading causes of food poisoning, the toxic-shock 
syndrome toxin 1 from Staphylococcus aureus, which induces an acute and sometimes lethal 
vaginal and wound tissue infection, and the pyrogenic toxins of Streptococcus pyogenes 
involved in scarlet fever (Brosnahan & Schlievert, 2011; Muller-Alouf et al, 2001; Proft & 
Fraser, 2003). 
 
 
Figure 1.2. Superantigen toxins. Representation of T-cell activation by conventional peptide antigens or by superantigen 
toxins. TCR: T-cell receptor; APC: antigen presenting cell; MHC class II: major histocompatibility complex class II. 
(Adapted from http://www.bio.davidson.edu/courses/immunology/students/spring2000/white/restricted/tss.html ) 
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2.2. Toxins acting by degrading membrane components  
Some toxins act at the plasma membrane by displaying enzymatic activity towards 
membrane components. The phospholipids, being ubiquitous and key constituents of 
biological membranes are thus preferential targets and their hydrolysis, not only induces 
major changes in membrane fluidity and integrity (often resulting in cell damage), but also 
interferes with intracellular signalling pathways. The hydrolytic products of phospholipids 
often serve as second messengers in various intracellular signalling cascades involved in the 
regulation of important physiologic processes such as cell death and the immune response 
(Geny & Popoff, 2006b; Songer, 1997) (Figure 1.3). 
 
 
Figure 1.3. Cellular disturbances induced by bacterial toxins acting on membrane phospholipids. Toxins with 
phospholipase activity act by degrading membrane phospholipids. These toxins induce various changes in host cells including 
changes in membrane fluidity and membrane lysis. Phospholipid degradation products also act as second messengers in 
various intracellular kinases and phospholipases pathways involved in several physiological processes. PhA: phosphatidic acid; 
DAG: diacylglycerol; LPA: lysophosphatidic acid; IP3: inositol triphosphate: PKC: protein kinase C, ER: endoplasmic reticulum, 
PIP2: Phosphatidylinositol 4,5-bisphosphate. (Adapted from (Geny & Popoff, 2006b)) 
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One example is the Clostridium perfringens α-toxin (Figure 1.3), which is a zinc-
dependent phospholipase C with preferential activity towards phosphatidylcholine and 
sphingomyelin, that affects a variety of cells including platelets, leukocytes, fibroblasts and 
erythrocytes, causing hemolysis, dermonecrosis and lethality (Sakurai et al, 2004). In small 
amounts, the toxin causes limited hydrolysis of those phospholipids, generating 
diacylglycerol and ceramide. These molecules modulate the activity of intracellular protein 
kinases and endogenous phospholipases involved in several intracellular signalling cascades 
and in membrane phospholipid metabolism, ultimately resulting in hemolysis, contraction of 
blood vessels and superoxide production (Geny & Popoff, 2006b; Goñi et al, 2012; Sakurai 
et al, 2004). Moreover, at high concentrations, a more drastic effect is observed, which 
results in massive degradation of the lipids leading to membrane disruption (Sakurai et al, 
2004). Another example is the Yersinia pestis murine toxin (Figure 1.3) with 
phosphospholipase D activity that hydrolyses the terminal phosphodiester bond of 
phospholipids (mainly phosphatidylethanolamine and, to a lesser extent, phosphatidylcholine 
and phosphatidylserine) generating phosphatidic acid (PhA) and an hydrophilic constituent 
(ethanolamine, serine or choline depending on the phospholipid hydrolysed) causing 
changes in membrane fluidity and also stimulating a variety of signal transduction pathways 
(Geny & Popoff, 2006b). Other bacterial phospholipases include phospholipase C from 
Pseudomonas, Listeria and various species of Clostridium, phospholipase A from 
Helicobacter pylori and phospholipase D from Corynebacterium (Songer, 1997; Titball, 
1998). 
 
2.3. Pore-forming toxins 
The pore-forming toxins (PFTs) are the largest class of exotoxins and represent about 
25% of all known bacterial toxins (Gonzalez et al, 2011; Iacovache et al, 2008). PFTs form 
pores in cell membranes and their action is often essential for the pathogenesis of their 
producing bacteria. Such pores are expectedly detrimental to the cell, allowing exodus of 
critical molecules, destroying the established membrane potential and ionic gradients, and 
contributing to osmotic swelling (Gonzalez et al, 2008). Notwithstanding, the events triggered 
by pore-formation in the membrane of a given target cell depend largely on toxin 
concentration, time of exposure and target cell type. At high concentrations PFTs induce 
numerous pores on the plasma membrane leading to cell necrosis. However, lower 
concentrations result in fewer pores, which may allow internalization and intracellular activity 
of PFT molecules (Geny & Popoff, 2006a). 
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One of the most fascinating aspects of these toxins is that, although they are secreted 
as fully soluble proteins, at their final stage they form a transmembrane pore/channel in the 
target membrane (Bischofberger et al, 2012). PFTs bind to the cell membrane, often through 
specific receptors, prior to pore-formation (Anderluh et al, 2003). The transition from 
membrane-bound to membrane-inserted state is often a multistep process, driven by 
structural rearrangements generating or exposing hydrophobic patches that spontaneously 
insert into the lipid bilayer to form a pore. According to the type of secondary structure of the 
membrane-spanning region, PFTs can be broadly classified as α-PFTs or β-PFTs (Iacovache 
et al, 2010). 
The α-PFTs contain α-helical hydrophobic stretches that span the membrane 
(Gonzalez et al, 2008; Iacovache et al, 2010; Iacovache et al, 2008). The α-helical family 
includes the colicins produced by Escherichia coli (Cascales et al, 2007), the Cry toxins from 
Bacillus thuringiensis (Pardo-Lopez et al, 2012) and the cytolysin A (ClyA), also known as 
hemolysin E, from Escherichia coli and Salmonella enterica strains (Wallace et al, 2000). 
Whereas the structure of the soluble form of several α-PFTs has been determined 
(Iacovache et al, 2008), ClyA is the only α-PFT to which three-dimensional structures of both 
the soluble (Wallace et al, 2000) and pore structures are available (Mueller et al, 2009). 
Soluble ClyA is an elongated molecule composed exclusively of α-helices, with the exception 
of a short solvent exposed hydrophobic β-hairpin (Figure 1.4). Conversion of the soluble form 
of the toxin into its membrane inserted state requires oligomerization and major 
rearrangements in the toxin structure. Upon membrane encounter, the hydrophobic β-tongue 
converts into a hydrophobic α-helix, thought to spontaneously insert into the lipid bilayer, 
driving subsequent structural changes, oligomerization and pore formation (Iacovache et al, 
2010; Mueller et al, 2009). The assembled ClyA pore forms a hollow cylinder composed of 
twelve toxin monomeric units with the structure of each protomer being substantially different 
from that in the soluble monomer (Figure 1.4) (Mueller et al, 2009). Nonetheless, it is 
important to note that cytolysin A is not a typical representative of the α-PFT, in particular 
because most other α-PFTs do not form well-defined stable oligomers (Iacovache et al, 
2010). Indeed, this class of PFTs is a very heterogeneous group, gathering together toxins 
with very different structures, and the fact that most of these toxins do not form stable 
oligomeric complexes is a major drawback for structural studies. Therefore, the molecular 
details and the series of events that lead to the formation of a membrane inserted pore in 
many α-PFTs are yet unclear. For instance, the colicins contain a pore-forming domain that, 
in their soluble form, is composed by a bundle of α-helices sandwiching a hydrophobic helical 
hairpin (Hilsenbeck et al, 2004; Vetter et al, 1998; Wiener et al, 1997). It is known that pore 
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formation involves structural rearrangements within the toxin, driving the exposure of the 
hydrophobic helical hairpin and its insertion into the lipid membrane (Kienker et al, 1997; 
Song et al, 1991). However, a high-resolution structure of the pore formed by these toxins is 
still unavailable and although toxin multimerization is most likely required for the formation of 
a transmembrane open pore structure, definitive proof is still lacking (Iacovache et al, 2008).  
 
 
Figure 1.4. Three-dimensional structures of pore-forming toxins (PFTs). Structures of Escherichia coli cytolysin A and of 
Staphylococcus aureus α-haemolysin. A) Structure of soluble monomeric cytolysin A (left), structure of cytolysin A protomer 
(middle) and structure of cytolysin A dodecameric pore (right). The hydrophobic hairpin (“β-tong”) is represented in black and 
the pore-forming domain in blue. B) Structure of soluble monomeric α-haemolysin (left), structure of α-haemolysin protomer 
(middle) and structure of α-haemolysin heptameric pore (right). The pore-forming domain is represented in blue. Note the 
conformational differences between the soluble and the protomeric toxin forms (Adapted from (Iacovache et al, 2010)).  
 
The β-PTFs have so far been the largest and most studied class of PFTs and to 
which pore-formation is better understood. To this group of PFTs belong, among others, the 
Staphylococcus aureus α-hemolysin (Song et al, 1996), the aerolysin produced by various 
species of Aeromonas (Fivaz et al, 2001) and the cholesterol dependent cytolysins (CDCs) 
which include the Streptococcus pyogenes streptolysin O, the Streptococcus pneumonia 
pneumolysin and the Clostridium perfringens perfringolysin O (Hotze & Tweten, 2012). The 
β-PFTs are characterized by containing pairs of amphipathic β-strands that, when combined 
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in oligomeric structures (a step that for certain toxins requires proteolytic activation) generate 
the hydrophobic surface required for membrane insertion to occur (Iacovache et al, 2010; 
Iacovache et al, 2008). Each protomer usually contributes with one or two amphipathic β-
hairpins that together create an amphipathic β-barrel with a hydrophilic cavity and a 
hydrophobic outer surface (Iacovache et al, 2010; Iacovache et al, 2008). Exposure of the 
hydrophobic surface on the outside of the formed β-barrel is thought to provide the energy for 
membrane insertion, even though no evidence is currently available to support this 
hypothesis (Gonzalez et al, 2008). For most β-PFTs, membrane insertion is a concerted 
event preceded by toxin oligomerization into pre-pore structures (Gonzalez et al, 2008). 
(Iacovache et al, 2010; Iacovache et al, 2008). Yet, in the case of aerolysin, formation of the 
pre-pore-structure has never been observed and it appears that oligomerization, folding of 
the amphipathic β-barrel and membrane insertion are coupled events (Geny & Popoff, 
2006a; Iacovache et al, 2006). Although for many toxins, the events driving the conversion of 
the pre-pore into membrane-inserted pores remain obscure, in general these events involve 
a second series of conformational changes (Thompson et al, 2011). The only high resolution 
structure of a β-PFT pore is of the Staphylococcus aureus α-haemolysin (Song et al, 1996). 
The pore has a mushroom structure and is composed by 7 toxin units with a transmembrane 
domain comprising a 14-strand antiparallel β-barrel (each protomer contributes with two β-
strands) (Figure 1.4). Nevertheless, depending on the toxin, the number of monomers 
involved in pore formation can vary from 7 (as in the case of α-haemolysin, aerolysin 
(Iacovache et al, 2006) and staphylococcal α-toxin (Menestrina et al, 2003)) to up to 50 (in 
the case of CDCs (Hotze & Tweten, 2012)).  
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3. Exotoxins that enzymatically modify cytosolic targets 
3.1. Overview 
Many of the most potent bacterial toxins act inside host cells. The potency of 
intracellularly acting toxins is derived, in part, from the fact that most are enzymes that 
catalyse the covalent modification of specific cytosolic targets. Depending on their specific 
target and type of modification, these toxins can interfere with a variety of cellular processes 
that include inhibition of protein synthesis (e.g. diphtheria and shiga toxins), increase in 
second messenger cyclic adenosine monophosphate (cAMP) (e.g. cholera and adenylate 
cyclase toxins), disaggregation of the microfilament structure (e.g. Clostridium difficile toxins 
A and B) and inhibition of neurotransmitter release (tetanus and botulinum toxins) (Popoff, 
2005) (Table 1.1).  
To be successful, intracellularly acting toxins must access their substrates inside 
target cells. To enter the cells, these toxins bind to receptors at the cell surface and exploit 
the endocytic pathway to reach the cytosol from intracellular compartments (Montecucco & 
Papini, 1995; Sandvig et al, 2004). However, exceptions exist as is the case of Bordetella 
pertussis adenylate cyclase A that delivers its adenylate cyclase enzyme component into the 
cell cytoplasm directly from the plasma membrane in a process that does not depend on 
receptor-mediated endocytosis (Gordon et al, 1988; Osickova et al, 2010). Two conformers 
of this toxin, which exert different activities, are known. One is able to insert into the cell 
plasma membrane as a toxin translocation precursor that accomplishes delivery of the 
catalytic domain into the cytosol, while the other forms cation-selective pores that 
permeabilize the membrane for efflux of cytosolic potassium (Benz et al, 1994; Fiser et al, 
2012; Osickova et al, 2010; Vojtova et al, 2006). 
Apart from the above mentioned exception, cell entry/intoxication by toxins targeting 
cytosolic substrates is a four-step process involving (i) specific binding of the toxin to the cell 
surface, (ii) internalization, (iii) membrane translocation and, finally, (iv) modification of the 
cytosolic target (Montecucco & Papini, 1995; Montecucco et al, 1994). This elaborate 
mechanism of cell entry and action relies in a multi-domain architecture that has evolved and 
adapted to play specific roles in each of the above mentioned intoxication steps (Montecucco 
et al, 1994; Rossetto et al, 2000). 
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3.2. The AB structure 
In general terms, toxins that act intracellularly and enzymatically modify cytosolic 
targets are composed by two functional subunits: a catalytic moiety (also designated A 
subunit) that holds the toxin enzymatic activity and a binding moiety (also designated B 
subunit) involved in cellular uptake and delivery of the enzymatic component into the cytosol. 
Individually the two subunits are non-toxic and a concerted action of the two subunits is need 
for cell intoxication. Because of their architecture, these toxins are referred as AB toxins 
(Montecucco et al, 1994; Rossetto et al, 2000).  
Toxins belonging to the AB toxin family can be synthesized and arranged in a 
multiplicity of ways (Figure 1.5). The different folding and assemblies of the A and B subunits 
to form a final toxin are closely related with the molecular processes of toxin biogenesis, and 
their structural features are adapted to the specific requirements of the intoxication pathway 
(Montecucco & Papini, 1995). 
 
Figure 1.5. Molecular organizations of AB toxins. The A subunit is the enzymatically active portion of the toxin and the B 
moiety is the one responsible toxin binding and internalization. Protease cleavage sites are indicated by black arrows. (Adapted 
from (Jianjun, 2012)) 
 
3.2.1. AB toxins secreted as a single polypeptide chain  
Toxins such as diphtheria toxin (DT) (Collier, 2001) and the clostridial neurotoxins 
(comprising the tetanus neurotoxin (TeNT) and the seven antigenically distinct botulinum 
neurotoxins (BoNT/A-G)) (Turton et al, 2002) are secreted by their producing bacteria as 
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single-chain polypeptides that upon secretion undergo proteolytic processing at a flexible and 
exposed region between two cysteine residues, yielding an A chain/subunit bound by a 
disulphide bridge to a B chain/subunit. Proteolytic processing of TeNT and BoNT results from 
the action of endogenous clostridial proteases (Ahnert-Hilger et al, 1990; DasGupta, 1971; 
Krieglstein et al, 1991; Weller et al, 1989), whereas in the case of DT it can result from the 
action of bacterial proteases or occur at the cell surface mediated by a furin or furin-like 
protease (Gill & Dinius, 1971; Tsuneoka et al, 1993). The X-ray crystal structures of DT (Bell 
& Eisenberg, 1997; Choe et al, 1992) and intact BoNT/A (Lacy et al, 1998) and BoNT/B 
(Eswaramoorthy et al, 2004; Swaminathan & Eswaramoorthy, 2000) have been solved. 
However, in the case of TeNT, only the crystal structures of the isolated A- and B-chains 
(also called light and heavy chains, respectively) have been determined so far (Breidenbach 
& Brunger, 2005; Rao et al, 2005; Umland et al, 1997). These toxins share the same overall 
structure with three structural/functional domains: an N-terminal catalytic domain, which 
makes the A subunit, disulphide-bounded to a B subunit comprising a membrane 
translocation (T) domain and a receptor binding (R) domain (Collier, 2001; Turton et al, 2002) 
(Figure 1.6). Nonetheless, the spacial arrangement of the domains among these toxins 
differs. In BoNT, the three functional domains are arranged in a linear fashion, with the 
translocation domain flanked by the catalytic and binding domains, whereas in DT and the 
three domains are arranged in the shape of an “Y” with the T domain forming the lower 
segment and the T and R domains the upper angled segments of the “Y” (Figure 1.6). 
 
 
Figure 1.6. Three-dimensional structures of AB toxins secreted as a single polypeptide chain. Crystal structures of 
diphtheria toxin (PDB ID: 1SGK), botulinum neurotoxin A (PDB ID: 3BTA) and Pseudomonas exotoxin A (PDB ID: 1IKQ). PDB: 
Protein data bank. 
 
The Pseudomonas exotoxin A (PE) is another example of an AB toxin secreted as a 
single polypeptide chain (Weldon & Pastan, 2011; Wolf & Elsasser-Beile, 2009). However, in 
contrast with the above mentioned toxins, PE proteolytic processing takes place upon toxin 
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internalization at an acidic compartment, presumably the endosomes, and is mediated by 
furin (Corboy & Draper, 1997; Fryling et al, 1992; Inocencio et al, 1994; Ogata et al, 1990; 
Ogata et al, 1992). PE is composed by three structural and functional domains (denominated 
I, II and III) (Allured et al, 1986; Hwang et al, 1987; Siegall et al, 1989; Wedekind et al, 2001). 
The X-ray crystal structures of PE revealed that the N-terminal domain I is divided into two 
non-sequential but structurally adjacent domains named Ia and Ib. Residues between Ia and 
Ib comprise domain II and domain III lies in the C-terminus (Allured et al, 1986; Wedekind et 
al, 2001) (Figure 1.6). Functionally, domain Ia is the receptor-binding domain and the major 
component of the B subunit, domain II contains the furin cleavage site and is involved in toxin 
translocation and intracellular trafficking, and domain III is the catalytically active domain and 
the primary constituent of the A subunit (Hwang et al, 1987; Siegall et al, 1989; Theuer et al, 
1993; Wedekind et al, 2001); the functions of domain Ib are not yet clarified. 
Equally secreted by their producing bacteria as single polypeptide chains are the 
clostridial glucosylating toxins (i.e. Clostridium dificille toxin A and B, the hemorrhagic and 
lethal toxins from Clostridium sordelli and the α-toxin from Clostridium novyi), also known as 
large clostridial toxins (Jank & Aktories, 2008; Just & Gerhard, 2004; Popoff & Bouvet, 2009). 
However, in contrast to DT, TeNT, BoNT, and PE, the proteolytic processing of the clostridial 
glucosylating toxins is the result of auto-catalytic activity (Aktories, 2007; Giesemann et al, 
2008; Shen, 2010). In addition to the catalytic, translocation and binding domains, these 
toxins possess an autocatalytic/self-cutting protease domain (Aktories, 2007; Albesa-Jové et 
al, 2010; Giesemann et al, 2008; Shen, 2010) located in the N-terminal region preceded by 
the catalytic domain. The receptor binding domain is located in the C-terminus of the toxin 
and downstream to a hydrophobic region putatively involved in membrane translocation 
(Aktories, 2007; Albesa-Jové et al, 2010; Jank & Aktories, 2008).Thus, in these toxins, the 
AB model can be extended to an ABCD model where A is responsible for the catalytic 
activity, B for binding to target cells, C for auto-proteolysis, and D for delivering/translocation 
(Jank & Aktories, 2008).  
 
3.2.2. AB5 toxins 
Toxins including cholera toxin (CT) (Bharati & Ganguly, 2011), shiga toxin (Stx) 
(Sandvig, 2001), heat-labile enterotoxins (LT) (Beddoe et al, 2010) and pertussis toxin (PT) 
(Locht et al, 2011) consist of an assembly of independently synthesized A and B subunits 
that associate by non-covalent bonds to form a final multimeric toxin. The toxin complexes 
consist of hetero-hexameric assemblies comprising a single A subunit linked to a pentamer 
of B-subunits (Figures 1.5), and thus the AB5 designation (Beddoe et al, 2010; Merritt & Hol, 
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1995). The X-ray structures of several AB5 members are known and reveal a remarkable 
degree of structural homology, despite the lack of sequence homology (Fraser et al, 2004; 
Stein et al, 1994; van den Akker et al, 1996; Zhang et al, 1995) (Figure 1.7).  
 
 
Figure 1.7.  Three-dimensional structures of AB5 toxins. Crystal structures of cholera toxin (PDB ID: 1XTC), heat-labile 
enterotoxin IIb (PDB ID: 1TII) shiga toxin (PDB ID: 1R4Q) and pertussis toxin (PDB ID: 1PRT). PDB: Protein data bank.  
 
In AB5 toxins, the B-pentamer is usually composed of identical B subunits (Beddoe et 
al, 2010; Merritt & Hol, 1995), with exception of PT where the B-pentamer is composed of 
four different subunits, named S2 to S5 (Locht et al, 2011). Assembly of the A and B subunits 
into AB5 oligomers is a complex process that occurs in the periplasmic compartment of the 
bacterial cell envelope (Hirst et al, 1984; Mekalanos et al, 1983; Neill et al, 1983). The 
precise order of subunit interaction and the molecular determinants of the oligomerization 
process are not yet completely clarified. It is known that pentamerization of the B subunit(s) 
can be achieved in vitro in the presence or absence of the A subunit, indicating that the 
sequence of the B subunit contains all the necessary information for pentamer assembly (Lai 
et al, 1976; Locht et al, 2011; Olsnes et al, 1981; Sandvig, 2001; Spangler, 1992; Zrimi et al, 
2010). However, A subunits are only able to interact with immature (not pentameric) B 
oligomers and oligomerization is faster in the presence of A subunits (Hardy et al, 1988; 
Streatfield et al, 1992), suggesting that binding of the A subunit must occur prior to complete 
B subunit pentamerization. 
Upon secretion, AB5 toxins undergo proteolytic activation within their A subunit at a 
trypsin- and/or furin-sensitive loop located at the C-terminal end yielding two disulphide- 
bridged domains (A1 and A2) (Booth et al, 1984; Garred et al, 1995; Grant et al, 1994; 
Krueger et al, 1991). The A1 domain comprises the catalytic function and is responsible for 
the modification of the intracellular target whereas the A2 domain consists of an α-helix that 
penetrates into the central pore of the pentameric B-subunit, thereby non-covalently 
17 
 
CHAPTER I- INTRODUCTION 
 
anchoring the A- and B-subunits together (Beddoe et al, 2010; Fraser et al, 2004; Sixma et 
al, 1993; Stein et al, 1994; Stein et al, 1992; Zhang et al, 1995). In the case of CT, the 
proteolytic processing of the A domain results from the activity of a Vibrio cholerae protease 
(Booth et al, 1984), whereas in the case of Stx (Garred et al, 1995), LT (Grant et al, 1994) 
and PT (Finck-Barbançon & Barbieri, 1996; Krueger et al, 1991) cleavage occurs at early 
stages of intracellular transport and is mediated by a target cell protease. 
 
3.2.3. AB7/8 toxins 
Anthrax toxins (lethal toxin and edema toxin), which derive form the combination of 
two independent A subunits (edema factor and lethal factor) with the same oligomeric B 
component, the protective antigen (PA), and Clostridium botulinum C2 toxin are the most 
prominent examples of the AB7/8 toxins (Barth & Aktories, 2011; Barth et al, 2004; Young & 
Collier, 2007). Similarly to AB5, the AB7/8 toxins consist of a complex of independently 
synthesized A and B subunits that associate non-covalently to form a final multimeric toxin. 
The toxin complexes consist on a B heptameric or octameric oligomer, bound to multiple A 
subunits (Bann, 2012) (Figure 1.5). 
In contrast with AB5 toxins, formation of the AB7/8 toxin complexes occurs upon 
secretion of the A and B components by the producing bacteria. Assembly can take place at 
the extracellular medium (Ezzell et al, 2009; Kaiser et al, 2006; Panchal et al, 2005) or at the 
cell surface, upon binding of the B component to cell receptors (Barth et al, 2000; 
Beauregard et al, 2000; Ohishi & Miyake, 1985). Either way, toxin assembly requires 
proteolytic activation of the B component, as the result of the action of serum proteases 
(Ezzell & Abshire, 1992) or furin proteases located at the cell surface (Klimpel et al, 1992). 
Proteolytic processing drives oligomerization of the B components into ring shaped 
structures called pre-pore (Figure 1.8). Pre-pore formation precedes the binding of the A 
components to form the functional toxin complex (Ascenzi et al, 2002; Barth et al, 2000; 
Beauregard et al, 2000; Mogridge et al, 2002). Until recently, only heptameric structures of 
pre-pore complexes, able to bind three A subunit molecules, were known (Barth et al, 2000; 
Lacy et al, 2004; Milne et al, 1994; Petosa et al, 1997; Santelli et al, 2004; Schleberger et al, 
2006). However, in 2009, Kintzer and colleagues reported the existence of functional anthrax 
PA octameric pre-pore structures, capable of binding four A subunits (Kintzer et al, 2010; 
Kintzer et al, 2009) (Figure 1.8).  
Anthrax toxins are the most extensively studied AB7/8 toxins and for which the 
molecular details of the assembly and intoxication are best understood (Bann, 2012; Puhar & 
Montecucco, 2007; Thoren & Krantz, 2011; Young & Collier, 2007). By contrast, structural 
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information regarding the C2 toxin is scarce and only a low resolution crystal structure is 
available (Schleberger et al, 2006). However, and even though the enzymatic components of 
C2 and anthrax toxins are structurally and functionally divergent, the binding components of 
those toxins share considerable sequence and structural homology (Barth et al, 2000; Popoff 
& Bouvet, 2009; Schleberger et al, 2006; Young & Collier, 2007). Both binding components 
consist of four functional domains: domain I is proteolytically cleaved during toxin activation 
and is involved in the interaction with the enzymatic components (domain I’); domain II is a 
flexible hydrophobic loop that inserts in the membrane playing a role in membrane 
translocation; domain III is involved in B subunit oligomerization; and domain IV is 
responsible for binding to the cell surface receptors (Lacy et al, 2004; Petosa et al, 1997; 
Schleberger et al, 2006) (Figure 1.8). 
 
 
Figure 1.8. Three-dimensional structures of anthrax protective antigen (PA). Crystal structure of monomeric PA (PDB 
ID:1ACC) and axial views of X-ray crystal structures of heptameric (PDB ID:1TZO) and octameric (PDB ID: 3HVD) pre-pore 
structures. PDB: Protein data bank. 
 
3.3. Mechanisms of intoxication 
The first step of the entry of a bacterial protein toxin into the host cell is the binding to 
a specific receptor at the cell surface, which can be of proteic, lipidic or carbohydrate nature. 
Binding to the receptor not only determines cell target specificity, but also provides toxin 
anchoring to the cell membrane which is essential in the following intoxication steps (Lord et 
al, 1999; Montecucco et al, 1994). Host cells lacking the receptors for a particular toxin are 
generally resistant to intoxication, underscoring the importance of toxin-receptor complexes. 
Some receptor-bound toxins (e.g., DT and ST) are targeted for clathrin-dependent 
endocytosis (Murphy, 2011; Sandvig et al, 2010a; Sandvig et al, 2004), while other toxins, 
including CT and TeNT, enter cells by one of several alternative “clathrin-independent” 
endocytic pathways (Deinhardt et al, 2006; Torgersen et al, 2001).  
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The cytosol is the final destination of these toxins (or at least of the catalytic A 
subunit) and, when it comes to cytosolic entry these toxins fall into two main groups: (i) the 
“short-trip” toxins that reach the cytosol from the endosomal compartment, and the (ii) “long-
trip” toxins that reach the cytosol from the endoplasmic reticulum (ER) (Figure 1.9) (Falnes & 
Sandvig, 2000; Montecucco & Papini, 1995; Montecucco et al, 1994; Sandvig et al, 2004). 
Either way, in order to reach the cytosol, toxins need to cross the membrane barrier and this 
is still the most obscure step of the entire intoxication process. Considering the hydrophilic 
nature of protein toxins and the hydrophobic nature of the membrane, it is clear that 
membrane translocation represents a major fundamental biologic problem for toxin activity 
and toxins have developed different strategies to overcome it (Falnes & Sandvig, 2000). 
 
 
Figure 1.9. Intracellular pathways of AB toxins. Toxin B subunit(s) bind to cellular receptors and the AB toxin complex is 
internalized via receptor-mediated endocytosis. The “short-trip” toxins reach the endosomal compartment and exploit the 
endosomal acidification to translocate their catalytic A subunit to the cytosol. Under the low pH of the endodomal lumen the 
toxin undergoes conformational rearrangements that lead to the exposure of hydrophobic regions allowing membrane insertion 
of the toxin’s B subunit(s) and formation of ion-conducting channels across which partially unfolded A fragments translocate into 
the cytosol. The “long-trip” toxins follow a longer intracellular route and exploit the degradation pathways for misfolded proteins. 
These toxins travel retrogradely from the plasma membrane, via the trans-Golgi network (TGN) and the Golgi stack, to the 
endoplasmic reticulum (ER), from where the A subunit translocates to the cytosol using ER secretion machinery. (Adapted from 
(Geny & Popoff, 2006a)) 
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3.3.1. “Short-trip” toxins 
To transport their A fragments into the cytosol, several toxins including DT (see box1) 
(Murphy, 2011), anthrax toxins (see box2) (Young & Collier, 2007), the clostridial neurotoxins 
TeNT and BoNT (Turton et al, 2002), and the large clostridial toxins (Jank & Aktories, 2008; 
Pruitt & Lacy, 2012), exploit the acidification of the endocytic vesicles, as they traffic from the 
plasma into the cell, and translocate their A subunits into the cytosol from this acidic 
compartment (Figure 1.9). 
Although the structural architecture of DT and clostridial neurotoxins differ greatly from 
anthrax toxins and the large clostridial toxins (discussed above in section 2.2.1), these toxins 
share molecular and structural features that meet the specific requirements to cross a lipid 
membrane. All these toxins share the property of forming ion channels in lipid bilayers at low 
pH (Bachmeyer et al, 2001; Barth et al, 2001; Blaustein, 2011; Giesemann et al, 2006; Hoch 
et al, 1985). Formation of these channels was observed not only in artificial membranes 
(Bachmeyer et al, 2001; Barth et al, 2001; Blaustein et al, 1989; Giesemann et al, 2006; 
Hoch et al, 1985; Koehler & Collier, 1991; Lang et al, 2008) but also in living cells 
(Bachmeyer et al, 2001; Barth et al, 2001; Eriksen et al, 1994; Giesemann et al, 2006; Lang 
et al, 2008; Li & Shi, 2006; Milne & Collier, 1993; Rainey et al, 2005; Sandvig & Olsnes, 
1988) and in this sense, the B components of these toxins are also considered as pore-
forming toxins (Bischofberger et al, 2012; Gonzalez et al, 2008; Reig & van der Goot, 2006). 
Channel formation involves conformational rearrangement of the toxin with insertion into the 
membrane of hydrophobic stretches within the B-subunit (T domain of DT and clostridial 
neurotoxins and domain II of anthrax PA) (Albesa-Jové et al, 2010; Bann, 2012; Barth et al, 
2001; Blaustein et al, 1987; Chenal et al, 2009; Chenal et al, 2002; Galloux et al, 2008; 
Giesemann et al, 2006; Hoch et al, 1985; Montecucco et al, 1986; Qa'Dan et al, 2000; Shone 
et al, 1987; Silverman et al, 1994). 
It is now currently accepted that the acid endosomal pH triggers conformational 
rearrangements within the toxin that enable: (i) the B subunit to insert into the membrane and 
form a transmembrane pore that serves as a tunnel for the A subunit to cross the membrane 
protected from the contact with lipids, and (ii) the A chain to unfold and translocate into the 
cytosol through the formed pore (Bann, 2012; Montal, 2010; Murphy, 2011; Pentelute et al, 
2011; Rodnin et al, 2010; Thoren & Krantz, 2011; Turton et al, 2002; Wu et al, 2006). Under 
the neutral reducing environment of the cytosol, the A subunit refolds and the disulphide 
bond linking the A and B subunits is reduced, leaving behind the B subunit (Montal, 2010; 
Murphy, 2011; Thoren & Krantz, 2011; Turton et al, 2002). The molecular determinants 
involved in this last step of the intoxication process, particularly regarding the translocation 
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Box 1. Diphtheria toxin 
Diphtheria toxin (DT) is one of the most extensively studied and well understood bacterial toxins (Collier, 2001). The toxin is 
secreted by Corynebacterium diphtheria, the causative agent of the diphtheria disease, an infectious disease that primarily 
affects the mucous membranes of the respiratory tract (respiratory diphtheria). Although not so commonly, diphtheria may also 
affect the skin (cutaneous diphtheria) and lining tissues in the ear, eye, and the genital areas ( http://www.cdc.gov/ ). DT is 
composed by three domains: a catalytic domain, a binding domain which mediates the binding of the toxin to cell surface 
receptors and a translocation domain involved in the translocation of the catalytic domain into the cell cytosol (Collier, 2001). 
The toxin binds to the membrane anchored heparin binding epidermal growth factor-like precursor hb-EGF (Naglich et al, 1992). 
Receptor bound toxin is concentrated in clathrin coated pits and internalized into clathrin coated vesicles and then trafficked to 
the endosomomal compartment (Moya et al, 1985; Murphy, 2011). Once in endosomes, acidification of the luminal pH triggers 
the dynamic unfolding of the toxin, with the exposure of hydrophobic regions, leading to toxin insertion into the endosomal 
membrane and formation of a cation-selective pore from across which unfolded catalytic domain translocates to the cytosol. 
Membrane insertion is mediated by the α-helical translocation domain comprising nine α-helices arranged in three helical layers 
(Collier, 2001; Geny & Popoff, 2006a; Murphy, 2011). It is widely recognized that the endosomal acidification is a key trigger 
event that induces conformational changes necessary for membrane insertion and pore formation (Collier, 2001; Geny & Popoff, 
2006a; Murphy, 2011). Concerted protonation of key histidines located throughout the translocation domain and acidic amino 
acid residues within the loop between helices TH8-TH9, are thought to trigger conformational changes that drive membrane 
interaction and insertion of the transmembrane α-helices TH5–TH7 and TH8–TH9 (Kaul et al, 1996; Perier et al, 2007; Rodnin 
et al, 2010; Wang & London, 2009). However, membrane insertion and pore formation are not self-sufficient to conduct 
translocation of the catalytic domain across the endosomal membrane and some host cell factors (Murphy, 2011) along with 
ATP (Lemichez et al, 1997) have been suggested to be involved in the process. Several studies have demonstrated the 
involvement of COPI (coatomer protein complex I) complex in facilitating the delivery of the catalytic domain into the cell cytosol 
(Lemichez et al, 1997; Ratts et al, 2005; Trujillo et al, 2010). Additionally, the cytoplasmic thioredoxin reductase was also found 
to be essential for release of the DT catalytic domain into the cytosol and the cytosolic chaperone heat-shock protein 90 
(Hsp90) likely to be involved in the refolding of the catalytic domain to generate a catalytically active ADP-rybosyltransferase 
(Ratts et al, 2003). Once at the cytosol, the catalytic domain of DT catalysis the transfer of the ADP-ribose moiety of NAD to the 
elongation factor 2 (EF-2) leading to the inhibition of protein synthesis (Honjo et al, 1968).  
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Box 2. Anthrax toxins 
Anthrax toxins (lethal toxin and 
edema toxin) are secreted by Bacillus 
anthracis, the causative agent of 
anthrax disease. In its systemic form, 
anthrax infections are rapid-course 
deadly infections that result from 
inhalation or ingestion of Bacillus 
anthracis spores (Ascenzi et al, 
2002). Lethal toxin and edema toxin 
derive form two independent 
enzymatically active subunits, the 
edema factor (EF) and lethal factor 
(LF), that associate with the common 
receptor-binding subunit, the 
protective antigen (PA) (Ascenzi et al, 
2002; Young & Collier, 2007). Initial 
steps in the cellular intoxication 
involve assembly of the toxin 
complexes and binding of toxin to the 
cellular receptor. Formation of the PA/LF or EF complexes can occur either at the cell surface, upon binding to the cell receptor, 
or at the extracellular medium (i.e. blood serum) (Bann, 2012; Kintzer et al, 2010). Either way, toxin assembly requires 
proteolytic activation of the PA resulting in the formation of a C-terminal 63 kDa fragment (PA63) that oligomerizes into 
heptameric (Lacy et al, 2004; Milne et al, 1994) or octameric (Kintzer et al, 2010; Kintzer et al, 2009) ring-shaped structures 
(pre-pore) capable of binding 3 or 4 molecules, respectively, of LF or EF. Three anthrax cell receptors have been identified: the 
tumour endothelial marker-8 (ANTXR1) (Bradley et al, 2001), the capillary morphogenesis protein 2 (ANTXR2) (Scobie et al, 
2003) and more recently, the integrin β1 complexes (identified as a  low-affinity PA receptor that was also found to potentiate 
ANTXR2-mediated endocytosis )(Martchenko et al, 2010). Nonetheless, a very recent study showed that ANTRX1 and ANTRX2 
are the only two anthrax toxin receptors mediating lethality in vivo (Liu et al, 2012). Following lipid raft association, anthrax toxin-
receptor complexes are internalized presumably via clathrin coated pits and then trafficked to early endosomes (Abrami et al, 
2010; Abrami et al, 2003), where the acidic environment induces a series of conformational changes on the toxin complex that 
allow the pre-pore insertion into the membrane, forming a membrane spanning pore (Bann, 2012). There is only one model for 
the membrane active PA-pore (Nguyen, 2004), based on the mushroom shaped resolved structure of α-hemolysin (Song et al, 
1996) (see Figure 1.4), according to which, the pore is an extended 14-stranded β-barrel structure (Nguyen, 2004) that acts as a 
protein-conducting translocase channel from where unfolded EF and LF translocate to the cytosol (Bann, 2012; Thoren & 
Krantz, 2011). The proton gradient (ΔpH) generated by the endosomal acidification is thought to be a major driving force 
promoting pore-formation and EF and LF unfolding and translocation (Krantz et al, 2006). Nevertheless, the binding of the 
translocating chains to the surface of the PA channel is proposed to assist the unfolding step (Thoren & Krantz, 2011; Thoren et 
al, 2009) and, auxiliary host cell factors such as the COPI complex (Tamayo et al, 2008) and the chaperones Hsp90 and 
cyclophilin A (Dmochewitz et al, 2011) have been proposed to assist the delivery of LF into the cytosol. LF is a zinc 
metalloprotease that specifically cleaves and inactivates mitogen activated protein (MAP) kinase kinases (Duesbery et al, 1998; 
Vitale et al, 1998) causing the impairment of the host immune responses (Turk, 2007). EF is a calcium- and calmodulin-
dependent adenylate cyclase that catalysis the synthesis of cAMP from cellular ATP (Leppla, 1982) increasing cAMP 
intracellular levels, thus interfering with several intracellular signalling pathways and upsetting the water homeostasis causing 
edema (Turk, 2007). 
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of the catalytic A subunit across the pore, are not yet completely understood and differ 
among toxins. Nevertheless, evidences suggest that it is not exclusively toxin- and pH-
dependent since ATP (Lemichez et al, 1997) as well as several cytosolic proteins such as 
coatomer protein complex I (COPI) (Lemichez et al, 1997; Ratts et al, 2005; Tamayo et al, 
2008; Trujillo et al, 2010), chaperoning proteins (Dmochewitz et al, 2011; Haug et al, 2004; 
Haug et al, 2003; Kaiser et al, 2011; Ratts et al, 2003) thioredoxin reductase (Ratts et al, 
2003) and cyclophilin A, a peptidyl-prolyl cis/trans isomerase (Kaiser et al, 2011; Kaiser et al, 
2009), have been reported to be involved in the translocation process. 
 
3.3.2.  “Long-trip” toxins 
Members of the AB5 toxin family such as CT (see box 3), Stx, LT and PT follow a 
different route and take a longer trip to access cytosolic substrates (Beddoe et al, 2010) 
(Figure 1.9). These toxins exploit one of several retrograde trafficking pathways and travel 
from the plasma membrane, via early endosomes and Golgi network, to the ER (Beddoe et 
al, 2010; Locht et al, 2011; Sandvig et al, 2010a; Spooner & Lord, 2012; Wernick et al, 
2010). Once at the ER these toxins disguise themselves as misfolded proteins and use the 
machinery of the ER-associated protein degradation (ERAD) pathway (the process by which 
misfolded proteins are sorted and exported from the ER lumen to the cytosol for proteasomal 
degradation) to translocate to the cytosol (Beddoe et al, 2010; Locht et al, 2011; Sandvig et 
al, 2010a; Spooner & Lord, 2012; Wernick et al, 2010).  
The pentameric B components of these AB5 toxins are multivalent lectins that 
recognize the oligosaccharide domain of membrane glycolipids at the cell surface: Upon 
association with lipid rafts, the toxin-receptor complexes have the ability to move retrogradely 
and function as transport vehicles from the plasma membrane to the ER, via Golgi network 
(Cho et al, 2012; Lencer & Saslowsky, 2005). At the C-terminus of their A2 domain, CT and 
LT contain a KDEL or a KDEL-like (RDEL) sequence (known ER retention and retrieval 
signals that bind to KDEL-receptors (Munro & Pelham, 1987; Raykhel et al, 2007)), 
respectively, that emerge beyond the boundaries of the B-subunits and were shown to be 
important for toxicity of those toxins (Hazes & Read, 1997; Lencer et al, 1995). AB5 toxins 
arrive the ER as fully folded stable molecules and are thus poor substrates for dislocation 
processes. The key to their toxicity hence lies on the ability to unfold upon ER arrival (Pande 
et al, 2007; Spooner & Lord, 2012). The molecular mechanisms involved in toxin unfolding 
and translocation are yet mostly obscure. Nevertheless, ER chaperones such as the redox-
dependent chaperone, protein disulphide isomerase (PDI) were reported to be involved in 
the release of the A1 fragment (Taylor et al, 2011; Tsai et al, 2001) and the Sec61 translocon 
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and the derlin-1-Hrd1 complex to be involved in toxin translocation to the cytosol (Bernardi et 
al, 2008; Bernardi et al, 2010; Koopmann et al, 2000; Schmitz et al, 2000). Once at the 
cytosol, the A1 fragment must refold and escape the ultimate destination of the ER 
associated degradation (ERAD) pathway: the proteasomal degradation (Spooner & Lord, 
2012; Wernick et al, 2010). The catalytic portions of these ER-trafficking toxins have an 
unusual low lysine contents which presumably helps them to escape ubiquitination and 
subsequent proteasomal degradation (Hazes & Read, 1997). 
 
Box 3. Cholera toxin 
Cholera toxin (CT) is secreted by the bacterium Vibrio cholerae the causative agent of cholera disease. CT is secreted in the 
intestinal lumen and acts on intestinal epithelial cells causing profuse, watery diarrhea and vomiting. CT is a hetero-hexameric 
protein complex composed of a catalytic subunit (A) bound to a pentameric ring shaped structure of identical (B) subunits 
responsible for the binding of the toxin to target cells 
(Wernick et al, 2010). CT binds to the ganglioside GM1 
(monosialotetrahexosylganglioside) found in the plasma 
membrane microdomains (lipid rafts) (Fujinaga et al, 2003), 
and can cluster five GM1 molecules at once due to the ring-
like pentameric structure of its binding domain (Merritt et al, 
1994). Endocytosis of the toxin complex from the plasma 
membrane to early endosomes can occur by various 
mechanisms involving clathrin- and caveolin-dependent and 
independent mechanisms, and is followed by traffic of the 
toxin to early and recycling endosomes (Massol et al, 2004; 
Orlandi & Fishman, 1998; Torgersen et al, 2001). From the 
recycling endosomes, CT travels to the TNG, through an yet 
not completely understood process,  but in general believed 
to be independent of the late endosomal pathway (Amessou 
et al, 2007; Ganley et al, 2008; Mallard et al, 2002), from 
where it is transported to the ER, apparently bypassing the 
Golgi-cisternae (Feng et al, 2004). Once at the ER, through 
the action of the chaperone protein disulphide isomerase 
(PDI), the catalytic domain unfolds and is released from the 
rest of the toxin (Tsai et al, 2001). The unfolded domain is 
then transferred across the ER membrane into the cytosol, 
presumably using the Sec61 channel (Schmitz et al, 2000), 
or the derlin-1–Hrd1 complex (Bernardi et al, 2008; Bernardi 
et al, 2010). Upon entry on the cytosol, the CT catalytic 
domain is refolded to a stable enzymatically active 
conformation and escapes proteasomal degradation, 
possibly with the help of cytosolic chaperones (Ampapathi 
et al, 2008; Pande et al, 2007; Wernick et al, 2010). At the 
cytosol, CT binds to NAD and catalyzes the ADP ribosylation of GTP-binding protein G of the adenylate cyclase complex 
(Cassel & Selinger, 1977; Spangler, 1992) leading to its super-activation and thus increasing intracellular cAMP concentrations 
interfering with several intracellular signalling pathways that lead to deregulation of intestinal fluid homeostasis (Viswanathan et 
al, 2009).  
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3.3.3. Pseudomonas exotoxin A: the double-route toxin 
So far, the PE is the only example of a toxin reported to be able to translocate into the 
cytosol from the endosomal compartment and also to follow the retrograde pathway and 
translocate from the ER (Morlon-Guyot et al, 2009; Weldon & Pastan, 2011). Upon receptor-
mediated endocytosis, the toxin reaches the endosomal compartment, where exposure to 
the low endosomal pH induces major conformational changes within the toxin (Farahbakhsh 
et al, 1987; Jiang & London, 1990; Mere et al, 2005). From this step two different scenarios 
have been described: i) the entire toxin inserts and translocates across the endosomal 
membrane in a process driven by ATP hydrolysis (Alami et al, 1998; Jiang & London, 1990; 
Mere et al, 2005; Morlon-Guyot et al, 2009; Taupiac et al, 1996) or ii) the toxin can be 
proteolytically processed (by furin) (Inocencio et al, 1994) and reduced (presumably by PDI 
or PDI like enzyme) (McKee & FitzGerald, 1999) generating a 37 kDa C-terminal fragment 
(lacking the receptor binding domain) which is retrogradely transported to the ER and 
translocated into the cytosol using ER machinery (Jackson et al, 1999; Ogata et al, 1990; 
Smith et al, 2006; Yoshida et al, 1991). 
The relevance of each of the described pathways in PE toxicity is still controversial. 
Data from Morlon-Guyot and colleagues indicate that PE processing is dispensable for cell 
intoxication and that cytotoxicity results largely from the endosomal translocation of the entire 
toxin (Morlon-Guyot et al, 2009). However, several lines of evidence support the importance 
of the retro translocation from the ER for toxicity. At its C-terminus, PE contains a REDLK 
sequence that resembles the ER retrieval motif KDEL (Chaudhary et al, 1990). Deletion or 
the REDLK sequence significantly reduces PE toxicity (Chaudhary et al, 1990), and 
replacement of the REDLK sequence by KDEL results in an increased toxicity (Seetharam et 
al, 1991). In addition, the use of antibodies preventing the retrograde transport of the KDEL 
receptor from the Golgi complex to the ER resulted in reduced PE cytotoxicity (Jackson et al, 
1999). Furthermore, treatment with drugs that disrupt the Golgi - ER transport protected cells 
from PE intoxication (Seetharam et al, 1991; Yoshida et al, 1991). Therefore, additional 
studies are needed in other in order to fully understand the intricate mechanisms of PE 
intoxication.  
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B. AIP56 toxin  
1.  AIP56: a key virulence factor of Photobacterium damselae piscicida  
AIP56 (apoptosis inducing protein of 56 kDa) is an exotoxin secreted by the Gram-
negative Photobacterium damselae piscicida (Phdp), the causative agent of fish 
pseudotuberculosis or photobacteriosis, a bacterial infection that seriously affects warm 
water marine fish species (Romalde, 2002; Romalde & Magarinos, 1997). Due to its wide 
host range, massive mortality, ubiquitous geographical distribution, widespread antibiotic 
resistance and lack of effective vaccines the disease is considered one of the most 
threatening infections in marine culture worldwide (Romalde, 2002; Toranzo et al, 2005). 
Phdp infections are of a necrotizing character and are characterized by generalized 
septicaemia and bacteraemia with exuberant cytopathology with numerous foci of cell 
necrosis (do Vale et al, 2007a). Internally, infected fish exhibit haemorrhagic septicaemia and 
granulomatous lesions in the kidney, spleen and liver (Barnes et al, 2005; Magariños et al, 
1996c; Thune et al, 1993). These granulomatous lesions appear as white tubercles, hence 
the designation of the diseases as pseudotuberculosis, and consist of accumulations of 
bacteria and apoptotic and necrotic cell debris (do Vale et al, 2007a; Magariños et al, 1996c; 
Romalde, 2002). In advanced phases of the disease, lesions in gut lamina propria were also 
observed, which are accompanied by extensive detachment of epithelial linings and 
shedding of isolated enterocytes that undergo anoikis (do Vale et al, 2007b).  
Different studies have identified several factors/mechanisms participating in Phdp 
virulence (do Vale et al, 2007a; do Vale et al, 2003; do Vale et al, 2005; Magariños et al, 
1996a; Magariños et al, 1994; Magariños et al, 1996b; Magariños et al, 1992; Noya et al, 
1995). However, it is now well established that AIP56 is the main virulence factor of Phdp (do 
Vale et al, 2005), as supported by the fact that: (i) AIP56 is only secreted by Phdp virulent 
strains, (ii) passive immunization of sea bass with anti-AIP56 antibodies provides significant 
protection against Phdp challenge and, (iii) intraperitoneal injection of AIP56 reproduces the 
pathology of the disease and leads to a dose-dependent lethality (do Vale et al, 2007a; do 
Vale et al, 2005).  
AIP56’s virulence mechanism relies on the destruction of the host phagocytic cells 
(macrophages and neutrophils) (do Vale et al, 2005) through a process involving both the 
extrinsic and intrinsic apoptotic pathways, with activation of caspases -8, -9, and -3 and with 
the involvement of mitochondria (with loss of mitochondrial membrane potential, release of 
cytochrome c and over production of reactive oxygen species) (Costa-Ramos et al, 2011). 
This simultaneous targeting of both professional phagocytes is a powerful pathogenic 
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strategy that inevitably leads to a severe depletion in the number of these leukocytes, 
causing not only the impairment of phagocytosis (do Vale et al, 2007a; do Vale et al, 2007b; 
do Vale et al, 2003; do Vale et al, 2005) but also affecting cytokine production (Nascimento 
et al, 2007a; Nascimento et al, 2007b). The dramatic weakening of the host immune 
responses allows the rapid spread of the bacteria throughout the infected host, with massive 
extracellular multiplication occurring mainly in spleen and head kidney, hence contributing to 
the establishment of a septicaemic infection (do Vale et al, 2007a; do Vale et al, 2003). The 
bacterial spread with colonization of the organs triggers a local inflammatory response with 
the recruitment to the infectious foci of phagocytic cells that also undergo AIP56-induced 
apoptosis (do Vale et al, 2007a; do Vale et al, 2003; Silva, 2010). 
Under normal conditions apoptotic cells are efficiently phagocytosed by scavenger 
cells, mainly macrophages, thus preventing necrotic cell death with autolysis (Maderna & 
Godson, 2003; Ren & Savill, 1998; Silva et al, 2008). However, in the context of Phdp 
infections, due to the depletion of macrophages, there is an inefficient clearing of the 
apoptosing cells, and the AIP56-induced phagocyte apoptosis culminates in secondary 
necrosis, with the release of their highly cytotoxic content (do Vale et al, 2007a). One of the 
most potent proteolytic and destructive enzymes is the neutrophil elastase, which was found 
in the blood of fish with terminal infection and whose levels correlate with the ones of active 
caspase-3 (do Vale et al, 2007a).  
AIP56 toxin is the most abundant protein of mid-exponential phase virulent Phdp 
culture supernatants (do Vale et al, 2005) but, more importantly, during the course of 
infection it is abundantly secreted and systemically distributed, being detected in the plasma 
of the diseased animals as well as in areas with accumulation of apoptosing cells, namely in 
the spleen, head kidney and gut (do Vale et al, 2007a). Being an exotoxin, AIP56 exerts its 
cytotoxic activity at a distance without requiring direct contact between the pathogen and the 
target cells, which is decisive for the rapid course and high mortality of acute fish 
pasteurellosis. This AIP56-dependent pathogenicity mechanism is central in the 
etiopathogenesis of the disease and results in two effects that operate in concert against the 
host: evasion of the pathogen from a crucial defence mechanisms and the release of 
cytotoxic molecules causing tissue damage (do Vale et al, 2007a). 
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2.  AIP56 primary structure and homologies  
AIP56 is a plasmid-encoded exotoxin, synthesized as a precursor protein of 520 
amino acids with an N-terminal cleavable signal peptide of 23 residues (Silva et al, 2010). 
When first characterized, (do Vale et al, 2005), the protein was annotated as a 513 amino 
acid precursor protein with a 16 amino acid residues cleavable signal peptide. However, an 
alternative GTG start codon exists 21 nucleotides upstream of the previously annotated ATG 
start codon (Silva et al, 2010). AIP56 has a conserved zinc metalloprotease signature 
(HEXXH) (Jongeneel et al, 1989), consisting of the amino acid sequence HEIVH, and only 
two cysteine residues (do Vale et al, 2005). Several AIP56 homologue proteins, from 
different organisms (Figure 1.10), were retrieved by Blast analysis of AIP56 against the non-
redundant protein sequences database (Silva et al, 2010). The retrieved hits include full-
length uncharacterized homologues of Vibrio species and Arsenophonus nasoniae (Wilkes et 
al, 2010), bacteria pathogenic to aquatic organisms and wasps, respectively. The N-terminal 
region (first 324 amino acids) of AIP56 also shares homology with NleC (do Vale et al, 2005; 
Silva et al, 2010), a type III secreted effector present in several enteric pathogenic bacteria, 
while the C-terminal region was found to be identical to an uncharacterized hypothetical 
protein of Acrythosiphon pisum bacteriophage APSE-2 (Degnan et al, 2009) and to the C-
terminal of a recently annotated hypothetical protein of the monarch butterfly Danaus 
plexippus.  
Recently, the AIP56 N-terminal homologue, NleC, was shown to be a zinc dependent 
metalloprotease with specific activity towards NF-κB p65. This cleavage led to NF-κB 
inactivation and consequent repression of NF-κB-dependent gene transcription, particularly 
inhibiting the tumour necrosis factor (TNF)-α induced interleukin (IL)-8 expression and thus 
contributing to the dampening of the host inflammatory response during infection (Baruch et 
al, 2010; Muhlen et al, 2011; Pearson et al, 2011; Sham et al, 2011; Yen et al, 2010).  
Although the pathological consequences of AIP56 have been well studied and 
documented, very little is known about its structure and how it exploits the host cellular 
machinery to reach its cellular targets and kill the cells. 
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C- Nuclear factor-κB (NF-κB)  
1. Overview 
The nuclear factor-κB (NF-κB) is a family of transcription factors consisting of homo- 
or heterodimers formed by association of different members of the Rel/NF-κB family. The 
NF-κB was first identified as a protein that binds to a specific decameric DNA sequence (ggg 
ACT TTTC C) within the intronic enhancer of the immunoglobulin kappa light chain in mature 
B and plasma cells (Sen & Baltimore, 1986). Presently, it is acknowledged that these 
proteins regulate the expression of hundreds of genes that are associated with diverse 
cellular processes, such as development, cellular growth and apoptosis, as well immune and 
inflammatory responses thereby playing a central role in the host response to infection by 
microbial pathogens (Gilmore & Wolenski, 2012; Le Negrate, 2012; Neish & Naumann, 2011; 
Rahman & McFadden, 2011; Vallabhapurapu & Karin, 2009).  
Rel/NF-κB proteins are evolutionarily conserved from the fruit fly Drosophila 
melanogaster to humans (Gilmore & Wolenski, 2012; Wang et al, 2006). More recently, 
Rel/NF-κB homologues were also found in simple organisms such as sea anemones and 
corals (Meyer et al, 2009; Shinzato et al, 2011; Wolenski et al, 2011), sponges (Gauthier & 
Degnan, 2008) and in the horseshoe crab, Carcinoscorpius rotundicauda, considered to be a 
living fossil (Wang et al, 2006). Despite there is a paucity of information on the molecular 
components and regulation of the most primitive NF-κB signalling pathways, their 
evolutionary conservation underlines the pivotal role of NF-κB pathways in a multitude of 
important cellular processes (Gilmore & Wolenski, 2012). 
 
2. The NF-κB family of transcription factors 
Transcriptionally active NF-κB dimers are formed by combinatorial association of five 
subunits: NF-κB 1 (p50), NF-κB 2 (p52), RelA (p65), RelB and c-Rel (Figure 1.11). Fifteen 
possible combinations can arise from these five different proteins and this multiplicity 
contributes to transcriptional selectivity of the NF-κB response (Oeckinghaus & Ghosh, 2009; 
Smale, 2012). All these dimers share the ability to bind a family of DNA-binding sites (9-11 
base pairs in length) collectively known as κB sites (Natoli et al, 2005). Each homo- or 
heterodimer may be activated in a cell type- and stimulus-specific manner and, while most 
dimer combinations are abundant in diverse cell types, others are rare and a few have not 
been detected directly. Nevertheless, it remains likely that the rare ones (such as c-Rel:RelB 
heterodimer) also exist in some cells under specific regulatory conditions (Ghosh et al, 2012; 
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Smale, 2012). The term NF-κB commonly refers specifically to the p50/p65 heterodimer 
since it is the most abundant in most cells and was the first NF-κB dimer to be identified 
(Gilmore, 1999). 
 
 
Figure 1.11. Members of the NF-κB transcription factor family. The five protein members share a highly conserved Rel 
homology domain (RHD) at their N-terminal region that can be divided into three structural regions: the N-terminal domain 
(NTD) that contains sequences required for dimerization and nuclear localization, the dimerization domain (DD) that mediates 
the association of NF-κB subunits to form combinatorial dimers, and the nuclear localization signal (NLS) (in grey). The RelA, 
RelB and c-Rel family members at C-terminal region contain the transcriptional activation domain (TAD). The p50 and p52 are 
synthesized as large precursors (p100 and p105, respectively) which undergo proteolytic processing. These proteins lack a C-
terminal TAD and instead contain a glycine-rich region (GRR), remnant of their processing from p105 and p100 precursors. IκB 
proteins are characterized by the presence of multiple ankyrin repeats and include the p105 and p100 proteins. (From (Ghosh et 
al, 2012)) 
 
The proteins in the NF-κB family are related through the highly conserved N-terminal 
region, called Rel homology domain (RHD). This domain is roughly 300 residues in length 
and is responsible for the most critical NF-κB functions (Ghosh et al, 2012). It can be divided 
into three structural regions: the N-terminal domain (NTD), the dimerization domain (DD) and 
the nuclear localization signal (NLS) (Figure 1.11). The DD alone mediates association of 
NF-κB subunits to form dimers and together with the NTD perform the DNA binding function, 
which is further modulated by additional post-translational modifications, including 
phosphorylation and acetylation (Ghosh et al, 2012; Huang et al, 2010; Zheng et al, 2010). 
Based on sequences C-terminal to the RHD, the proteins of this family can be divided into 
two classes: (i) the p65, c-Rel and RelB, which contain a C-terminal transactivation domain 
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(TAD) essential for transcriptional activation, and (ii) the p50 and p52 proteins, which lack the 
TAD and instead contain a C-terminal glycine-rich region (Ghosh et al, 2012; Gilmore & 
Wolenski, 2012; Smale, 2012) (Figure 1.11). The TAD region mediates the interaction with 
various components of the transcriptional apparatus, including TATA-binding protein, 
transcription factor IIB, p300, and CBP transcriptional co-activators and is not conserved, at 
the amino acid level, between the different NF-κB subunits (Chen & Greene, 2004). Thus, as 
a consequence of their lack of a C-terminal TAD, NF-κB dimers composed only of p50 and/or 
p52 subunits fail to activate transcription (Ghosh et al, 2012). The p50 and p52 proteins are 
synthesized as large precursors, p105 and p100 which undergo processing with selective 
degradation of their C-terminal region containing ankyrin repeats (Figure 1.11). Processing is 
mediated by the ubiquitin/proteasome pathway and in the case of p100 processing is a 
postranslational and signal induced event whereas in the case of p105 processing is 
constitutive (Ghosh et al, 2012; Sun, 2012).  
 
3. NF-κB activation and gene expression 
In quiescent cells, NF-κB dimers are held captive in the cytoplasm via non-covalent 
interactions with a class of proteins called inhibitors of NF-κB (IκBs ) (Hinz et al, 2012) 
(Figure 1.11). These NF-κB inhibitors are characterized by the presence of multiple ankyrin 
repeats which mediate the association between IκB and NF-κB dimers. As with the Rel/NF-
κB proteins, there are several IκB proteins, with different affinities for individual Rel/NF-κB 
complexes, which are regulated and expressed differently (Hinz et al, 2012). The IκB 
proteins also include the NF-κB precursor’s p105 and p100, which contain at their C-terminal 
halves multiple ankyrin repeats that allow them to display an IκB-like function (Figure 1.11). 
These ankyrin repeats interact with the DD and NLS regions of NF-κB subunits, thus 
preventing their translocation to the nucleus (Ghosh et al, 2012; Hinz et al, 2012; 
Oeckinghaus & Ghosh, 2009). Activation of NF-κB involves phosphorylation and degradation 
of IκB or IκB-like proteins, freeing NF-κB dimers to migrate to the nucleus where they bind to 
κB sites within the promoters/enhancers of target genes, and regulate transcription through 
the recruitment of co-activators and co-repressors (Gilmore & Wolenski, 2012; Hayden & 
Ghosh, 2008; Wang et al, 2006; Wolenski et al, 2011). Many different stimuli involved in 
several signalling cascades lead to activation of NF-κB transcription factors. Nevertheless, in 
general terms, NF-κB activation is controlled by two main signalling pathways: the canonical 
and the non-canonical pathway, which differ on the stimuli and on the activated NF-κB 
dimers (Figure 1.12) (Oeckinghaus & Ghosh, 2009). 
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Figure 1.12. NF-κB activation pathways. Under resting conditions, NF-κB dimers are sequestered in the cytoplasm bound to 
inhibitory IκB proteins. The canonical NF-κB activation (left) is induced manly by inflammatory stimuli including activation of TNF 
receptor-1 (TNFR1), IL-1 receptor (IL-1R) and Toll-like receptors (TLRs). Ligand binding to these receptors triggers signalling 
cascades involving several adaptor and signal transduction proteins that culminate in the activation of the protein kinase TAK-1 
which in turn phosphorylates and activates the IκB kinase (IKK) complex (consisting of two catalytically active kinases, IKKα and 
IKKβ, and a regulatory subunit NEMO). Activated IKK phosphorylates IκB proteins bound to NF-κB dimers, mostly p65-
containing heterodimers. Phosphorylated IκB proteins are targeted for ubiquitination and proteasomal degradation, freeing NF-
κB dimers that translocate to the nucleus. In contrast, non-canonical NF-κB activation (right) leads to nuclear translocation of 
p100-containing dimers and is induced by a subset of TNF family cytokines, such as CD40 ligand, B-cell activating factor 
(BAFF) and lymphotoxin-β (LT-β) causing activation of the NF-κB-inducing kinase (NIK). NIK activation leads to phosphorylation 
and activation of the IKKα complexes, which in turn phosphorylate C-terminal residues in p100 leading to its ubiquitination and 
proteasomal processing into transcriptionally competent p52/RelB complexes that translocate to the nucleus and induce target 
gene expression. (BAFFR: B-cell activating factor receptor, LT-βR: lymphotoxin-β receptor, TRAF: TNFR-associated factor, 
MYD88: myeloid differentiation primary response protein 88; TIRAP: Toll-interleukin 1 receptor domain-containing adaptor 
protein; RIPs: receptor-interacting proteins) (Adapted from (Chen, 2005)) 
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In the canonical pathway, the inducible degradation of IκBs, particularly IκBα, leads to 
nuclear translocation of various NF-κB complexes, comprising dimeric combinations of p65, 
c-Rel, RelB and p50, from which p50/p65 and c-Rel:p50 are the predominant activated dimers 
(Vallabhapurapu & Karin, 2009) (Figure 1.12). This pathway is considered to be the central 
initiating event of host responses to invasion by microbial pathogens and, typically, responds 
to (i) proinflammatory cytokines, which bind to cytokine receptors, such as IL-1 receptor (IL-
1R) and TNF receptor-1 (TNFR1), or to (ii) pathogen-associated molecular patterns 
(PAMPs), including microbial and viral products, which bind to pattern-recognition receptors 
(PRRs), such as Toll-like receptors (TLRs), RIG-I-like receptors, nucleotide oligomerization 
domain (NOD)-like receptors, and C-type lectin receptors (Le Negrate, 2012; Neish & 
Naumann, 2011; Vallabhapurapu & Karin, 2009). Ligand binding to these receptors, triggers 
distinct signalling cascades that use multiple adaptors (including TNFR-associated factors 
(TRAFs), myeloid differentiation primary response protein 88 (MYD88) and Toll-interleukin 1 
receptor domain-containing adaptor protein (TIRAP)) and intermediate transducing 
molecules (including IL-1 receptor-associated kinases (IRAK) and receptor-interacting 
proteins (RIPs)) converging in activation of the IκB kinase (IKK) complex (Oeckinghaus & 
Ghosh, 2009). The IKK complex is composed by two highly homologous kinase subunits 
IKKα and IKKβ and a regulatory subunit IKKγ (also named NEMO) (Israel, 2010) (Figure 
1.12). Signal-induced activation of this complex, results in phosphorylation of IκBα (bound to 
NF-κB dimers) leading to its polyubiquitination subsequent proteasomal degradation, 
exposing NF-κB nuclear localization domain and leading to nuclear translocation of the 
liberated NF-κB dimers (Oeckinghaus & Ghosh, 2009). The IKK complex may also 
phosphorylate the TAD regions of p65 and c-Rel, while in the cytoplasm, thus also regulating 
their transcriptional activity. Once at the nucleus, NF-κB dimers up-regulate the expression of 
a battery of genes, mostly related with the immune and inflammatory responses, including 
chemotactic chemokines (such as IL-8 and monocyte chemoattractant protein 1), 
immunoregulatory cytokines (such as TNF-α and IL-1) and neutrophil adhesion proteins 
(such as the Intracellular Adhesion Molecule). Furthermore, the secreted TNF-α and IL-1β 
also start a feedback loop for a second phase of NF-κB activation that continues the 
induction of robust immune responses (Le Negrate, 2012; Neish & Naumann, 2011; 
Vallabhapurapu & Karin, 2009).  
The non-canonical NF-κB activation pathway relies on the inducible processing of the 
ankyrin repeats of the p100 subunit through the activation of the NF-κB-inducing kinase (NIK) 
(Razani et al, 2011; Sun, 2011; Sun, 2012) (Figure 1.12). NIK activation triggers IKKα 
phosphorylation and activation. The NIK-activated IKKα phosphorylates NF-κB p100 within 
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its C-terminal region (containing the ankyrin repeats), leading to its polyubiquitination and 
subsequent proteasomal processing into the mature p52 form. As p100 preferentially 
interacts with RelB, the processing of p100 not only generates p52 but also causes p52/RelB 
nuclear translocation (Razani et al, 2011; Sun, 2011; Sun, 2012). Non-canonical NF-κB 
activation is involved in the regulation of lymphoid organogenesis, B-cell survival and 
maturation, dendritic cell activation, and bone metabolism (Razani et al, 2011; Sun, 2011; 
Sun, 2012). In contrast to the canonical activation, which responds to signals elicited by 
diverse stimuli, non-canonical NF-κB activation, is restricted to specific members of the TNF 
cytokine family including B-cell activating factor (BAFF), CD40 ligand, lymphotoxin-β, TNFR2 
ligands among others (Sun, 2011). A common feature on the non-canonical NF-κB-
stimulating receptors is the possession of a TRAF-binding motif, involved in the recruitment 
of TRAF members (particularly TRAF2 and TRAF3) to the receptor complex. This 
recruitment is essential to the activation of NIK and to the subsequent p100 processing (Sun, 
2011). 
The mechanisms involved in NF-κB activation and in the regulation of its 
transcriptional activity are of remarkable complexity and are not yet completely understood. 
The intricacy of these mechanisms transcends the signalling cascades that lead to the 
release of NF-κB proteins from their inhibitory IκB proteins. Additional posttranslational 
modifications of NF-κB subunits, including phosphorylation, acetylation, ubiquitination and 
methylation, also modulate target gene specificity and transcriptional activity, adding another 
layer to the regulation of NF-κB activity (Chen & Greene, 2004; Huang et al, 2010; Perkins, 
2006). 
Deregulation of NF-κB activity is a common scenario in many diseases. Uncontrolled 
NF-κB activation is often associated with multiple inflammatory, autoimmune and cancer 
diseases (DiDonato et al, 2012; Rayet & Gelinas, 1999; Staudt, 2010). Furthermore, and 
given the central role of NF-κB in coordinating host immune responses, many successful 
pathogens have acquired sophisticated mechanism to shut off NF-κB signalling by 
developing subversive proteins or hijacking host signalling molecules (Le Negrate, 2012; 
Neish & Naumann, 2011; Rahman & McFadden, 2011). 
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AIP56 was identified as an exotoxin secreted by the fish bacterial pathogen 
Photobacterium damselae piscicida (Phdp). It acts by triggering apoptosis in macrophages 
and neutrophils, resulting in lysis of these phagocytes by post-apoptotic secondary necrosis. 
This AIP56-induced phagocyte cell death results not only in an impairment of host immune 
defenses, through the destruction of phagocytes, but also in the release of the cytotoxic 
contents of the phagocytes, leading to tissue damage and contributing to the formation of the 
necrotic lesions observed in the diseased animals. 
Although in vivo studies showed that AIP56 is a key virulence factor of Phdp, many 
questions remain to be answered regarding the AIP56 molecular mechanism(s) of action. 
Analysis of the AIP56 sequence suggests the existence of two domains/subunits, as in many 
other bacterial toxins such as diphtheria and the clostridial neurotoxins, which have an 
enzymatic domain responsible for toxicity and a binding domain responsible for cell binding 
and internalization. Within its N-terminal region AIP56 also processes a zinc binding 
signature, typical of zinc-dependent metalloproteases, which would presumably be involved 
in the toxin’s catalytic activity. 
In this thesis, we aimed at extending the characterization of AIP56 by: 
• 1. Analysing AIP56 catalytic activity and establishing its relevance for the toxin’s 
biological activity 
• 2. Identifying AIP56 molecular target(s) 
• 3. Investigating the AIP56 domain structure and defining the role played by the 
AIP56 domains 
• 4. Attempting to solve AIP56 crystal structure 
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1. Recombinant proteins 
The recombinant proteins used in this work are listed in table 3.1. Some were 
expressed in E. coli while others were synthesized in vitro as 35S-labeled proteins using 
rabbit reticulocyte lysates. 
Table 3.1. Recombinant proteins used in this study. 
Name Description Expression system 
AIP56 Wild type, full length AIP56 toxin E. coli 
AIP56AAIVAA AIP56 mutant in the zinc metalloprotease signature (His
165, 
Glu166, His169 and His170 mutated to Ala) E. coli 
AIP561-285 AIP56 N-terminal portion (Asn1-Phe285) E. coli 
AIP56286-497 AIP56 C-terminal portion (Phe286-Asn497) E. coli 
AIP561-285C262S AIP561-285 cysteine mutant (Cys262 mutated to Ser) E. coli 
AIP56286-497C298S AIP56286-497 cysteine mutant (Cys298 mutated to Ser) E. coli 
LF11-263∙AIP561-261 
Chimera consisting of the amino-terminal portion of anthrax 
lethal factor (Val11-Arg263) fused to AIP56 N-terminal region 
(Asn1-Phe261) 
E. coli 
LF11-263∙AIP56299-497 
Chimera consisting of the amino-terminal portion of anthrax 
lethal factor (Val11-Arg263) fused to AIP56 C-terminal region 
(Thr299-Asn497) 
E. coli 
NleC Type III secreted effector from enteropathogenic bacteria 
homologous to AIP56 N-terminal region E. coli 
NleC1-270∙AIP56251-497 Chimera consisting of the first 270 amino acid residues (Met
1-
Glu270) of NleC fused to AIP56 C-terminal region (AIP56251-497) E. coli 
LF11-263∙NleC Chimera consisting to the amino- terminal portion of anthrax 
lethal factor (Val11-Arg263) fused to NleC E. coli 
LF11-263∙NleCMut LF
11-263∙NleC chimera cysteine mutant where Cys107 and Cys149 
of NleC were mutated to His and Tyr, respectively 
E. coli 
sbp65Rel Sea bass NF-κB p65 Rel homology domain (Met1-Arg188) E. coli / Rabbit reticulocyte 
sbp65RelC39A Sea bass NF-κB p65 Rel homology domain Cys39 mutant Rabbit reticulocyte 
sbp65RelE40A Sea bass NF-κB p65 Rel homology domain Glu40 mutant Rabbit reticulocyte 
sbp65C39AE40A Sea bass NF-κB p65 Rel homology domain Cys
39-Glu40 double 
mutant 
Rabbit reticulocyte 
 
 
1.1. Constructs 
For E. coli protein expression, DNA coding sequences were cloned into the NcoI/XhoI 
restriction sites of pET-28a(+) vector (Novagen) in frame with a C-terminal 6xHis-tag. For 
production of 35S-labeled proteins, untagged versions were engineered using a reverse 
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primer that introduces a stop codon before the 6xHis-tag of the pET-28a(+)vector. The 
primers used are listed in table 3.2. 
Mutated versions of the proteins were obtained by site-directed mutagenesis using 
QuickChange Site-Directed Mutagenesis Kit (Stratagene) following the manufacturer 
instructions. 
Table 3.2. Primers used in this study. Restriction enzyme recognition sequences are underlined. 
Primer designation Nucleotide sequence 5′→3′ 
AIP56EHECFw1BstBI CGCTTCGAAAGGCTGGGTACGATCAGTGACCGATATGAGGCTTCGCCTGACTTCGGCACCCTGACCTCTTTT 
AIP56Fw4NcoI GCGCCATGGACAACGATAAACCAGATGCAAGC 
AIP56Fw6NcoI GCGCCATGGTTCTCCCTAGCGCTAGCGCCG 
AIP56Rv5XhoI GCGCTCGAGATTAATGAATTGTGGCGCGTGGG 
AIP56Rv7XhoI GAGCTCGAGAAAGGCGCCGCCCCCGTTG 
AIP56Rv9XhoI GAGCTCGAGAAAAGAGGTCAGGGTGCCGAA 
CtermAIP56Fw1SacI GCGGAGCTCACTTTTGATGTACTAAATCGAAT 
DLp65Fw1NcoI  CGCCCATGGAAGGTGTGTATGGATGGAGCCTG 
DLp65Rv2XhoI GCGCTCGAGTCACCTGTTGTCATAGATGGGCTGCG 
DLp65Rv4XhoI GCGCTCGAGCCTGTTGTCATAGATGGGCTGCG 
EHECFw1NcoI CATGCCATGGAAATTCCCTCATTACAG 
EHECRv1XhoI CCGCTCGAGTTGCTGATTGTGTTTGTC 
LFFw1NcoI GCGCCATGGTAAAAGAGAAAGAGAAAAATAAAG 
LFRv1SacI CGCGAGCTCCCGTTGATCTTTAAGTTCTTC 
NleCFw1SacI GCGGAGCTCATGGAAATTCCCTCATTACA 
NtermAIP56Fw1SacI GCGGAGCTCAACAACGATAAACCAGATGCAAGC 
 
AIP56 
Recombinant AIP56 was expressed using the plasmid pETAIP56H+ (do Vale et al, 
2005). This plasmid contains the AIP56 coding sequence including the 16-amino acid signal 
peptide that is removed from the protein upon secretion yielding a mature recombinant AIP56 
(do Vale et al, 2005). 
AIP56AAIVAA 
The plasmid (pETAIP56AAIVAA) coding for a mutated version of AIP56, in which His165, 
Glu166, His169, and His170 of the zinc-binding signature were replaced by Ala, was obtained by 
site-directed mutagenesis of the pETAIP56H+ plasmid (do Vale et al, 2005). As AIP56AAIVAA 
could not be produced as a soluble protein (see section 1.2 below) a construct coding for 
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mature AIP56AAIVAA (lacking the signal peptide) was produced using pETAIP56AAIVAA as 
template and the AIP56Fw4NcoI/AIP56Rv5XhoI primer combination. 
AIP561-285, AIP56286-497, AIP561-285C262S and AIP56286-497C298S  
Plasmids coding for truncated versions of AIP56 were designed based on the 
chymotrypsin cleavage site (see section 2.6). pETAIP56H+ (do Vale et al, 2005) was 
subjected to PCR amplification using primers AIP56Fw4NcoI/AIP56Rv7XhoI for AIP561-285 
and AIP56Fw6NcoI/AIP56Rv5XhoI for AIP56286-497. PCR fragments were cloned into pET-
28a(+) in frame with a C-terminal His-tag, yielding pETAIP561-285 and pETAIP56286-497. 
Plasmids pETAIP561-285C262S and pETAIP56286-497C298S, coding for mutated versions of AIP561-
285 and AIP56286-497, in which Cys262 or Cys298 were mutated to Ser (AIP561-285C262S or 
AIP56286-497C298S), were obtained by site directed mutagenesis of pETAIP561-285 or 
pETAIP56286-497. 
NleC 
The NleC-coding sequence was amplified by PCR with primers EHECFw1NcoI and 
EHECRv1XhoI using total DNA (Sambrook & Russel, 2001) from E. coli O157:H7 strain 4462 
as template. PCR products were cloned into pET-28a(+) in frame with a C-terminal 6xHis-tag 
yielding pETNleC. 
NleC1-270∙AIP56251-497 
For production of a chimeric protein consisting of NleC1-270 fused to AIP56251-497, the 
sequence coding for NleC1-270 was amplified from pETNleC (see above) using the 
EHECFw1NcoI/ EHECRv1XhoI primer combination and the sequence coding for AIP56251-497 
was amplified from pETAIP56H+ (do Vale et al, 2005) using primers AIP56EHECFw1BstBI 
and AIP56Rv5XhoI. The PCR products were cloned into the pGEM-T-easy vector (Promega) 
and pGEM-T-easy carrying nleC1-270 was digested with BstBI/XhoI to allow ligation of the 
aip56251-497 fragment, excised from the pGEM-T-easy carrying aip56251-497 by digestion with 
BstBI/XhoI. The resulting plasmid was digested with NcoI/XhoI and the excised fragment 
cloned into pET-28a(+), yielding pETNleC1-270∙AIP56251-497. 
LF11-263∙AIP561-261, LF11-263·AIP56299-497, LF11-263·NleC and LF11-263∙NleCMut 
Chimeric proteins consisting of the amino-terminal region of anthrax lethal factor 
(LF11-263) fused to AIP56 N-terminal segment (AIP561-261), AIP56 C-terminal portion (AIP56299-
497) or NleC were constructed. The sequence encoding LF11-263 was amplified with primers 
LFFw1NcoI/LFRv1SacI from plasmid pRSET A containing the LF gene (Zornetta et al, 2010), 
the regions encoding AIP561-261 and AIP56299-497 were amplified from pETAIP56H+ (do Vale 
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et al, 2005) using primer combinations NtermAIP56Fw1SacI/AIP56Rv9XhoI and 
CtermAIP56Fw1SacI/AIP56Rv5XhoI, respectively, and the sequence coding for NleC1-330 
was amplified from pETNleC (see above) with primers NleCFw1Sac1/EHECRv1XhoI. PCR 
fragments were digested with SacI, and LF11-263 ligated to AIP561-261, AIP56299-497 or NleC. 
Ligations were subjected to PCR using the primer combination LFFw1NcoI/AIP56Rv9XhoI 
for LF11-263·AIP561-261, LFFw1NcoI/AIP56Rv5XhoI for LF11-263·AIP56299-497, or 
LFFw1NcoI/EHECRv1XhoI for LF11-263·NleC and PCR products were cloned into pET-28a(+). 
A mutated version of LF11-263∙NleC (LF11-263∙NleCMut), in which the NleC conserved Cys107 and 
Cys149 were replaced by His and Tyr, respectively, was produced by site-directed 
mutagenesis using the plasmid pETLF11-263∙NleC as template. 
sbp65Rel, sbp65RelC39A, sbp65RelE40A and sbp65C39AE40A  
The coding region (Met1-Arg188) of sea bass p65 REL domain (sbp65Rel) was 
amplified by PCR from cDNA obtained as described in (Pinto et al, 2012) using primers 
DLp65Fw1NcoI and DLp65Rv4XhoI. For production of 35S-labeled sbp65Rel the primer 
DLp65Rv2XhoI, that introduces a stop codon before the XhoI restriction site, was used 
instead of DLp65Rv4XhoI, with the purpose of producing a protein without a 6xHis-tag. PCR 
products were cloned in pET-28a(+). Additional sbp65Rel mutants, where Cys39 and/or Glu40 
were mutated to Ala (sbp65RelC39A, sbp65RelE40A, and sbp65C39AE40A, respectively) 
were produced. 
 
1.2. Production of recombinant proteins 
1.2.1. Cell-free expression of 35S-labeled proteins 
Untagged sbp65Rel and sbp65Rel mutants (sbp65RelC39A, sbp65RelE40A, and 
sbp65C39AE40A) were produced as 35S-labeled proteins in rabbit reticulocyte lysates by in 
vitro translation using the TNT T7 Quick Coupled transcription/Translation kit (Promega), in 
the presence of RedivueTM L-[35S] methionine (specific activity of N1000 Ci/mmol) following 
the manufacturer’s instructions. 
 
1.2.2. Protein production in bacteria 
Before large-scale protein production, expression conditions and protein solubility 
were evaluated in small-scale cultures. Expression and solubility of the recombinant proteins 
was assessed by SDS-PAGE analysis. Different E. coli host strains and variable induction 
times and temperatures were tested to select the protocols resulting in higher yield of soluble 
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proteins. With exception of AIP56AAIVAA and AIP561-285C262S that could only be obtained in the 
insoluble fraction as inclusion bodies, the remaining proteins were recovered soluble. 
Recombinant His-tagged proteins were expressed in E. coli BL21(DE3) cells grown in 
Lysogenic broth (LB) (Bertani, 2004) supplemented with 50 μg/ml kanamycin. Protein 
expression was induced with 1 mM Isopropyl β-D-1-thiogalactopyranoside (IPTG) and 
carried out overnight at 17 ºC, except for AIP56AAIVAA, AIP561-285C262S, NleC, LF11-263∙NleC, 
LF11-263∙NleCMut and sbp65Rel, which were expressed at 37 ºC for 4 h. Starting cultures were 
grown overnight at 37 ºC, used to inoculate fresh medium at 1:100 dilution and grown at 37 
ºC. For expressions at 17 ºC, cultures were equilibrated to this temperature prior to induction. 
Protein expression was induced when bacterial cultures reached an OD, at 260 nM, of 
approximately 0.6. Induced bacterial cells were collected by centrifugation and resuspended 
in 50 mM sodium phosphate buffer pH 7.4, 500 mM NaCl, 200 µg/ml lysozyme, 250 µg/ml 
phenylmethylsulfonyl fluoride (PMSF), in the proportion of 5 ml buffer per gram of cell pellet. 
Bacterial cells were lysed by freeze/thaw cycles followed by 20 min incubation on ice, in the 
presence of 10 μg/ml DNase I from bovine pancreas type IV (Sigma) and 10 mM MgCl2, and 
sonication to ensure complete cell lysis. For AIP56 used in crystallization trials, induced 
bacterial cells were resuspended in 50mM sodium phosphate buffer pH 7.4, 500 mM NaCl, 
1% (v/v) Triton X-100, 100 µg/ml PMSF, and immediately lysed by sonication. Soluble and 
insoluble fractions were obtained by centrifugation of the total cell lysates at 16000 g for 15 
min at 4 ºC. 
 
1.3. Protein purification  
Recombinant proteins produced in E. coli were purified by chromatographic methods 
using commercially available chromatography columns and following the manufacturer’s 
instructions. Affinity and ion-exchange chromatography was performed on a Biologic LP 
system (BioRad) at room temperature and size-exclusion chromatography was performed on 
a Biologic DuoFlow system (BioRad) at 4ºC. Before loading onto chromatography columns, 
protein samples were centrifuged at 16000 g for 15 min at 4 ºC. All chromatography buffers 
were filtered through 0.45 µm filters and degassed before use. Purified proteins were 
dialysed against the specified buffers and concentrated by ultrafiltration using Amicon Ultra-
15 Centrifugal Filter Units (Millipore), divided into small aliquots, frozen in liquid nitrogen, and 
stored at -80 ºC. The purification procedures (optimised for each protein) are described 
below. 
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1.3.1. Proteins purified from the soluble faction of induced bacterial cells 
AIP56 
The protocol for AIP56 production was adapted from (do Vale et al, 2005) with some 
modifications to increase protein purity. The soluble fraction of induced bacterial cells, 
obtained as described in section 1.2.2, was supplemented with 20 mM imidazole and loaded 
onto HisTrap HP columns (GE Healthcare). Bound proteins were eluted with step-increasing 
concentrations of imidazole in 50 mM sodium phosphate buffer pH 7.4, 500 mM NaCl. Eluted 
fractions were collected into tubes containing 50 mM sodium phosphate buffer pH 7.4, 500 
mM NaCl, to lower protein and imidazole concentrations and minimize AIP56 precipitation. 
Fractions containing high ratio of AIP56/contaminant proteins, were pooled and dialysed 
overnight at 4 ºC against 2 x 50 volumes of 20 mM Tris-HCl pH 8.0, 200 mM NaCl, using 
Spectra/Por 3 dialysis membrane (Spectrum Laboratories). Dialysed sample was subjected 
to anion-exchange chromatography using a Bio-ScaleTM Unosphere Q cartridge (BioRad). 
Prior to loading into the column, the sample was diluted in 20 mM Tris-HCl to lower NaCl 
concentration to 66 mM. Protein elution was done using a linear NaCl gradient (66 mM to 1 
M) in 20 mM Tris-HCl pH 8.0, at a flow rate of 2.5 ml/min for 60 min, and fractions containing 
AIP56 were pooled, dialysed against 10 mM Tris-HCl pH 8.0, 200 mM NaCl, and stored as 
described above. 
To purify AIP56 for crystallization trials some modifications were introduced, resulting 
in significantly purer and more homogeneous protein preparations. AIP56 was isolated from 
the soluble fraction of induced bacterial cells by affinity chromatography as described above. 
Fractions containing high ratios of AIP56/contaminants were pooled, dialyzed against 20 mM 
Tris-HCl pH 8.0, 300 mM NaCl, using PD-10 desalting columns (GE Healthcare) and stored 
overnight on ice. The second purification step consisted in an anion-exchange 
chromatography using in a Bio-ScaleTM High Q cartridge (BioRad). Before loading onto the 
column, the NaCl concentration was lowered to 100 mM by dilution in 20 mM Tris pH 8.0. 
Protein was eluted using a linear NaCl gradient (100 mM to 1 M) as described above. Eluted 
fractions containing highly pure AIP56 were pooled, dialyzed against 10 mM Tris-HCl pH 8.0, 
200 mM NaCl, concentrated to 10 mg/ml, aliquoted and stored as described above (section 
1.3). 
AIP561-285, AIP56286-497 and AIP56286-497C298S 
Purification of AIP561-285 and AIP56286-497 was done as described above for AIP56. 
Purified AIP561-285 and AIP56286-497 were dialysed against 20 mM Tris-HCl pH 8.0, 200 mM 
NaCl and stored as described above (section 1.3). 
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AIP56286-497C298S was purified by nickel-affinity chromatography as described for 
AIP56, except for the presence of 10% (v/v) glycerol in elution buffers. Selected elution 
fractions were pooled and subjected to size exclusion chromatography using a Sephacryl 
S100 HR column (GE Healthcare) equilibrated in 20 mM Tris-HCl pH 8.0, 200 mM NaCl. 
Protein was eluted in the same buffer, and fractions containing pure AIP56286-497C298S were 
pooled, dialysed against 20 mM Tris-HCl pH 8.0, 200 mM NaCl and 10% (v/v) glycerol, and 
stored as described above (section 1.3). 
NleC 
NleC was purified by affinity chromatography as described for AIP56 but using 20 mM 
sodium phosphate buffer pH 8.0, 500 mM NaCl, with increasing concentrations of imidazole 
for protein elution. Fractions containing low amounts of contaminating proteins were pooled 
and subjected to size-exclusion chromatography (Sephacryl S100 HR column, GE 
Healthcare) in 20 mM Tris-HCl pH 8.0, 50 mM NaCl. Fractions containing NleC were pooled, 
dialysed against 20 mM Tris-HCl pH 8.0, 50 mM NaCl and stored as described above 
(section 1.3). 
NleC1-270∙AIP56251-497 
NleC1-270∙AIP56251-497 was purified by nickel-affinity chromatography followed by anion-
exchange chromatography as described for AIP56. Purified protein was dialysed against 20 
mM Tris-HCl pH 8.0, 200 mM NaCl and stored as described above (section 1.3). 
LF11-263∙AIP561-261, LF11-263·AIP56299-497, LF11-263·NleC and LF11-263∙NleCMut 
LF11-263∙NleC and LF11-263∙NleCMut were purified by nickel-affinity chromatography 
followed by anion-exchange chromatography as described for AIP56. LF11-263∙AIP561-261 and 
LF11-263∙AIP56299-497 were purified by nickel-affinity chromatography as described for AIP56. In 
the case of LF11-263∙AIP561-261, to avoid the formation of protein aggregates, sonication of cell 
lysates was omitted and glycerol (5% (v/v) final concentration) was added to cell lysates and 
affinity chromatography buffers. Purified LF∙AIP56 and LF∙NleC chimeras were dialysed 
against 10 mM Tris-HCl pH 8.0, 200 mM NaCl and stored as described above (section 1.3). 
sbp65Rel 
His-tagged sbp65Rel was purified from the soluble fraction of induced bacterial cells 
by affinity chromatography using HIS-Select Nickel Affinity Gel (Sigma). The protein bound to 
the resin was eluted with increasing concentrations of imidazole in 50 mM sodium phosphate 
buffer pH 7.4, 300 mM NaCl. Fractions containing sbp65Rel were pooled, dialysed against 
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50 mM sodium phosphate buffer pH 7.4, 300 mM NaCl and stored as described above 
(section 1.3). 
 
1.3.2. Proteins purified from the insoluble fraction of induced bacterial cells 
AIP56AAIVAA and AIP561-285C262S were obtained in the insoluble fraction of induced 
bacterial cells and therefore, were subjected to a refolding protocol. Refolding conditions 
were first optimised using AIP56 obtained as inclusion bodies from E. coli cells induced at 37 
ºC (do Vale et al, 2005), because its correct folding could be functionally assessed by testing 
its ability to induce apoptosis in sea bass peritoneal leukocytes. The established protocol 
was applied to AIP56AAIVAA and AIP561-285C262S, and the biochemical and biophysical 
properties of the refolded proteins, determined by Native-PAGE, size-exclusion 
chromatography and circular dichroism spectroscopy (CD), compared to those of AIP56 or 
AIP561-285. 
AIP56AAIVAA 
Inclusion bodies were extracted by washing the insoluble fraction of induced bacterial 
cells (obtained as described in section 1.2.2) with 20 mM sodium phosphate buffer (pH 7.4), 
500 mM NaCl, 1% (v/v) Triton X-100, 5% (v/v) glycerol, 0.5 mM EDTA followed by two 
washes in 20 mM sodium phosphate buffer (pH 7.4), 500 mM NaCl, 5% (v/v) glycerol, 0.5 
mM EDTA; centrifugations were performed at 10000 g for 15 min at 4 ºC. Inclusion bodies 
were solubilized in 8 M urea, 20 mM Tris-HCl pH 8.0, 0.5 M NaCl, 1 mM 2-mercaptoethanol, 
5 mM imidazole and purified by zinc-affinity chromatography (HisTrap HP columns, GE 
Healthcare) under denaturing conditions. The protein was eluted with increasing 
concentrations of imidazole in 8 M urea, 20 mM Tris-HCl pH 8.0, 0.5 M NaCl, 1 mM 2-
mercaptoethanol. Fractions containing AIP56AAIVAA were pooled, quantified by densitometric 
analysis of Coomassie Blue-stained gels (as described below in section 6.3) and 
concentration adjusted to 0.1 mg/ml. The protein was then subjected to refolding through 
dialysis against 3 x 50 volumes of sea bass phosphate saline buffer (sbPBS), 10% (v/v) 
glycerol, at 4 ºC using Spectra/Por 3 dialysis membrane. The refolded protein was purified by 
size exclusion chromatography using a Sephacryl S200 HR column (GE Healthcare) in 20 
mM Tris-HCl pH 8.0, 200 mM NaCl, 10% (v/v) glycerol and fractions containing pure 
AIP56AAIVAA were pooled, dialysed against 10 mM Tris-HCl pH 8.0, 200 mM NaCl and stored 
as described above (section 1.3). 
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AIP561-285C262S 
AIP561-285C262S was purified as described above for AIP56AAIVAA except that size 
exclusion chromatography was performed in a Sephacryl S100 HR column (GE Healthcare) 
and the protein was stored in 20 mM Tris-HCl pH 8.0, 200 mM NaCl, 10% (v/v) glycerol. 
 
1.4. Chemically and enzymatically modified AIP56 
Alkylated AIP56 
In order to disrupt the disulphide bridge linking Cys262 and Cys298 by alkylation, AIP56 
at 63 μM in 20 mM Tris-HCl pH 8.0, 200 mM NaCl, 10 mM DTT was incubated with 5 mM 
iodoacetamide (Sigma) for 30 min at RT, dialysed against 20 mM Tris-HCl pH 8.0, 200 mM 
NaCl and stored as described in section 1.3. Disruption of the disulphide bridge was 
confirmed by reducing and non-reducing SDS-PAGE analysis. 
Nicked AIP56 
In order to obtain nicked AIP56, purified recombinant AIP56 adjusted to 0.6 mg/ml in 
10 mM Tris-HCl pH 8.0 with 200 mM NaCl was incubated with 0.05 mg/ml of chymotrypsin 
for 45 min on ice. The reaction was stopped by addition of 250 μg/ml PMSF. Digestion 
products were applied to a HisTrap HP column (GE Healthcare) and the bound proteins 
eluted with step-increasing concentrations of imidazole in 50 mM sodium phosphate buffer 
pH 7.4, 500 mM NaCl. Elution fractions were analysed under reducing and non-reducing 
SDS-PAGE and the ones containing the two AIP56 digestion fragments linked by a 
disulphide bridge, pooled, dialysed against 10 mM Tris-HCl pH 8.0, 200 mM NaCl and stored 
as described in section 1.3. 
 
1.5. Reconstitution of AIP56 from AIP56 truncates 
Reconstituted AIP56 (AIP56rec) consists of AIP561-285 and AIP56286-497 linked by a 
disulphide bridge. Purified AIP561-285 and AIP56286-497 were mixed in equimolar amounts in 8 
M urea, 1mM DTT, refolded by extensive dialysis against sbPBS and stored as described in 
section 1.3. Formation of the disulphide-bound heterodimer (AIP561-285/AIP56286-497) was 
confirmed by reducing and non-reducing SDS-PAGE analysis. Quantification of the 
heterodimer was performed by densitometric analysis of Coomassie Blue-stained gels (as 
described below section 6.3). 
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2. Biochemical, biophysical and structural characterization  
2.1. Dynamic light scattering  
Dynamic light scattering (DLS) was performed in Zetasizer Nano ZS (Malvern 
Instruments) at 20 ºC in a 45 µL quartz cuvette (Hellma). Stability and homogeneity of 
purified AIP56 (1 mg/ml) in different buffers was evaluated by measuring scattering intensity 
(kilo counts per second) as a function of hydrodynamic diameter (nm) at fixed conditions 
(temperature and pH). 10 mM Tris-HCl pH 8.0 with NaCl concentrations ranging from 100 to 
500 mM with or without glycerol (5 or 10% v/v) were tested. Data analysis was performed 
using the Dispersion Technology Software (DTS) 5.03 (Malvern Instruments). The 
polydispersity index (PI), which is representative of particle width distribution, was used as 
indicator of protein homogeneity and stability (Borgstahl, 2007). 
 
2.2. Size exclusion chromatography 
Protein samples at 0.25 mg/ml in 10 mM Tris-HCl pH 8.0, 200 mM NaCl were 
subjected to analytical size-exclusion chromatography in a Superose 12 10/300 column (GE 
Healthcare) using an ÄKTA Purifier FPLC system (GE Healthcare) at room temperature and 
a 0.5 ml/min flow rate. The column was pre-equilibrated with 10 mM Tris-HCl pH 8.0, 200 
mM NaCl and protein elution was monitored by measuring the absorbance at 280 nm. 
 
2.3. Circular dichroism spectroscopy 
Far UV circular dichroism (CD) spectra were acquired on an Olis DSM 20 circular 
dichroism spectropolarimeter continuously purged with nitrogen, equipped with a Quantum 
Northwest CD 150 Temperature-Controlled cuvette holder and controlled by the Globalworks 
software. Scans were collected between 190 and 260 nm in 1 nm intervals at 20 °C with a 
0.2 mm path-length cuvette. Three scans with an integration time of 4 seconds were 
averaged for each measurement. Protein concentration was determined by absorbance 
measurements as described above. Proteins were dissolved in 10 mM Tris-HCl pH 8.0, 50 
mM NaCl. The results are expressed in terms of mean residue ellipticity [Θ]MRW in deg cm2 
dmol-1, according to the equation [Θ]MRW = Θobs * Mw * 100 / (l * c * N) where Θobs is the 
observed ellipticity in mdeg, Mw is the protein molecular weight in g/mol, l is the cuvette path 
length in cm, c is the protein concentration in g/l and N is the number of residues of the 
protein. Analysis of the protein secondary structure was performed using the Globalworks 
software algorithm. 
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2.4. Analysis of zinc content 
The zinc content of the proteins (0.1-0.2 mg/ml) was determined by atomic absorption 
spectroscopy with flame optimisation in an Atomic Absorption Spectrometer PU 9200X 
(Philips). All buffers were prepared with chemicals of the highest purity available and using 
Milli-Q grade water. All material was previously immersed for 24 h in 10% (v/v) nitric acid, 
washed with Milli-Q grade water and autoclaved in paper bags. Before metal determination, 
protein samples were extensively dialyzed against 10 mM Tris-HCl pH 8.0, 200 mM NaCl 
using Amicon Ultra-15 centrifugal filter devices (Millipore). Metal content was measured after 
standardization in the linear concentration range (0-1 ppm). Results are expressed as the 
mean ± SD of three independent measurements carried out in triplicate. 
 
2.5. Differential scanning fluorimetry 
The thermal stability of AIP56, AIP56nic, LF11-263∙AIP561-261, LF11-263∙NleC, or LF11-
263∙NleCMut at different pH was monitored by following SYPRO Orange (Invitrogen) 
fluorescence at 585 nM (excitation = 545nM) on an iQ5 Real Time PCR System (BioRad) 
Protein samples in 150mM phosphate/citrate buffer pH 7.0, 6.5, 6.0, 5.5 or 5.0 with 150 mM 
NaCl were mixed 1:1 (v/v) with dye solution in the same buffer in a final volume of 30 μl in 
96-well plates. AIP56 and nicked AIP56 were used at 5 μM with 10x SYPRO Orange, LF11-
263∙AIP561-261 at 10 μM with 20x SYPRO Orange, LF11-263∙NleC at 1 μM with 40x SYPRO 
Orange and LF11-263∙NleCMut at 5μM with 40x SYPRO Orange. Controls included no protein 
and/or no dye. The melting curves were analysed using CFX Manager (BioRad) and the 
melting temperature (Tm) was calculated as the inflection point of the fluorescence curve of 
at least 7 measurements in 2 independent experiments. 
 
2.6. Limited proteolysis 
Recombinant proteins at 0.6 mg/ml in 10 mM Tris-HCl pH 8.0, 200 mM NaCl were 
incubated with trypsin, chymotrypsin or proteinase K at concentrations ranging from 0.25 to 
25 μg/ml for 30 min on ice. Proteases were inactivated by the addition of PMSF at a final 
concentration of 250 μg/ml. Digests were analysed by SDS-PAGE under reducing and non-
reducing conditions. The two major chymotrypsin digestion fragments were subjected to N-
terminal sequencing. 
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3. Bioinformatic analysis 
3.1. Biochemical parameters 
Theoretical molecular weights and isoelectric points were calculated using the 
ProtParam tool (http://web.expasy.org/protparam/). 
 
3.2. Secondary structure prediction 
The secondary structures of AIP56 (NCBI accession number ABA00995) and NleC 
(NCBI accession number NP_286533) were predicted using the program PSIPRED via its 
web interface (http://bioinf.cs.ucl.ac.uk/psipred/) (Jones, 1999; McGuffin et al, 2000) and 
confirmed using PredictProtein (http://www.predictprotein.org/) (Rost et al, 2004). 
 
3.3. Protein sequence alignments and similarity analysis 
Protein sequence alignments were performed using ClustalW2 multiple sequence 
alignment tool (http://www.ebi.ac.uk/Tools/msa/clustalw2/) (Dunbrack, 2006). The 
percentages of similarity and identity were calculated with MatGAT (Campanella et al, 2003) 
using default parameters. 
 
4. Activity assays 
4.1. Fish and cells 
Sea bass (Dicentrarchus labrax) were kept in a recirculating, ozone-treated salt-water 
(25-30 ‰) system at 20 ± 1 ºC, and fed at a ratio of 2% body weight per day. Before 
collection of peritoneal leukocytes fish were euthanized with 2-phenoxyethanol (Panreac; >5 
ml/10 L). This study was carried out in accordance with European and Portuguese legislation 
for the use of animals for scientific purposes (Directive 86/609/EEC; Decreto-Lei 129/92; 
Portaria 1005/92). The work was approved by Direcção Geral de Veterinária, the Portuguese 
authority for animal protection (ref. 004933, 2011-02-22). Sea bass peritoneal leukocytes 
were obtained as described (Costa-Ramos et al, 2011). Briefly, 12 to 20 days after 
stimulation with Incomplete Freund’s Adjuvant, the peritoneal cells were collected in L-15 
medium (Gibco) adjusted to 322 mOsm and supplemented with 10% (v/v) inactivated (60 ºC, 
40 min) fetal bovine serum (FBS, Gibco), 1% (w/v) penicillin/streptomycin (P/S, Gibco) and 
20 U/ml heparin (Braun) (supplemented L-15). The peritoneal population of cells consists of 
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approximately 70% macrophages and 20% neutrophils with the presence of small numbers 
of eosinophilic granular cells, lymphocytes and erythrocytes (Costa-Ramos et al, 2011). Cells 
were used at a density of 2x106 cells/ml. 
 
4.2. Apoptogenic activity assays 
Cells were incubated for 4 h at 22 ºC with the specified recombinant proteins at the 
indicated doses. Where indicated, the cells were pre-treated for 30 min at 22 ºC with 25 μM 
of the pan-caspase inhibitor N-Benzyloxycarbonyl-Val-Ala-Asp(O-Me) fluoromethyl ketone 
(Z-VAD-FMK). In experiments using LF chimeric proteins, cells were incubated with 20 nM of 
LF11-263∙AIP561-261 (1.2 mg/ml) or LF11-263∙AIP56299-497 (1.1 mg/ml) or 700 nM of LF11-263∙NleC 
or LF11-263∙NleCMut (48 mg/ml) with or without 10 nM of anthrax protective antigen (PA) and 
obtained as described (Tonello et al, 2004). Mock-treated cells were used as control. 
Apoptosis was assessed by analysis of cytospin preparations, using a set of morphological 
markers such as occurrence of cell rounding and shrinkage, nuclear fragmentation and/or 
chromatin condensation, cell blebing and formation of apoptotic bodies (Hacker, 2000). 
Experiments were performed using cells collected from at least 3 individual fish. The 
percentage of apoptotic cells was determined in a blind fashion by scoring a minimum of 350 
cells per slide. 
 
4.3. NF-κB p65 cleavage assays 
In vitro: NF-κB p65 cleavage was assessed using cell lysates, recombinant sbp65Rel 
produced in E. coli or translated in vitro as a 35S-labeled protein. HeLa cells and sea bass 
peritoneal leukocytes were used to prepare cell lysates. Cells were incubated in 10 mM Tris-
HCl pH 8.0, 150 mM NaCl, 0.5% (v/v) Triton X-100 and 10% (v/v) glycerol for 30 min on ice, 
sonicated briefly and centrifuged. The supernatant of 2x106 cells (for sea bass cells) or 
(1x106 cells for HeLa cells) was incubated with 1 μM of the indicated proteins for 2 h at 22 ºC 
and p65 cleavage evaluated by Western blotting as described in section 6.2. Recombinant 
sbp65Rel (7.5 μM in 50 mM sodium phosphate buffer pH 7.4, 300 mM NaCl ) was incubated 
for 3 h at 22 ºC with 1 μM AIP56 and p65 cleavage evaluated by SDS-PAGE. In vitro 
translated 35S-labeled sbp65Rel and 35S-labeled sbp65Rel mutants (sbp65RelC39A, 
sbp65RelE40A, and sbp65C39AE40A) were incubated with the indicated proteins in 10 mM 
Tris-HCl pH 8.0, 150 mM NaCl and 10% (v/v) glycerol for 2 h at 22 ºC, and p65 cleavage 
assessed by autoradiography. When specified 1,10-phenanthroline (Sigma) was used at 5 
mM. 
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Ex vivo: Peritoneal leukocytes were incubated for 2 or 4 h as described in section 4.2. 
After treatment, cells were collected by centrifugation, washed, resuspended in sbPBS and 
lysed by addition of SDS-PAGE sample buffer (50 mM Tris-HCl pH 8.0, 2% (w/v) SDS, 10% 
(v/v) glycerol, 0.017% (w/v) bromophenol blue, 2 mM EDTA pH 8.8, 10 mM DTT). Cleavage 
of p65 was evaluated by Western blotting, as described in section 6.2. 
 
4.4. Competition assays 
AIP56AAIVAA, AIP561-285C262S, AIP56286-497C298S, AIP56nic and NleC1-270∙AIP56251-497 were 
tested for their ability to inhibit AIP56’s apoptogenic activity and AIP56-mediated p65 
cleavage. Cells were pre-incubated for 15 min on ice with different concentrations (350 nM to 
3.5 μM) of AIP56AAIVAA, AIP561-285C262S, AIP56286-497C298S, AIP56nic or NleC1-270∙AIP56251-497 
followed by incubation for further 15 min on ice with 8.75 nM (0.5 µg/ml) of AIP56 in 
presence of the competitors. Unbound proteins were removed by washing with ice cold L-15 
medium supplemented as described above and cells incubated at 22 ºC for 4 h. AIP56’s 
apoptogenic activity and AIP56-mediated p65 cleavage was assessed as described above 
(section 4.3). 
 
5. AIP56 crystallization trials 
5.1. Crystallization condition screening 
AIP56 crystallization was screened using the vapor diffusion method at 22 °C in 
sitting drops. In order to identify potential crystallization conditions an extensive screening 
was performed using sparse-matrix crystallization kits from Hampton Research, namely 
IndexTM, Crystal ScreenTM, Crystal Screen 2TM, Crystal Screen CryoTM and PEG/Ion 
ScreenTM. Crystals were grown in 24 well plates (Cryschem plate, Hampton Research) 
containing 800 μl of reservoir solution in each well and 4 µl drops containing 2 µl of AIP56 
(10 mg/ml in 10 mM Tris-HCl pH 8.0, 200 mM NaCl) and 2 µl of reservoir solution. 
Optimization of conditions that yielded microcrystals was performed by variation of pH, 
concentration of the precipitant agent and by testing different ratios of crystallization solution 
and protein within the drop. The effect of the presence of additives such as small molecules 
and detergents was also tested, for condition 0.2 M KSCN, 25% (w/v) PEG 2000, 0.1 M 
HEPES pH 7.9, 0.2% (v/v) glycerol using Additive ScreenTM and Detergent ScreensTM kits 
from Hampton Research. 
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5.2. Seeding 
Streak-seeding (Stura & Wilson, 1991) was performed using microcrystals or small 
crystal plates grown as described above (section 5.1), using 0.2 M (NH4)2HPO4, 10% (w/v) 
PEG 6000, 0.1 M Tris-HCl pH 7.0 or 0.2 M KSCN, 25% (w/v) PEG 2000, 0.1 M HEPES pH 
7.9 as reservoir solution. Seeds were transferred to sitting drops consisting of 2 µl of protein 
solution mixed with 2 µl of reservoir solution after overnight equilibration at 22 ºC against 400 
µl reservoir solution. Prior to being transferred to the new drop, crystals were washed in a 
clean drop of a solution with a lower precipitant concentration, to induce partial removal of 
the external layers of the crystals and generate a fresh crystallization surface. Crystallization 
solutions used in seeding experiments are summarized in table 3.3. 
Table 3.3. List of conditions tested in seeding experiments. 
Chemical composition of reservoir solution 
0.2 M (NH4)2HPO4, 20% (w/v) PEG 2000, 0.1M Tris-HCl pH 7.0 
0.2 M (NH4)2HPO4, 20% (w/v) PEG 2000, 0.1M Tris-HCl pH 7.9 
0.2 M (NH4)2HPO4, 15% (w/v) PEG 8000, 0.1M Tris-HCl pH 7.0 
0.2 M (NH4)2HPO4, 15% (w/v) PEG 8000, 0.1M Tris-HCl pH 7.9 
0.2 M (NH4)2HPO4, 15%(w/v) PEG 8000, 0.1M Tris-HCl pH 7.0, 10% (v/v) glycerol 
0.2 M (NH4)2HPO4, 15% (w/v) PEG 8000, 0.1M Tris-HCl pH 7.0, 15% (v/v) glycerol 
0.2 M KSCN, 20% (w/v) PEG 2000, 0.1 M HEPES pH 7.9 
0.2 M KSCN, 25% (w/v) PEG 2000, 0.1 M HEPES pH 7.9 
0.2 M KSCN, 15% (w/v) PEG 6000, 0.1 M HEPES pH 7.9 
0.2 M KSCN, 20% (w/v) PEG 6000, 0.1 M HEPES pH 7.9 
0.2 M KSCN, 10% (w/v) PEG 8000, 0.1 M HEPES pH 7.9 
0.2 M KSCN, 15% (w/v) PEG 8000, 0.1 M HEPES pH 7.9 
0.2 M KSCN, 20% (w/v) PEG 6000, 0.1 M HEPES pH 7.9, 0.2%(v/v) glycerol 
0.2 M KSCN, 20% (w/v) PEG 6000, 0.1 M HEPES pH 7.9, 0.5% (v/v) glycerol 
0.2 M KSCN, 20% (w/v) PEG 6000, 0.1 M HEPES pH 7.9, 1% (v/v) glycerol 
 
 
5.3. In situ proteolysis crystallization 
AIP56 (10 mg/ml) in 10 mM Tris-HCl pH 8.0, 200 mM NaCl was mixed with 
chymotrypsin at a 1:10000 (molar ratio) and used in crystallization trials with the sparse 
matrix crystallization kits PEG/Ion ScreenTM and Crystal Screen CryoTM from Hampton 
Research as described above (section 5.1). 
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5.4. Data collection 
Glycerol was used as cryoprotective agent and concentrations that ensure cryo-
protection were determined for each crystallization condition. Crystals were transferred from 
their mother liquor to 10 μl drops of mother liquor containing increasing concentrations of 
glycerol (up to 20% v/v), mounted in loops (Molecular Dimensions), flash-cooled and stored 
in liquid nitrogen until data collection. 
 
6. Miscellaneous 
6.1. SDS-PAGE, Native-PAGE 
SDS- and Native-PAGE were performed using the Laemmli discontinuous buffer 
system (Laemmli, 1970). Gels were stained with Coomassie Brilliant Blue R-250 (BioRad). 
For SDS-PAGE analysis samples were boiled for 5 min in sample buffer (50 mM Tris-HCl pH 
8.0, 2% (w/v) SDS, 10% (v/v) glycerol, 0.017% (w/v) bromophenol blue, 2 mM EDTA pH 8.8) 
with or without 100 mM DTT before loading. Proteins were resolved in 10-15% (w/v) 
polyacrylamide gels with 1% (w/v) SDS, prepared with acrylamide:bis-acrylamide (30:0.4) 
stock solution. Native-PAGE was performed in 10% (w/v) polyacrylamide gels prepared with 
acrylamide:bis-acrylamide (30:1) stock solution, but omitting SDS. Furthermore, samples 
were not subjected to thermal denaturation prior to loading and reducing agents and SDS 
were omitted from the loading buffer. 
 
6.2. Western blotting 
After SDS-PAGE proteins were transferred onto nitrocellulose membranes in a Trans-
Blot SD Semi-Dry Electrophoretic Transfer Cell (Bio Rad) with an applied current of 2 
mA/cm2 of membrane for 1h. Detection of AIP56 was done using an anti-AIP56 rabbit serum 
(do Vale et al, 2005). For detection of sea bass NF-κp65, an anti-sea bass NF-κB p65 rabbit 
serum (produced using the peptide SIFNSGNPARFVS located at the C-terminal region of 
sea bass p65 as antigen) was used and for detection of human NF-κB p65 a commercially 
available α-p65 antibody (NFκB p65 (C-20): sc-372, Santa Cruz Biotechnology) was used. 
Reactive bands were detected using anti-rabbit IgG alkaline phosphatase conjugate (Sigma) 
followed by BCIP/NBT development or using an anti-rabbit IgG horseradish peroxidase-
linked secondary antibody (The binding site) followed by detection with SuperSignal West 
Dura Extended Duration Substrate (Pierce biotechnology). Blots shown are representative of 
at least three independent experiments. 
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6.3. Protein quantification 
Unless otherwise specified, proteins were quantified by measuring absorbance at 280 
nm and using the extinction coefficient calculated by the ProtParam tool 
(http://www.expasy.org/tools/protparam.html), using the Edelhoch method (Edelhoch, 1967), 
but with the extinction coefficients for Trp and Tyr determined by Pace et al (Pace et al, 
1995). Alternatively, proteins were quantified by densitometric analysis of Coomassie Blue-
stained gels with protein concentration inferred from BSA standards calibration curve. 
 
6.4. Determination of AIP56 concentrations in the plasma of infected fish 
Sea bass weighting 16.3 ± 2.4 g were infected intraperitoneally with a lethal dose 
(1.8x106 CFU/fish) of Photobacterium damselae piscicida (Phdp) strain PP3 (do Vale et al, 
2007a). Growth conditions and inoculum preparation were carried out as described (do Vale 
et al, 2003; do Vale et al, 2005). Bacterial concentrations of the inoculum were confirmed by 
plating serial dilutions of the final bacterial suspensions onto TSA-1 plates and counting the 
number of CFU following incubation at 22 ºC for 2 days. Plasmas were collected from 
moribund fish as previously described (do Vale et al, 2007a). Five-microliter aliquots of 
plasma or recombinant AIP56 standards (at 50, 25, 10, 2 and 1 µg/ml) were analysed by 
Western blotting. The concentrations of AIP56 in plasma were determined by densitometric 
analysis of the blot and inferred from AIP56 standards calibration curve. 
 
6.5.  Statistical analysis 
Statistical analysis was performed using a randomized block design, where fish are 
treated as blocks and the concentration of the treatments/competitors as a factor. The data, 
percentage of apoptotic cells, have been transformed using the arcsine transformation. Post-
hoc comparisons were performed using the Tukey´s Honest Significant Difference test. 
Significance was defined for p<0.05.  
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1. Recombinant proteins  
To conduct AIP56 structural and functional characterization studies, several 
recombinant proteins were engineered and produced. These are represented in Figure 4.1 
and include AIP56, AIP56’s N-terminal homologue, NleC, as well as several variants of these 
proteins and wild type and mutant versions of the Rel homology domain of sea bass NF-κB 
p65 (the AIP56 putative target). 
 
Figure 4.1. Schematic representation of recombinant proteins used in this study. A) Recombinant AIP56, NleC and their 
variants produced in E. coli. B) Recombinant sea bass p65 Rel homology domain and sea bass p65 Rel homology domain 
mutants produced in E. coli or in vitro in a rabbit reticulocyte system as 35S-labelled proteins. 
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Recombinant proteins were expressed in E. coli, or in vitro in rabbit reticulocyte 
lysates as 35S-labeled proteins. Those produced in E. coli contained a C-terminal 6xHis tag 
added for purification purposes. Conditions for protein expression in E. coli were individually 
established and are detailed in chapter III section 1.1. NleC, LF11-263∙NleC, LF11-263∙NleCMut 
and sbp65Rel were obtained in the soluble fraction of induced bacterial cells at 37 ºC (not 
shown), while soluble AIP56, AIP561-285, AIP56286-497, AIP56286-497C298S, LF11-263∙AIP561-261, 
LF11-263∙AIP56299-497 were only obtained when protein expression was carried at 17ºC (not 
shown). However, and despite our efforts to obtain soluble proteins, AIP56AAIVAA and AIP561-
285C262S were exclusively expressed as insoluble proteins and accumulated in bacterial 
cytoplasm as inclusion bodies (not shown). Hence, to obtain properly folded and functional 
proteins, refolding conditions were established using AIP56 inclusion bodies (obtained from 
E. coli BL21 (DE3) cells induced for 4 hours at 37 ºC (do Vale et al, 2005)). Considering that 
the metalloprotease mutant was expected to not display catalytic activity, wild type AIP56 
was used as control because the correct folding of the wild type protein could be assessed 
by testing the apoptogenic activity of the toxin in sea bass peritoneal leukocytes (not shown). 
The established protocol was applied to AIP56AAIVAA and AIP561-285C262S, and the correct 
folding of the proteins was confirmed by comparing the biochemical and biophysical 
properties of the refolded proteins (determined by Native-PAGE, size exclusion 
chromatography and circular dichroism (CD) spectroscopy), to those of AIP56 or AIP561-285 
as described in detail in the sections below. 
The purification protocols were optimised for each protein. Considering that all 
recombinant proteins contained a C-terminal 6xHis-tag, nickel-affinity chromatography was 
the first purification step, followed by ion-exchange chromatography or size exclusion 
chromatography, depending on the molecular weight of protein contaminants. While NleC, its 
derived proteins and sbp65Rel are stable proteins and caused no major problems during 
purification, AIP56 and AIP56 derived proteins were unstable in solution, with high tendency 
to precipitate often leading to poor yields at the end of the purification process. These 
proteins were particularly prone to precipitate after affinity chromatography while in the 
presence of imidazole (the competitor ligand to protein elution). Thus, addition of imidazole to 
the bacterial fractions containing AIP56 was done just prior to loading the extract into the 
affinity chromatography column and its final concentration in eluted fractions was quickly 
reduced by dilution with imidazole-free buffer. Addition of glycerol to purification and/or 
storage buffers also successfully increased AIP56AAIVAA, AIP56286-497C298S, LF11-263·AIP561-261 
and AIP561-285C262S stability. Final purification protocols of each individual protein are 
described in detail in chapter III section 1.3 and the purity of the produced recombinant 
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proteins was assessed by SDS-PAGE in Figure 4.2. Given the high purity and homogeneity 
requirements of protein samples to be used in crystallization trials, additional optimisations in 
the purification of AIP56 to be used for that purpose were undertaken (see section 5 of this 
chapter). 
 
Figure 4.2. SDS-PAGE analysis of purified recombinant proteins produced in E. coli. Purity of the recombinant proteins 
was analysed by reducing SDS-PAGE, carried out on 12.5% separating gel and stained with Coomassie Blue. 10 µg of 
recombinant proteins were loaded onto the gel. Numbers on the left of the panels refer to the position and mass, in kDa, of the 
molecular weight markers  
 
2. AIP56: a zinc metalloprotease targeting NF-κB p65 
2.1. The metalloprotease signature of AIP56 is essential for its 
apoptogenic activity 
Bioinformatic analysis of AIP56 primary structure revealed the presence of a 
conserved zinc-binding region signature, HEIVH, at positions 165-169 (do Vale et al, 2005; 
Jongeneel et al, 1989), suggesting that the toxin could be a zinc-metalloprotease. The 
HEIVH sequence corresponds to the consensus sequence HEXXH (where X is any amino 
acid) and contains all of the residues identified as part of the active site (Jongeneel et al, 
1989). In zinc enzymes, the essential zinc ion is coordinated by the two histidines together 
with a more C-terminal residue (histidine, cysteine or glutamate) and a water molecule. In 
these enzymes, the hydrolysis is mediated by the nucleophilic attack of the activated water 
molecule on the carbonyl of the scissile bond (Vallee & Auld, 1990a; Vallee & Auld, 1990b). 
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During catalysis, the glutamate between the two histidine residues acts as nucleophile and 
activates the water molecule (Vallee & Auld, 1990a; Vallee & Auld, 1990b).  
In order to study the role played by the putative zinc metalloprotease activity in the 
toxin’s biological activity, a mutated version of the toxin (AIP56AAIVAA) within the zinc-binding 
signature was produced (see section 1). Residues predicted to be involved in zinc ion 
coordination (His165 and His169) and in water molecule activation (Glu166) together with a 
proximal histidine residue (His170) were mutated to alanines. To ensure that no dramatic 
conformational changes occurred as a result of the introduced mutations, the oligomerization 
state, stokes radius and secondary structure content of the wild type and mutant toxin were 
compared by Native-PAGE, size exclusion chromatography and CD spectroscopy, 
respectively. No differences between wild type and mutant toxin were observed using the 
above mentioned techniques (Figure 4.3) indicating that, despite the introduced mutations, 
the overall folding of the toxin was undisturbed. 
 
 
Figure 4.3. Disruption of the zinc-metalloprotease signature does not induce major structural changes in AIP56. (A) 
Native-PAGE analysis of AIP56 and AIP56AAIVAA. BSA was run for control purposes. The depicted protein bands were from the 
same gel and were cut out and juxtaposed for presentation in the figure. (B) Size exclusion chromatography of AIP56 and 
AIP56AAIVAA showing that disruption of the zinc-binding motif did not affect the monodispersity/stokes radius of the protein. 
(C) Far-UV CD spectra of wild-type AIP56 (thick line) and AIP56AAIVAA (thin line) showing that the secondary structure content of 
the toxin was also unaffected by the introduced mutations. 
 
In addition, to confirm that the residues composing the zinc-binding signature are in 
fact involved in zinc ion coordination the zinc content, of wild type and mutant AIP56 was 
determined by atomic absorption spectroscopy. Stoichiometric amounts of zinc are present in 
wild type AIP56 (0.93±0.04 mol zinc/mol protein) while no zinc could be detected in 
AIP56AAIVAA, which is in agreement with this region being the active site of the toxin. Hence, 
to evaluate if the disruption of the AIP56’s metalloprotease signature would affect the toxin’s 
apoptogenic activity, AIP56AAIVAA was tested for its ability to induce apoptosis of sea bass 
phagocytes, using a previously established ex vivo model (Costa-Ramos et al, 2011; do Vale 
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et al, 2003) consisting of cells collected from inflamed fish peritoneal cavities. Apoptosis was 
assessed by analysis of typical apoptotic morphological characteristics (Hacker, 2000). The 
results showed that even when tested in doses of 50 μg/ml, AIP56AAIVAA failed to induce 
apoptosis, in opposition to AIP56 that at 0.1 μg/ml induced an increased number of cells with 
apoptotic morphology (Figure 4.4A). These results suggest that AIP56 is a zinc 
metalloprotease whose catalytic activity is essential for toxicity. It is worth noting that the 
AIP56 concentrations used in the present work are biologically relevant, since they are in the 
same range of the ones detected in the plasma of infected fish (Figure 4.4B). 
 
 
Figure 4.4. Disruption of the zinc-metalloprotease signature abolishes AIP56 apoptogenic activity. A) Sea bass 
peritoneal leukocytes collected from 5 animals were incubated with AIP56 or AIP56AAIVAA, for 4 h at 22 ºC. Mock-treated cells 
were used as controls. Images shown are representative cytospin preparations stained with Antonow’s (Afonso et al, 1998; do 
Vale et al, 2002) for labelling neutrophils (brown) followed by Hemacolor. Note the presence of several apoptotic cells 
(arrowheads) in the sample incubated with AIP56 and their absence in cells incubated with AIP56AAIVAA and in mock-treated 
cells. The percentage of apoptotic phagocytes was determined by morphological analysis and is depicted in the dot plot. B) The 
AIP56 concentrations in the plasma of infected fish are in the same range as the ones used in the present work. The presence 
of AIP56 in plasmas (5 µl aliquots) from sea bass infected with a lethal dose of Phdp strain PP3 was determined by Western 
blotting and its concentration determined by densitometric analysis of the blot, and inferred from AIP56 standard curve (5 µl of 
AIP56 at different concentrations were loaded as standards). Numbers at the left refer to the position and mass, in kDa, of the 
molecular weight markers.  
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2.2. AIP56 cleaves NF-κB p65 within the Rel homology domain 
The AIP56’s N-terminal homologue NleC, a type III secreted effector present in 
several enteric pathogenic bacteria, was recently shown to be a zinc dependent 
metalloprotease with activity towards NF-κB p65 (Baruch et al, 2010; Muhlen et al, 2011; 
Pearson et al, 2011; Sham et al, 2011; Yen et al, 2010). The high degree of homology 
between AIP56 N-terminal region and NleC (Silva et al, 2010) prompted us to test if AIP56 
had a similar activity.  
The ability of AIP56 to cleave NF-κB p65 was assessed in vitro using sea bass 
peritoneal cell lysates. Recombinant NleC (see section 1) was used as control. The obtained 
results show that AIP56 cleaved NF-κB p65, similarly to NleC, with appearance of a lower 
molecular weight fragment (cl-p65), detected by Western blotting (Figure 4.5A). The p65 
cleavage fragment, obtained after incubation with AIP56, was recognised by an antibody 
designed against a peptide located at the C-terminal region of sea bass p65, indicating that 
the AIP56-mediated p65 cleavage occurred at the N-terminal region, where the Rel-
homology domain is located. By contrast, in cell lysates incubated with AIP56AAIVAA or with 
AIP56 in the presence of the metalloprotease inhibitor 1,10-phenanthroline, p65 remained 
intact, confirming the involvement of the metalloprotease signature in the catalytic process. 
To investigate if the cleavage of p65 resulted directly from proteolysis by AIP56, a 
recombinant sea bass p65Rel domain (sbp65Rel) was produced in E. coli (see section 1). 
SDS-PAGE analysis of sbp65Rel incubated with AIP56 showed that the toxin cleaved 
recombinant sbp65Rel in vitro (Figure 4.5B) and N-terminal sequencing of the cleaved 
fragment identified the peptide EGRSA, revealing that AIP56 cleaved sbp65Rel at the Cys39-
Glu40 peptide bond (the same residues previously identified as the cleavage site for NleC 
(Baruch et al, 2010)). This result was confirmed using 35S-labeled sbp65Rel mutated within 
the identified cleavage site. Two single mutants (sbp65RelC39A, sbp65RelE40A) and a 
double mutant (sbp65C39AE40A) were produced in vitro using a rabbit reticulocyte system 
(see above section 1 Figure 4.1) and incubated with AIP56. Cleavage was assessed by 
autoradiography and the results show that, indeed, double mutation of Cys39 and Glu40 
completely abolished p65 proteolysis by AIP56 and NleC (Figure 4.5C). Moreover, mutation 
in Glu40 partially inhibited the cleavage mediated by AIP56, but not by NleC, while mutation of 
Cys39 had no effect on the ability of either AIP56 or NleC to cleave p65 (Figure 4.5C). Taken 
together all the above presented results demonstrate that AIP56 cleaves NF-κB p65 at the 
Cys39-Glu40 peptide bond in a process that is dependent on the metalloprotease activity of 
the toxin. 
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The fact that the identified cleaving residues are absolutely conserved among p65 of 
different species (Figure 4.5D), suggests that AIP56 could likely cleave mammalian p65. This 
suggestion was confirmed by incubating HeLa cell lysates with AIP56, and assessing p65 
cleavage by Western blotting. The results presented in Figure 4.5E show that, similarly to 
NleC, AIP56 is able to cleave mammalian p65. 
 
 
Figure 4.5. AIP56 is a zinc-metalloprotease that cleaves NF-κB p65 at the conserved Cys39-Glu40 peptide bond. (A) 
Incubation of cell lysates with AIP56 and NleC resulted in p65 cleavage. Lysates were incubated for 2 h at 22 ºC with 1 µM of 
the indicated proteins in the presence or absence of the metalloprotease inhibitor 1,10-phenanthroline (O-phe), and p65 
cleavage assessed by Western blotting. The positions of the full length and cleaved p65 (cl-p65) are indicated. Numbers on the 
left of the panel refer to the position and mass, in kDa, of the molecular weight markers. (B) AIP56 cleaves NF-κB p65 at the 
Cys39-Glu40 peptide bond. Recombinant sea bass p65Rel was incubated in the presence or absence of 1 µM of AIP56 for 3 h at 
22 ºC and analysed by SDS-PAGE. Edman degradation of the cleaved sbp65Rel (cl-sbp65Rel) identified the sequence 
E40GRSA44 showing that cleavage occurred after the conserved C39. Numbers on the left of the panel refer to the position and 
mass, in kDa, of the molecular weight markers. (C) Mutation of both Cys39 and Glu40 of sbp65Rel inhibit proteolytic processing 
by AIP56 and NleC. 35S-labeled sbp65Rel (Met1-Arg188) and sbp65Rel mutants (sbp65RelC39A, sbp65RelE40A or 
sbp65C39AE40A) were incubated for 2 h at 22 ºC with 100 nM of the indicated proteins and cleavage assessed by 
autoradiography. (D) The AIP56 cleavage determining residues are highly conserved. Alignment of the p65 N-terminal region 
from different species (NCBI accession numbers: Homo sapiens, AAA36408; Mus musculus, NP_033071; Gallus gallus, 
NP_990460; Xenopus laevis, AAH70711; Monodelphis domestica, XP_001379658; Danio rerio, AAO26404). The AIP56 
cleavage site is shadowed in grey. (E) AIP56 is able to cleave mammalian p65. HeLa cell lysates were incubated for 2 h at 22 
ºC with 1 µM of the indicated proteins and p65 cleavage assessed by Western blotting using a commercially available antibody 
raised against a peptide mapping within the C-terminus of NF-κB p65 of human origin. The positions of the full length and 
cleaved p65 (cl-p65) are indicated. 
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2.3. Cellular intoxication by AIP56 involves cleavage of the NF-κB p65  
To determine if cellular NF-κB p65 is cleaved during AIP56 intoxication, sea bass 
peritoneal leukocytes were incubated with the toxin ex vivo and p65 proteolysis was 
assessed by Western blotting. Incubation of cells with AIP56 resulted in NF-κB p65 depletion 
(Figure 4.6A), with the appearance of a cleavage fragment similar to that observed in vitro 
with cell lysates (Figure 4.5A). Additionally, and also in agreement with the in vitro results, no 
changes in p65 cellular levels could be observed upon incubation with the metalloprotease 
mutant AIP56AAIVAA (Figure 4.6A). The fact that the AIP56 metalloprotease mutant lacking 
proteolytic activity was also unable to induce apoptosis suggests that the cleavage of NF-κB 
p65 and the occurrence of apoptosis are related events.  
It has been reported that activated caspase-3 can cleave p65 at its N-terminal region 
(Coiras et al, 2008; Kang et al, 2001). Considering that the AIP56’s apoptogenic activity is 
caspase-dependent and involves activation of caspases-8, -9 and -3 (Costa-Ramos et al, 
2011), the possible involvement of caspases in AIP56-mediated p65 cleavage was examined 
using a pan-caspase inhibitor (ZVAD-FMK) that has been previously shown to efficiently 
inhibit AIP56 induced caspase-3 activation and apoptosis (Costa-Ramos et al, 2011). In 
these experiments, ZVAD-FMK was effective in protecting cells from AIP56-induced 
apoptosis, but did not affect NF-κB p65 cleavage (Figure 4.6B) indicating that AIP56-
mediated p65 depletion is a caspase-independent event. 
 
 
Figure 4.6. Cellular intoxication by AIP56 involves cleavage of the NF-κB p65. (A) Incubation of leukocytes with AIP56, but 
not with AIP56AAIVAA leads to p65 depletion. Leukocytes were incubated with 10 µg/ml of the indicated proteins for 2 h at 22 ºC 
and p65 cleavage was assessed by Western blotting. Numbers on the left of the panels refer to the mass, in kDa, of the 
molecular weight markers. (B) AIP56-mediated p65 cleavage is caspase-independent. Leukocytes were incubated with 10 
µg/ml (cells 1) or 2 µg/ml (cells 2 and cells 3) of AIP56 in the presence or absence of 25 µM of the pan-caspase inhibitor ZVAD-
FMK for 4h at 22 ºC. NF-κB p65 cleavage was assessed after 2 h incubation by Western blotting and the occurrence of 
apoptosis accessed after 4 h incubation by morphological analysis of cytospin preparations. The blot shown refers to the 
analysis of p65 cleavage of “cells 3” samples.  
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3. AIP56 belongs to the AB toxin family 
3.1. AIP56 has a two-domain structure 
As reviewed in Chapter I, Blast analysis of AIP56 amino acid sequence revealed that 
the N-terminal region shares homology with a type III secreted effector present in several 
enteric pathogenic bacteria, and the C-terminal region is highly similar to an uncharacterized 
hypothetical protein of Acrythosiphon pisum bacteriophage APSE-2 (Degnan et al, 2009) and 
to the C-terminal part of a hypothetical protein of the monarch butterfly Danaus plexippus 
(Silva et al, 2010) (see Chapter I Figure 1.10). These observations suggested a two 
domain/subunit structure similar to the ones of diphtheria toxin and clostridial neurotoxins 
(Silva et al, 2010). 
In order to gain insights about domain boundaries within AIP56 and to identify 
possible flexibility regions, limited proteolysis experiments were performed. SDS-PAGE 
analysis of the digests resultant from controlled incubation of AIP56 with trypsin, 
chymotrypsin and proteinase K, revealed that the toxin was highly resistant to trypsin 
digestion, whereas chymotrypsin and proteinase K cleaved AIP56 in two main fragments with 
approximately 32 and 24 kDa, consistent with the size of the two domains predicted by 
sequence analysis (Figure 4.7A). When analysed under non-reducing conditions, 
chymotrypsin-digestion fragments appeared as a single band co-migrating with non-digested 
AIP56, showing that, after cleavage, the fragments remained linked by a disulphide bridge 
(Figure 4.7B). N-terminal Edman sequencing of the two major fragments obtained with 
chymotrypsin revealed that cleavage occurred between Phe285 and Phe286, in the amino acid 
stretch between the two unique cysteine residues (Cys262 and Cys298) of AIP56 (Figure 4.7C). 
These results are in accordance with the amino acid sequence alignment data and reveal the 
existence of two protease-resistant domains linked by an exposed region containing two 
cysteine residues involved in a disulphide bond. 
To better understand the function of the two identified structural domains, constructs 
corresponding to AIP56’s N- and C-terminal regions (AIP561-285 and AIP56286-497, 
respectively) were designed based on the chymotrypsin cleavage site and the proteins 
produced in E. coli (see section 1). SDS-PAGE analysis of the purified recombinant proteins 
under reducing and non-reducing conditions revealed that they display a major propensity to 
oxidize leading to the formation of DTT-sensitive dimers (Figure 4.8A), a phenomenon that 
could have a functional impact and complicate subsequent analyses. Therefore, mutated 
versions of AIP561-285 and AIP56286-497, where the single cysteine in each protein was 
replaced by a serine (AIP561-285C262S and AIP56286-497C298S), were obtained by site directed 
mutagenesis and produced in E. coli (see section 1). Non-reducing SDS-PAGE confirmed  
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Figure 4.7. AIP56 is composed of two domains linked by a disulphide bridge. (A) Limited proteolysis of AIP56 with 
chymotrypsin and proteinase K originates two major fragments. AIP56 (0.6 mg/ml) was incubated with 0.25, 1.25, 6.25 or 25 
μg/ml of chymotrypsin, trypsin and proteinase K for 30 min on ice and digests analysed by reducing SDS-PAGE. The proteases 
(marked as *) and undigested AIP56 (marked as **) were loaded as controls. The depicted protein bands were from the same 
gel and were cut out and juxtaposed for presentation in the figure. (B) The two AIP56 digestion fragments are linked by a 
disulphide bridge. AIP56 was incubated with or without 25 µg/ml chymotrypsin (Chym) for 30 min on ice and digests analysed 
under reducing (+DTT) or non-reducing (-DTT) SDS-PAGE. The depicted protein bands were from the same gel and were cut 
out and juxtaposed for presentation in the figure. Numbers to the left and right of the panels refer to the mass, in kDa, of the 
molecular weight markers. (C) Schematic representation of AIP56.  
 
that cysteine mutation abolished dimer formation (not shown). CD spectroscopy was used to 
assess the impact of the mutations on the protein folding (Figure 4.8B and C), indicating that 
mutation of the cysteine residues to serine did not induce major structural rearrangements. 
CD analysis revealed that the predominant secondary structural element of the N-terminal 
portion is the α-helix whereas in the C-terminal part β–sheets are the predominant 
elements (Figure 4.8D). Furthermore, the weighted sum of the CD spectra of the 
recombinant N- and C-terminal portions reproduces the spectrum of the entire protein (Figure 
4.8E), indicating that when produced independently, the two putative AIP56 functional 
domains maintain their native structures. Additionally, the position of the β-sheets and α-
helices in AIP56 primary structure was predicted using bioinformatic tools (Figure 4.9). The 
predictions are in accordance with the CD results, and together with the above presented 
results, support the existence of two structurally distinct domains/subunits, which may play 
different roles in the intoxication process, linked by a disulphide bridge.  
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Figure 4.8. Structural analysis of the recombinant AIP56 truncated versions. (A) AIP561-285 and AIP56286-497 have a 
propensity to oxidize resulting in the formation of DTT-sensitive dimers. Reducing (DTT +) and non-reducing (DTT -) SDS-
PAGE of purified AIP561-285 and AIP56286-497. Numbers on the left of the panels refer to the position and mass, in kDa, of the 
molecular weight markers. The depicted protein bands were from the same gel and were cut out and juxtaposed for 
presentation in the figure. (B) Secondary structure content of the N-terminal portion was unaffected by mutation of the single 
cysteine residue. Far-UV CD spectra of AIP561-285 (thick line) and AIP561-285C262S (thin line). (C) Secondary structure of the C-
terminal portion was unaffected by mutation of the single cysteine residue. Far-UV CD spectra of AIP56286-497 (thick line) and 
AIP56286-497C298S (thin line). (D) Secondary structure content of AIP56 and AIP56 truncates. (E) The weighted sum of the CD 
spectra of the recombinant N- and C-terminal portions reproduces the spectrum of the entire protein. Far-UV CD spectra of 
AIP56 (thick solid line), AIP561-285 (thin solid line), AIP56286-497 (thin dashed line) and the weighted sum of AIP561-285 and 
AIP56286-497 spectra (thick dashed line). 
 
Both wild type and cysteine mutant truncated versions of the toxin were used in 
functional assays (presented below) and similar results were obtained (not 
shown). Therefore, in this thesis only the results obtained using the cysteine mutants will be 
presented. 
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Figure 4.9. Prediction of AIP56 secondary structure. The secondary structure of mature AIP56 was predicted using the 
program PSIPRED via its web site interface (http://bioinf.cs.ucl.ac.uk/psipred/). The metalloprotease signature and two cysteine 
residues are boxed and highlighted in yellow and green, respectively. 
 
3.2. The N-terminal region is responsible for the toxin’s catalytic activity  
Considering the presence of the metalloprotease signature in the AIP56’s N-terminal 
region and its similarity with the type III secreted effector NleC, we hypothesised that this 
region would play the catalytic role, while the C-terminal region would be involved in the 
binding/entry of the toxin in target cells. 
The proteolytic activity of AIP56 truncated versions towards NF-κB p65 was assessed 
in vitro using sea bass leukocyte lysates (Figure 4.10A) or 35S-labeled sbp65Rel, translated 
in vitro using a rabbit reticulocyte system (Figure 4.10B). Both assays revealed that the 
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AIP56’s C-terminus did not display proteolytic activity, whereas the N-terminal portion 
cleaved p65 as efficiently as the full-length toxin by a mechanism likewise inhibited by the 
zinc metalloprotease inhibitor 1,10-phenanthrolin. 
 
 
Figure 4.10. AIP56 N-terminal region displays proteolytic activity towards NF-κB p65. (A) Incubation of cell lysates with 
AIP56 N-terminal portion resulted in p65 cleavage similar to the one induced by full length AIP56. Lysates were incubated for 2 
h at 22 ºC with 1 µM of AIP56, AIP561-285C262S (N-term), or AIP56286-497C298S (C-term) in the presence or absence of the 
metalloprotease inhibitor 1,10-phenanthroline (O-phe), and p65 cleavage assessed by Western blotting. The positions of the full 
length and cleaved p65 (cl-p65) are indicated. Numbers on the left of the panels refer to the position and mass, in kDa, of the 
molecular weight markers. The depicted protein bands were from the same membrane and were cut out and juxtaposed for 
presentation in the figure. (B) AIP56 N-terminal portion cleaves in vitro translated sea bass p65 Rel homology domain. 35S-
labeled sbp65Rel (Met1-Arg188) was incubated for 2 h at 22 ºC with 100 nM of AIP56, AIP561-285C262S (N-term) or AIP56286-497C298S 
(C-term) in the presence or absence of the metalloprotease inhibitor 1,10-phenanthroline (O-phe), and cleavage assessed by 
autoradiography.  
 
Toxicity of the two putative AIP56 domains was assessed by testing their ability to 
induce apoptosis and to cleave NF-κB p65 upon incubation with sea bass peritoneal 
leukocytes. Neither AIP561-285C262S nor AIP56286-497C298S displayed apoptogenic activity, even 
when tested in doses 500 times higher than the ones used for the full length toxin (Figure 
4.11A). Moreover, the same result was obtained when a mixture of both N- and C-terminal 
portions was tested (Figure 4.11A). Additionally, and in agreement with the observed lack of 
apoptogenic activity, no changes in p65 levels were observed in cells incubated with AIP56 
truncated versions alone or mixed (Figure 4.11B). These results indicate that independently 
the two AIP56’s domains are non-toxic and suggest that a concerted action of both regions 
as part of the same molecule is needed to elicit a biological effect.  
Given the cytosolic location of NF-κB p65, the lack of toxicity of the AIP56’s catalytic 
region is most likely related to its inability to enter the cells and reach its target. Hence, a 
strategy to deliver the AIP56 N-terminal portion into the cell cytosol was delineated based on 
the Bacillus anthracis lethal factor (LF) delivery system. The N-terminal portion (first 263 
residues) of LF was found to be sufficient for recognition and binding to the protective 
antigen (PA), the receptor-binding subunit for LF (Collier, 2009), and able to cause cellular 
uptake of fused polypeptides (Arora & Leppla, 1993). This strategy was previously used 
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successfully to deliver the catalytic domains of diphtheria toxin (DT), shiga toxin (Stx) and 
Pseudomonas exotoxin A (PE) into the cell cytosol (Arora & Leppla, 1993; Arora & Leppla, 
1994; Milne et al, 1995).  
 
 
Figure 4.11. The two AIP56 structural domains need to be part of the same molecule to display toxicity. (A) 
Independently, recombinant AIP56 N- and C-terminal portions lack apoptogenic activity. Leukocytes collected from 5 animals 
were incubated with AIP56, AIP561-285C262S (N-term), AIP56286-497C298S (C-term), or a mixture of AIP561-285C262S and AIP56286-497C298S 
(N-term+C-term) (50 µg/ml each) for 4 h at 22 ºC. The percentage of apoptotic phagocytes was determined by morphological 
analysis of cytospin preparations stained with Hemacolor. (B) Incubation of sea bass leukocytes with recombinant AIP56 N- and 
C-terminal domains did not result in NF-κB p65 depletion. Sea bass leukocytes were incubated as described in (A) and NF-κB 
p65 cleavage was assessed by Western Blotting. The positions of the full length and cleaved p65 (cl-p65) are indicated. 
 
Therefore, chimeric proteins consisting of the LF N-terminal region fused to AIP56’s 
N-terminus (LF11-263∙AIP561-261) or C-terminus (LF11-263∙AIP56299-497) were produced (see 
section 1). Intoxication assays were performed by incubating sea bass peritoneal leukocytes 
with the LF∙AIP56 chimeras in the presence of PA. In cells incubated with LF11-263∙AIP561-261 
the p65 levels were significantly reduced, confirming that LF11-263∙AIP561-261 was effectively 
delivered into the cell cytosol, while no changes in p65 were observed in cells incubated with 
LF11-263∙AIP56299-497 or with PA alone (Figure 4.12A). Accordingly, LF11-263∙AIP56299-497 did not 
display apoptogenic activity, while incubation with LF11-263∙AIP561-261 resulted in an increased 
number of cells with apoptotic morphology (Figure 4.12B), similar to what was observed in 
cells incubated with AIP56 (Figure 4.4). These results show that delivery of AIP56’s N-
terminal portion into the cytosol reproduces the toxic effect of the full length toxin and confirm 
that this region is the one responsible for the toxin’s catalytic and apoptogenic activities. 
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Figure 4.12. Delivery of the AIP56 N-terminal region into the cell cytosol, using the B. anthracis LF/PA system, 
reproduces the toxic effect of the full length toxin. (A) B. anthracis LF/PA system is able to deliver AIP56 N-terminal portion 
into the cell’s cytosol. Leukocytes collected from 4 animals were incubated for 4 h at 22 ºC with 20 nM LF11-263∙AIP561-261 
(LF∙AIP56Nterm) or LF11-263∙AIP56299-497 (LF∙AIP56Cterm) in the presence of 10 nM PA. Mock-treated cells and cells incubated with 
35 nM (2 µg/ml) AIP56 were used as controls. Cleavage of NF-κB p65 was detected by Western blotting. The positions of the 
full length and cleaved p65 (cl-p65) are indicated. (B) Deliver of AIP56 N-terminal portion into the cell’s cytosol is sufficient to 
induce apoptosis. Cells were treated as described in (A) and apoptosis assessed by morphological analysis. Images shown are 
representative cytospin preparations stained with Hemacolor. The percentages of apoptotic phagocytes are depicted in the dot 
plot.  
 
3.3. The C-terminal region mediates the interaction of the toxin with target 
cells 
To investigate the role played by the two AIP56 domains in the interaction of the toxin 
with target cells, AIP561-285C262S, AIP56286-497C298S and AIP56AAIVAA were used as competitors 
for AIP56 activity. Both p65 cleavage and apoptosis induction were monitored in these 
experiments. Competitor:AIP56 ratios ranged from 40:1 to 400:1 (mol/mol). Mock treated 
cells and cells incubated with each of the competitors alone were used as negative controls. 
As expected, no apoptosis was observed in neither of the negative control conditions (Figure 
4.13A). Moreover, AIP56286-497C298S and AIP56AAIVAA were found to compete with the full 
length toxin, inhibiting its apoptogenic activity in a dose dependent manner, whereas no 
effect was observed when AIP561-285C262S was used as a competitor (Figure 4.13A). Western 
blotting analysis of p65 levels in cells incubated with the highest dose of each competitor in 
the presence of AIP56 showed that AIP56AAIVAA and AIP56286-497 inhibited AIP56-mediated 
p65 degradation (Figure 4.13B) indicating that, when used as competitors, these proteins 
efficiently blocked the arrival of the toxin to the cytosol. In accordance with the results 
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obtained in the apoptogenic activity assays (Figure 4.13A), no inhibition of the AIP56-
dependent p65 cleavage was observed when AIP561-285C262S was used as a competitor 
(Figure 4.13B). These results implicate the C-terminal region in mediating the binding of the 
toxin to the cell surface and its entry into the cells. 
 
 
Figure 4.13. AIP56 C-terminal region plays a role in the toxin binding and entry into the target cells. (A) The 
metalloprotease mutant and the C-terminal portion, but not the N-terminal portion of AIP56, inhibits the toxin’s apoptogenic 
activity in a dose dependent manner. Leukocytes collected from 7 fish were incubated with AIP56AAIVAA, AIP561-285C262S (N-term) 
or AIP56286-497C298S (C-term) at final concentrations of 0.35, 1.75 or 3.5 µM for 15 min on ice, followed by further 15 min 
incubation on ice with 8.75 nM (0.5 μg/ml) AIP56 in the presence of the competitors. The competitor:AIP56 ratios (mol:mol) are 
indicated. Cells incubated with AIP56 in the absence of competitors or with 3.5 µM of each competitor alone were used as 
controls. Cells were washed, transferred to 22 ºC and incubated for 4 h prior to determination of the percentage of apoptotic 
cells by morphological analysis of cytospin preparations stained with Hemacolor. The figure presents the box plot of percentage 
of apoptotic cells (the middle bar corresponds to the median and the lower and upper side of the boxes, the first and third 
quartiles; circles signal extreme observations). (B) The metalloprotease mutant and the C-terminal portion, but not the N-
terminal portion, inhibits AIP56-associated p65 cleavage. Cells were incubated as described in (A) and the inhibitory effect of 
the highest dose of each competitor on AIP56-mediated cleavage of NF-κB p65 was assessed by Western blotting.  
 
3.4. Translocation of AIP56 requires integrity of the Cys262-Cys298 linker  
In toxins secreted as a single polypeptide chain, proteolytic cleavage at an exposed 
flexible region between two cysteine residues resulting in a toxin with an enzymatically active 
part linked to the rest of the molecule by a disulphide bond (commonly referred as nicking) is 
often associated with increased toxicity (Drazin et al, 1971; Knust et al, 2009; Krieglstein et 
al, 1991; Rupnik et al, 2005; Sandvig & Olsnes, 1981). The results obtained in experiments 
using the N- and C-terminal portions of AIP56 suggested that the two domains must be part 
of the same molecule to display toxicity. Therefore, in order to investigate whether the two 
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domains bound by a disulphide bridge were able to intoxicate cells, we reconstituted the full 
length toxin using the non-toxic AIP561-285 and AIP56286-497. To promote the formation the 
disulphide-bound heterodimer AIP561-285/AIP56286-497, the two proteins were mixed in 
equimolar amounts under denaturing and reducing conditions and subjected to refolding 
through extensive dialysis against sea bass PBS. Non-reducing SDS-PAGE confirmed that 
this reconstituted version of the toxin consists of disulphide-bound AIP561-285/AIP56286-497 
along with small amounts of AIP561-285 and of AIP56286-497 homodimers and monomers 
(Figure 4.14A). Additionally, a chymotrypsin-nicked version of the toxin was also produced. 
AIP56’s nicking and integrity of the disulphide bridge linking the two digestion fragments 
were confirmed by reducing and non-reducing SDS-PAGE (Figure 4.14A) and the structural 
impact of the cleavage was evaluated by CD spectroscopy and differential scanning 
fluorimetry (DSF). The Far-UV CD spectrum of the nicked toxin was found to be 
undistinguishable from that of AIP56 (Figure 4.14B), indicating that no changes in the 
secondary structure were induced by proteolysis. Moreover, when protein stability was 
evaluated by DSF, using the protein melting temperature as an indicator, we found that 
nicking of the toxin resulted only in a 1 ºC decrease in the Tm (39±0.13 ºC for AIP56 and 
38±0.25 ºC for nicked AIP56; mean±SD of 16 measurements in four independent 
experiments). Together, these results indicate that no major structural changes were induced 
by nicking. 
 
 
Figure 4.14. Structural analysis of nicked and reconstituted AIP56. (A) Reducing (+DTT) and non-reducing (-DTT) SDS-
PAGE of AIP56, nicked AIP56 (AIP56nic) and reconstituted AIP56 (AIP56rct). Numbers on the left of the panels refer to the 
position and mass, in kDa, of the molecular weight markers. The depicted protein bands were from the same gel and were cut 
out and juxtaposed for presentation in the figure. (B) Nicking of AIP56 does not affect its secondary structure content. Far-UV 
CD spectra of AIP56 (thick line) and nicked AIP56 (AIP56nic; thin line). 
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Toxicity of nicked and reconstituted AIP56 was tested by evaluating their ability to 
cleave NF-κB p65 and induce apoptosis of sea bass leukocytes. Surprisingly, no apoptosis 
was observed with nicked or reconstituted AIP56, even when tested at very high doses 
(Figure 4.15A). Accordingly, no changes in p65 cellular levels were observed upon 
incubation with neither of the proteins (Figure 4.15B).  
 
 
Figure 4.15. Integrity of the linker region, between the two cysteine residues, is essential for AIP56’s toxicity (A) Nicked 
and reconstituted AIP56 lack apoptogenic activity. Sea bass leukocytes, collected from 3 fish, were incubated with nicked or 
reconstituted AIP56 (AIP56nic and AIP56rct, respectively) at the indicated doses for 4 h at 22 ºC and the percentage of 
apoptotic cells determined by morphological analysis of cytospin preparations stained with Hemacolor. Cells treated with AIP56 
and mock-treated cells were used as positive and negative controls, respectively. (B) No changes on p65 cellular levels were 
observed upon incubation with nicked or reconstituted AIP56. Sea bass leukocytes were incubated with 10 µg/ml of nicked or 
reconstituted AIP56 (AIP56nic and AIP56rct, respectively), for 2 h at 22 ºC and the cleavage of p65 assessed by Western 
blotting. Mock treated cells and cells incubated with 10 µg/ml of AIP56, AIP561-285C262S (N-term) or AIP56286-497C298S (C-term) were 
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used as controls. The depicted protein bands were from the same membrane and were cut out and juxtaposed for presentation 
in the figure. (C) The culture conditions do not reduce the disulphide bridge of nicked AIP56 (AIP56nic). Nicked AIP56 was 
added to sea bass peritoneal cell suspension in supplemented L-15 medium and incubated up to 4 h at 22 ºC. An aliquot of 
nicked toxin not incubated with cells (0) and aliquots of the cell culture supernatant collected 2 or 4 h after incubation with cells 
(all containing 50 ng of nicked toxin) were run in reducing and non-reducing SDS-PAGE and subjected to Western blotting using 
an anti-AIP56 rabbit serum (do Vale et al, 2005). Numbers on the left indicate the position and mass, in kDa, of the molecular 
weight markers (D) Nicked AIP56 (AIP56nic) display proteolytic activity in vitro in the same dose range as AIP56. 35S-labeled 
sbp65Rel was incubated for 2 h at 22 ºC with wild type or nicked AIP56 at the indicated concentrations and cleavage assessed 
by autoradiography. The depicted protein bands were from the same membrane and were cut out and juxtaposed for 
presentation in the figure (E) Nicked AIP56 competes with AIP56 and inhibits its toxicity. Leukocytes collected from 3 animals 
were incubated with 3.5 µM nicked AIP56 (AIP56nic) for 15 min on ice followed by further 15 min incubation on ice with 8.75 nM 
(0.5 μg/ml) of AIP56. Mock-treated cells, cells incubated with 8.75 nM AIP56, or cells incubated with 3.5 µM of AIP56AAIVAA, 
AIP561-285C262S (N-term) and AIP56286-497C298S (C-term) before incubation with 8.75 nM of AIP56 were used as controls. Cells were 
washed, transferred to 22 ºC and incubated for 4 h. The percentages of apoptotic cells were determined as described in (A). 
 
To ensure that the incubation conditions were not leading to oxidation, and 
consequent disruption of the disulphide bridge linking the two protease-resistant domains, 
the oxidation state of nicked AIP56 during incubation with sea bass peritoneal cells was 
assessed. Supernatants of the sea bass peritoneal cell suspensions incubated with nicked 
AIP56 were analysed by reducing and non-reducing SDS-PAGE followed by Western blotting 
using an anti-AIP56 rabbit serum (do Vale et al, 2005). The results show that, even after 4 
hour incubation, nicked AIP56 remain in its oxidised state (Figure 4.15C). Furthermore, the 
observed lack of toxicity was also not related with a loss of catalytic activity, since nicked 
AIP56 retained proteolytic activity in vitro in the same dose range as AIP56 (Figure 4.15D), 
nor was related with impairment of the cell binding ability, as indicated by the ability of the 
nicked toxin to inhibit the AIP56-mediated p65 cleavage and apoptosis in competition 
experiments (Figure 4.15E). Taken together, these results indicate that the lack of toxicity of 
nicked AIP56 is related with the inability of the AIP56’s catalytic portion to reach the cytosol, 
suggesting that integrity of the linker region between the two cysteine residues is required for 
toxin internalization and arrival at the cytosol and pointing to a possible role of the linker 
region in the toxin’s translocation process.  
 
3.5. The disulphide bridge linking Cys262-Cys298 is not absolutely required 
for toxicity 
In TeNT and BoNT type A, it has been shown that the disulphide bridge linking the A 
and B domains is essential for neurotoxicity (de Paiva et al, 1993; Schiavo et al, 1990). 
AIP56 contains only two cysteine residues that establish a disulphide bond linking the two 
functional regions. To evaluate the importance of the inter-cysteine bridge in the intoxication 
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by AIP56, we disrupted it by alkylating the cysteine residues. Disruption of the disulphide 
bridge was confirmed by SDS-PAGE analysis under reducing and non-reducing conditions 
(Figure 4.16A). Proteolytic activity of alkylated AIP56 was tested in vitro using 35S-labeled 
sbp65Rel and the results show that alkylated AIP56 cleaved 35S-labeled sbp65Rel in the 
same dose range as AIP56 (Figure 4.16B) indicating that alkylation did not compromise the 
catalytic activity of the toxin. Nevertheless, cysteine alkylation was found to partially 
compromise AIP56’s toxicity. When tested ex vivo at the same doses, alkylated AIP56 
exhibited a lower apoptogenic and p65 cleaving activity than AIP56 (Figure 4.16C and D). 
These results suggest that in AIP56, though not being an absolute requirement for toxicity, 
the disulphide bridge plays a role in the intoxication process. 
 
 
Figure 4.16. The disulphide bridge of AIP56 increases the efficiency of the intoxication process but is not an absolute 
requirement for toxicity. (A) Alkylation disrupted the disulphide bridge linking the two AIP56 cysteine residues. Reducing 
(+DTT) and non-reducing (-DTT) SDS-PAGE of AIP56 and alkylated AIP56 (AIP56alk). Numbers on the left of the panels 
indicate the position and mass, in kDa, of the molecular weight markers. (B) Alkylated AIP56 (AIP56alk) display proteolytic 
activity in vitro in the same dose range as AIP56. 35S-labeled sbp65Rel was incubated for 2 h at 22 ºC with wild type or alkylated 
AIP56 at the indicated concentrations and cleavage assessed by autoradiography. Part of this blot was included in Figure 
4.15D. (C) and (D) Disruption of the disulphide bridge linking Cys262 and Cys298 partially compromises AIP56 toxicity. 
Leukocytes collected from 5 animals were incubated with AIP56 or alkylated AIP56 (AIP56alk) for 4 h at 22 ºC. The percentage 
of apoptotic cells was determined by morphological analysis of cytospin preparations stained with Hemacolor (C) and p65 
cleavage assessed by Western blotting (D). The box plot (C) presents the percentage of apoptotic cells (the middle bar 
corresponds to the median and the lower and upper side of the boxes, the first and third quartiles; circles and diamonds signal 
extreme observations). When used at the same concentration, AIP56alk resulted in lower percentage of apoptotic cells than 
AIP56, except for the dose of 0.5 µg/ml in which no statistical differences were observed.  
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4. AIP56 and NleC: structural and functional conservation but 
different unfolding properties 
 
4.1. NleC and AIP56 catalytic region share structural similarity 
The results presented so far revealed that, similarly to NleC, AIP56 is a zinc- 
dependent metalloprotease targeting the NF-κB p65, with this cleaving activity attributed to 
its N-terminal region. However, and despite the pathological consequences of AIP56 and 
NleC catalytic activities are known (Baruch et al, 2010; do Vale et al, 2007a; do Vale et al, 
2007b; do Vale et al, 2005; Muhlen et al, 2011; Pearson et al, 2011; Sham et al, 2011; 
Shames et al, 2011; Yen et al, 2010), structural data regarding these two proteins is still 
scarce and their crystal structures were not yet determined. The 47.0% similarity and the 
30.5% identity of the primary structures of the AIP56 N-terminal region (Asn1- Cys262) and 
NleC also suggests that, apart from function conservation, NleC and AIP56 catalytic region 
are structurally similar. Therefore, aiming at gathering partial structural information, the 
secondary structure of NleC and was analysed by CD. The results show that the NleC Far-
UV spectrum is indistinguishable from the one of AIP561-285 (Figure 4.17A) and that both 
proteins fold predominantly as α-helices. In addition, in silico analysis using bioinformatics 
tools predicts conservation of the position of the α-helices and β-strands in the primary 
AIP561-285 and NleC sequences (Figure 4.17B). Thus, the high sequence conservation, 
together with the functional and structural data suggest that NleC and AIP56 catalytic region 
have a similar secondary structure content and may display a common fold and thus similar 
three-dimensional structures. 
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Figure 4.17. AIP56 N-terminal region and NleC share structural similarity. (A) Far-UV CD spectra of AIP561-285 and NleC 
and secondary structure content of AIP561-285 and NleC. (B) Sequence alignment of AIP561-285 and NleC showing the predicted 
secondary structures. α-helices are represented by red cylinders and β-sheets by green arrows. Sequence alignment was 
performed using ClustalW2 (Dunbrack, 2006) and secondary structures were predicted using PSIPRED (Jones, 1999; McGuffin 
et al, 2000). 
 
4.2. NleC is not delivered into the cell cytosol by AIP56 C-terminal portion 
or LF/PA 
Although AIP56 and NleC share the same intracellular target, these proteins differ in 
the mechanism used to enter target cells. While NleC is directly injected into the host cell 
cytoplasm through a type III secretion system (Dean & Kenny, 2009; Tobe et al, 2006), 
AIP56 has a chimeric structure, with an N-terminal catalytic region and a C-terminal region 
playing a role in binding and entry into target cells, conferring to the toxin an intrinsic ability to 
enter cells. To see whether the AIP56 C-terminus was able to deliver NleC into the cells, we 
produced a chimera in which the AIP56 N-terminal region (AIP561-250) was replaced by NleC1-
270 (see section 1). The rational for this chimera was to join the NleC region that shares high 
similarity to AIP56, until the absolutely conserved motif ASPDF (see Figure 4.17) with the C-
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terminal of AIP56 (AIP56251-497) including the linker region, given the importance of those 
residues for the activity and delivery of the toxin (see above section 3.4). The delivery of 
NleC1-270 into the cell cytoplasm of sea bass peritoneal leukocytes was tested using p65 
cleavage as readout. No p65 cleavage could be observed upon incubation of NleC1-
270∙AIP56251-497 with cells, suggesting that the catalytic portion of the chimera (the NleC) was 
unable to reach the cytosolic compartment (Figure 4.18 A). The correct folding of the two 
fused protein domains was confirmed by testing NleC1-270∙AIP56251-497 proteolytic activity in 
vitro against 35S-labelled sbp65Rel (Figure 4.18B), and by using it as competitor for AIP56 
apoptogenic activity (Figure 4.18C). The results show that the fused regions are not impaired 
in their functions, suggesting that the inability of the chimera to intoxicate cells is related to 
an inefficient delivery into the cytosol. It should be noted that the exact boundaries of the 
AIP56 binding/translocation domain were not yet established and, therefore, whether the lack 
of toxicity of the NleC1-270∙AIP56251-497 chimera is related to the fusion of an incorrect AIP56 
portion or to an inability of NleC1-270 to translocate remains to be investigated. 
Given the success of anthrax LF/PA system in delivering the catalytic domain of 
several toxins (Arora & Leppla, 1993; Arora & Leppla, 1994; Milne et al, 1995), including 
AIP56 (see above section 3.2), we decided to attempt the delivery of NleC into the cell 
cytoplasm using this system. A LF·NleC chimera, consisting on the N-terminal portion of LF 
(LF11-263) fused with the full-length NleC, was produced (see section 1) and conservation of 
proteolytic activity towards p65 in vitro confirmed using 35S-labelled sbp65Rel homology 
domain as substrate (Figure 4.18B). However, and in contrast with LF11-263∙AIP561-261 
chimera (Figure 4.12), incubation of cells with LF11-263∙NleC in the presence of PA did not 
result in p65 cleavage (Figure 4.18D) indicating that the LF/PA system was unable to 
translocate and deliver NleC into the cell cytoplasm. 
A distinctive feature between AIP56 N-terminal region and NleC is the existence, in 
NleC, of three cysteine residues upstream the zinc metalloprotease signature, which are 
absent in AIP56 (Silva et al, 2010) (see chapter I Figure 1.10). Two of these cysteine 
residues (Cys107 and Cys149) are conserved among the NleC effectors from different 
enteropathogenic bacteria, suggesting that they may be involved in the formation of a 
disulphide bridge. Considering that translocation of protein cargos across the PA pores 
involves pH-driven unfolding of the passenger proteins, which can be impaired by the 
presence of disulphide bridges (Collier, 2009), the NleC putative disulphide bridge might 
constitute a structural restrainment to protein unfolding required for translocation. Therefore, 
we produced a mutant chimera (LF11-263∙NleCMut) where the two conserved cysteine residues, 
Cys107 and Cys149, were mutated to their correspondent amino acid residue in AIP56 (a 
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histidine and a tyrosine, respectively) (see section 1). Nevertheless, although LF11-263∙NleCMut 
still retained the catalytic activity towards p65 in vitro (Figure 4.18B), it did not cleave p65 
when added to cells in the presence of PA (Figure 4.18D), showing that the cysteine mutant 
LF·NleC chimera was also unable to translocate across the PA pores.  
 
Figure 4.18. NleC∙AIP56 and LF·NleC chimeras are catalytically active in vitro but do not cleave NF-κB p65 when 
incubated with cells. (A) NleC∙AIP56 chimera does not cleave p65 when incubated with cells. Leukocytes were incubated with 
10 µg/ml of NleC1-270∙AIP56251-497 (NleC∙AIP56Cterm) for 2 h at 22 ºC and p65 cleavage assessed by Western blotting. (B) 
NleC∙AIP56 and LF·NleC chimeras are catalytically active in vitro. 35S-labeled sbp65Rel (Met1-Arg188) was incubated for 2 h at 
22 ºC with 1 µM of AIP56, NleC, NleC1-270∙AIP56251-497 (NleC∙AIP56Cterm), LF11-263∙NleC (LF·NleC) and LF11-263∙NleCMut 
(LF∙NleCMut) and cleavage assessed by autoradiography. (C) NleC∙AIP56 chimera competes with AIP56 and inhibits its 
apoptogenic activity. Sea bass leukocytes collected from 3 animals were incubated with 3.5 µM of NleC1-270∙AIP56251-497 
(NleC∙AIP56Cterm) for 15 min on ice followed by further 15 min incubation on ice with 8.75 nM of AIP56. Cells incubated with 
AIP56 in the absence of competitor, mock-treated cells and cells incubated with 3.5 µM AIP56286-497 (C-term) before incubation 
with AIP56 were used as controls. Cells were washed, transferred to 22 ºC, incubated for 4 h and the percentage of apoptotic 
cells determined by morphological analysis of cytospin preparations stained with Hemacolor. (D) B. anthracis LF/PA system was 
not able to deliver NleC into the cells cytosol. Sea bass leukocytes were incubated for 4 h at 22 ºC with 700 nM (48 μg/ml) of 
LF11-263∙NleC (LF·NleC) or LF11-263∙NleCMut (LF∙NleCMut) in the presence of 10 nM of PA and cleavage of NF-κB p65 detected by 
Western blotting. Cells incubated with 2 µg/ml (35 nM) AIP56 or with 20 nM (1.2 μg/ml) LF11-263∙AIP561-261 (LF∙AIP56Nterm) in the 
presence of 10 nM PA were used as positive controls. The depicted protein bands were from the same membrane and were cut 
out and juxtaposed for presentation in the figure. Part of this blot was included in Figure 4.12A.  
 
4.3. AIP561-261 and NleC have different stability towards unfolding 
Considering that the ability to unfold in response to low pH is a requirement for 
proteins to translocate across the PA pores and in an attempt to explain the observed distinct 
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behaviour of AIP561-261 and NleC in the LF/PA delivery, protein stability of LF11-263∙AIP561-261, 
LF11-263∙NleC and LF11-263∙NleCMut at different pH was assessed by differential scanning 
fluorimetry (DSF). Variation of the protein melting temperature (Tm) at different pH values 
was used as measure of the energy requirements for pH-driven unfolding. It was observed 
that at neutral pH, the thermo stability of LF11-263∙NleC is higher than the one of LF11-
263∙AIP561-261, as indicated by the 15.4 ºC difference in their Tm (Figure 4.19). As expected, 
mutation of Cys107 and Cys149 of NleC, had a destabilizing effect with the Tm of LF11-
263∙NleCMut being 8.0 ºC below the one of LF11-263∙NleC. Still, LF11-263∙NleCMut is significantly 
more stable at pH 7.0 than LF11-263∙AIP561-261, as denoted by the 7.8 ºC difference in their Tm 
(Figure 4.19). Despite the differences in the thermo stability of the analysed proteins, in all of 
them, a marked effect of pH on the thermal stability was observed with the Tm decreasing as 
pH diminished. However, whereas LF11-263∙NleC was quite stable up to pH 5.0 (Tm of 36.4 ºC 
at pH 5.0), LF11-263∙AIP561-261 did not withstand pH values below 6.0 being already 
precipitated/unfolded at this pH (Figure 4.19). Despite LF11-263∙NleCMut was found to be more 
susceptible to pH-driven unfolding than LF11-263∙NleC (Figure 4.19), when compared with 
LF11-263∙AIP561-261, LF11-263∙NleCMut is significantly more stable at acidic pH values presenting 
at pH 6.0 and 5.5 Tm of 47.7 and 40.8 ºC, respectively. Together, these results indicate that 
LF11-263∙NleC and LF11-263∙NleCMut have a significantly higher resistance to pH-induced 
unfolding than LF11-263∙AIP561-261, a difference that may explain the inability of LF∙NleC 
chimeras to translocate across the PA pore. 
 
 
Figure 4.19. AIP56’s N-terminal region and NleC have different unfolding properties. Melting temperatures of LF11-
263∙AIP561-261, LF11-263∙NleC and LF11-263∙NleCMut at different pH values. The protein unfolding was monitored by DSF. The melting 
temperature (Tm) was calculated as the inflection point of the fluorescence curve. The results are the mean±SD of 7 
measurements performed in two independent experiments. The melting temperatures for LF11-263∙AIP561-261 at pH 5.5 and 5.0 
and for LF11-263∙NleCMut at pH 5.0 could not be determined due to protein precipitation. 
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5. AIP56 crystallization  
5.1. AIP56 purification and characterization 
The complete characterization of a given protein involves the understanding of its 
biochemical, biophysical and structural features which are ultimately unravelled by knowing 
the protein’s three-dimensional structure. The three-dimensional structures of AIP56 toxin or 
of its homologues are still unknown and their knowledge would provide an invaluable 
framework for detailed understanding of the molecular mechanisms of action of these 
molecules. X-ray crystallography was the method of choice to try to solve AIP56 three-
dimensional structure, since it is a powerful technique that allows the visualization of 
macromolecular structures at atomic resolution. However, determining the structure of a 
protein by this technique entails growing high-quality crystals of the purified protein, which 
are highly dependent on protein sample purity, not only in terms of the lack of non-wanted 
proteins but also in terms of homogeneity and stability of the protein in solution (Dale et al, 
2003; Durbin & Feher, 1996; Giergé R., 1992). 
The protocol for purification of recombinant AIP56 described in section 1 (where the 
protein was purified by nickel affinity chromatography followed by anion-exchange 
chromatography, used as a polishing step) yield fairly pure but unstable protein, with high 
tendency to precipitate, that does not abide the high quality requirements for crystallization 
trials. Thus, improving AIP56 purification in order to obtain high amounts of highly pure and 
stable protein was imperative before proceeding to crystallization trials.  
Taking into account that protein stability can also be significantly improved by 
changing buffer composition and knowing that AIP56 contains a zinc-binding signature (do 
Vale et al, 2005; Giergé R., 1992) addition of zinc chloride to cell lysis and affinity 
chromatography buffers was also attempted. However and contrary to what was expected, 
its presence in solution had a destabilizing effect and increased AIP56 precipitation. Pursuing 
the improvement of protein stability in solution, the effect of increasing glycerol and NaCl 
concentrations in the protein buffer were evaluated by Dynamic Light Scattering (DLS), using 
the polydispersity index (representative of the particle size distribution) as a measure of 
protein homogeneity and stability in solution (Table 4.1). High polydispersity index values 
were obtained for AIP56 in the majority of the tested buffer compositions. Yet, a decrease in 
the polydispersity index values, indicative of an increase in protein stability, was observed by 
increasing NaCl concentration (Table 4.1), while no significant improvement on the protein 
stability was achieved by addition of glycerol to the protein (Table 4.1). Thus, considering the 
observed stabilizing effect of NaCl, the concentration of this salt in cell lysis and affinity 
chromatography buffers was raised to 500 mM and the toxin was maintained at high NaCl 
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conditions whenever possible. Following this reasoning, substitution of the ion-exchange 
chromatography, by an alternative purification step would be desirable. However, the 
presence, in affinity chromatography eluted fractions, of contaminants with a molecular 
weight similar to that of AIP56 (not shown) dismissed the use of size exclusion 
chromatography as polishing step. Nonetheless, the time during which AIP56 was at lower 
NaCl concentrations was kept at minimum and by using a high resolution ion-exchange 
chromatography column, with higher affinity for AIP56, we were able to perform the binding 
of AIP56 to the chromatography column at a higher NaCl concentration and to improve 
protein purity. Additionally, reduced protein precipitation was achieved by performing the 
desalting of affinity chromatography elution fractions more rapidly using PD-10 columns 
instead for overnight dialysis (given the tendency of AIP56 to precipitate in the presence of 
imidazole, discussed in section 1), and by disrupting the bacterial cells by sonication instead 
of freezing/thawing cycles. 
 
Table 4.1. Analysis of AIP56 stability in different solutions by Dynamic Light Scattering. Values are means ± SD of 3 
independent measurements.  
 
 
(In terms of a protein analysis, a polydispersity index below 0.20 indicates that the sample is monodisperse (Borgstahl, 2007))  
 
All the above mentioned adjustments to the purification procedure contributed to the 
improvement of the protein sample quality. Thirty milligrams of highly pure AIP56 (in 10 mM 
Tris-HCl pH 8.0, 200 mM NaCl), produced from three different batches of bacterial cell 
culture (average yield 2 mg/L pure AIP56) (Figure 4.20A), were obtained. Quality of AIP56 
preparations was controlled in terms of purity (by SDS-PAGE) and in terms of homogeneity 
and monodispersity (by size exclusion chromatography, Native-PAGE and DLS) (Figure 
4.20). Size exclusion chromatography and Native-PAGE analysis indicate a homogenous 
protein preparation with purified AIP56 eluting from size exclusion chromatography as a 
Condition Polydispersity index 
10 mM Tris-HCl pH 8.0, 100 mM NaCl 0.488±0.022 
10 mM Tris-HCl pH 8.0, 200 mM NaCl 0.364±0.013 
10 mM Tris-HCl pH 8.0, 500 mM NaCl 0.276±0.014 
10 mM Tris-HCl pH 8.0, 200 mM NaCl, 5% (v/v) glycerol 0.408±0.003 
10 mM Tris-HCl pH 8.0, 500 mM NaCl, 5% (v/v) glycerol 0.426±0.008 
10 mM Tris-HCl pH 8.0, 200 mM NaCl, 10% (v/v) glycerol 0.382±0.017 
10 mM Tris-HCl pH 8.0, 500 mM NaCl, 10% (v/v) glycerol 0.426±0.012 
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single symmetrical peak (Figure 4.20B) and migrating as a single band in Native-PAGE 
(Figure 4.20C). However, DLS revealed the existence of high molecular weight species in the 
AIP56 preparation (Figure 4.20D). The fact that the scattering intensity is proportional to the 
particle molecular weight makes DLS a very sensitive technique to detect protein 
aggregation and/or the presence of large contaminants, even at very low concentrations 
undetectable in size exclusion chromatography, as it is the case. The measured AIP56 
samples presented a polydispersity index above 0.3 and thus were considered as 
polydisperse. However, it should be taken into consideration that the polydispersity index is 
representative of the particle size distribution and therefore the high value obtained can be 
related not only to the presence of protein aggregates but also to a possible non-globular 
shape. Therefore, and even though AIP56 preparation did not fully meet all the high quality 
criteria, we decided to follow with crystallization trials. 
 
 
Figure 4.20. Purity and homogeneity of AIP56 preparations used in crystallization trials. A) Ten μg AIP56 were analysed 
by SDS-PAGE (carried out in a 12.5% separating gel) and stained with Coomassie Blue. Numbers on the left of the panels refer 
to the position and mass, in kDa, of the molecular weight markers. B) Native-PAGE analysis of AIP56. BSA was run for control 
purposes. C) Analytical size exclusion chromatography of AIP56. Fifty µg of AIP56 in 10 mM Tris pH 8.0, 200 mM NaCl was 
injected onto Superose 12 10/300 column (GE Healthcare) pre-equilibrated in the same buffer. Protein elution was monitored by 
measuring the absorbance at 280 nm. D) Dynamic light scattering analysis of AIP56. Scattered light intensity vs. particle radius 
plot. The first peak of intensity corresponds to a population of molecules with a hydrodynamic radius of 4.22 nm. Note the 
presence of a peak correspondent to high molecular weight species.  
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5.2. Crystallization trials 
AIP56 crystallization screens were performed using the vapor diffusion method in 
sitting drops. Sparse-matrix commercial crystallization kits were used in the first screenings 
for crystallization conditions and formation of AIP56 microcrystals was observed in several 
conditions, (see annex 1 Table 4.2). An interesting observation was that in all crystallization 
conditions (with exception of condition I, see below), polyethylene glycol (PEG) was the 
precipitant agent. Conditions VIII, XV, XXVII, XXXII (see annex 1 Table 4.2) were selected 
for additional screening by varying pH of the crystallization solution, PEG molecular weight 
and concentration, salt concentration and addition of additives, as well as variation of drop 
volume and protein:crystallization solution ratio. Neutral or slightly alkaline pH were found to 
favour AIP56 crystallization. Furthermore, although variation of drop volume and ratio of 
crystallization solution:protein did not result in a significantly improvement of crystal growth, 
in most cases, variation of the polymeric range and concentration of the precipitant agent 
and the addition of glycerol significantly improved crystal size and singularity. The majority of 
the obtained crystals were composed of thin plates arranged in large clusters (Figure 4.21 A. 
B). Nonetheless, in some conditions, isolated crystals (mostly small thin crystal plates) 
(Figure 4.21 D, E and F) were obtained. These isolated crystals were flash-cooled and sent 
for testing at the European Radiation Facility (ESRF, Grenoble, France) (see annex 1 Table 
4.3). Although some of the tested crystals looked promising they were found to be composed 
by very thin superimposed crystal layers and showed poor diffraction properties. 
Flexibility in a protein and structural micro-heterogeneities adversely affect crystal 
growth, especially when structural heterogeneities concern regions involved in crystal 
packing. As presented above in section 3, AIP56 has a chimeric structure consisting in two 
disulphide-bound structural domains that are tethered by a flexible linker. While the two 
AIP56 domains are quite resistant to protease digestion in limited proteolysis experiments, 
the loop region is readily cleaved by chymotrypsin or proteinase K, originating the separation 
of two domains that are still held together through the disulphide bond (Figure 4.8). Hence, in 
situ proteolysis crystallization experiments, a technique proven to be successful in the 
crystallization of several multidomain proteins, which consists on crystallization of a protein in 
the presence of residual amounts of proteases (Bai et al, 2007; Dong et al, 2007; Mandel et 
al, 2006; Wernimont & Edwards, 2009), was attempted. Sparse-matrix crystallization kits 
were tested using a sample of AIP56 containing small amounts of chymotrypsin. However, 
no crystalline structures were obtained and formation of protein precipitates occurred in the 
vast majority of the conditions tested, even in those that yielded crystals with AIP56 alone. 
Additionally, in an attempt to control nucleation, and thus improve crystal size and singularity, 
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seeding techniques (Stura & Wilson, 1991) were employed. However, again, no significant 
improvements in crystal quality were achieved with crystal plate clusters obtained in most of 
the drops. 
 
 
Figure 4.21. AIP56 crystals. (A) AIP56 crystal cluster grown in 0.2 M ammonium citrate tribasic pH 7.0, 15% (w/v) polyethylene 
glycol 3350. (B) AIP56 crystal cluster grown in 0.2 M potassium thiocyanate, 15% (w/v) polyethylene glycol 2000, 0.1 M HEPES 
pH 7.0, 1% glycerol. (C) AIP56 crystal plates grown in 0.2 M potassium thiocyanate, 15% (w/v) polyethylene glycol 2000, 0.1 M 
HEPES pH 7.0, 0.5% (v/v) glycerol. (D) AIP56 crystal plate grown in 0.2 M potassium thiocyanate, 15% (w/v) polyethylene 
glycol 2000, 0.1 M HEPES pH 7.0, 0.5% (v/v) glycerol (Crystal XVIII, table 4.3, annex 1). (E) AIP56 crystal plates grown in 
AIP56 crystal plate grown in 0.2 M potassium thiocyanate, 20% (w/v) polyethylene glycol 8000, 0.1 M HEPES pH 7.9. (Crystals 
XXXIII and XXXIV, table 4.3, annex 1). (F) AIP56 crystal plate grown in 0.2 M potassium thiocyanate, 20% (w/v) polyethylene 
glycol 6000, 0.1 M HEPES pH 7.9. (Crystal XXIV, table 4.3, annex 1). 
 
As mentioned before, well-succeed protein crystallization, depends largely on the 
purity of protein samples, not only in terms of unwanted contaminating proteins but also in 
terms of structural and conformational homogeneity of the intended-protein (Dale et al, 2003; 
Giergé R., 1992). Structural micro-heterogeneities in the protein are known to adversely 
affect crystal growth, especially when structural heterogeneities concern domains involved in 
crystal packing (Durbin & Feher, 1996; Van der Laan et al, 1989). Thus, in the case of 
AIP56 crystallization, the observed AIP56 instability and heterogeneity are likely causes for 
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the multiplicity of the obtained AIP56 crystals and improvement of AIP56 stability seems to 
be imperative before undertaking new crystallization trials. Nevertheless, although we were 
unable to obtain AIP56 crystals suitable for performing X-ray diffraction studies, these studies 
allowed the identification of promising preliminary crystallization conditions and provided 
important knowledge regarding AIP56 stability and behaviour in solution useful for future 
AIP56 crystallization projects. 
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Table 4.2. List of conditions that produced crystals. (Conditions in bold were selected for optimisation) 
Condition Chemical composition Result 
I 0.1 M Bis-Tris pH 6.5, 3.0 M sodium chloride small crystals 
II 0.1 M Bis-Tris pH 6.5, 28% (w/v) polyethylene glycol 2000 microcrystals 
III 0.2 M ammonium sulfate, 0.1 M HEPES pH 7.5, 25% (w/v) polyethylene glycol 3350 microcrystals 
IV 0.2 M ammonium sulfate, 0.1 M Tris pH 8.5, 25% (w/v) polyethylene glycol 3350 small crystals 
V 0.2 M lithium sulfate monohydrate, 0.1 M Tris-HCl pH 8.5, 25% (w/v) polyethylene glycol 3350 microcrystals 
VI 0.2 M potassium sodium tartrate tetrahydrate, 20% (w/v) polyethylene glycol 3350 microcrystals 
VII 0.2 M sodium malonate pH 7.0, 20% (w/v) polyethylene glycol 3350 microcrystals 
VIII 0.2 M ammonium citrate tribasic pH 7.0, 20% (w/v) polyethylene glycol 3350 small crystals 
IX 0.2 M sodium formate, 20% (w/v) polyethylene glycol 3350 microcrystals 
X 0.15 M DL-malic acid pH 7.0, 20% (w/v) polyethylene glycol 3350 small crystals 
XI 0.2 M sodium citrate tribasic dihydrate, 20% (w/v) polyethylene glycol 3350 microcrystals 
XII 0.1 M potassium thiocyanate, 30% (w/v) polyethylene glycol 2000 microcrystals 
XIII 0.15 M potassium bromide, 30% (w/v) polyethylene glycol 2000 microcrystals 
XIV 0.2 M lithium sulfate monohydrate, 0.1 M Tris-HCl pH 8.5, 30% (w/v) polyethylene glycol 4000 microcrystals 
XV 0.1 M HEPES pH 7.5, 10% (w/v) polyethylene glycol 6000, 5% (v/v) (+/-)-2-methyl-2,4-pentanediol crystal plates 
XVI 0.1 M HEPES pH 7.5, 8% (v/v) ethylene glycol, 10% (w/v) polyethylene glycol 8000 small crystals 
XVII 0.1 M HEPES pH 7.5, 20% (w/v) polyethylene glycol 10000 microcrystals 
XVIII 1.5 M ammonium sulfate, 0.1 M Tris-HCl pH 8.5, 12% (v/v) glycerol microcrystals 
XIX 0.16 M magnesium chloride hexahydrate, 0.08 M Tris-HCl pH 8.5, 24% (w/v) polyethylene glycol 4000, 20% (v/v) glycerol needle clusters 
XX 0.17 M lithium sulfate monohydrate, 0.085 M Tris-HCl pH 8.5, 25.5% (w/v) 
polyethylene glycol 4000, 15% (v/v) glycerol 
microcrystals 
XXI 0.16 M magnesium acetate tetrahydrate, 0.08 M sodium cacodylate trihydrate pH 
6.5, 16% (w/v) polyethylene glycol 8000, 20% (v/v) glycerol 
microcrystals 
XXII 0.17 M sodium acetate trihydrate, 0.085 M Tris-HCl pH 8.5, 25.5% (w/v) polyethylene 
glycol 4000, 15% (v/v) glycerol 
microcrystals 
XXIII 0.2 M potassium chloride, 20% (w/v) polyethylene glycol 3350 microcrystals 
XXIV 0.2 M sodium iodide, 20% (w/v) polyethylene glycol 3350 microcrystals 
XXV 0.2 M potassium iodide, 20% (w/v) polyethylene glycol 3350 microcrystals 
XXVI 0.2 M sodium thiocyanate, 20% (w/v) polyethylene glycol 3350 microcrystals 
XXVII 0.2 M potassium thiocyanate, 20% (w/v) polyethylene glycol 3350 small crystals 
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Table 4.2. List of conditions that produced crystals. (Cont) 
Condition Chemical composition Result 
XXVIII 0.2 M sodium formate, 20% (w/v) polyethylene glycol 3350 microcrystals 
XXIX 0.2 M potassium formate, 20% (w/v) polyethylene glycol 3350 microcrystals 
XXX 0.2 M sodium tartrate dibasic dihydrate, 20% (w/v) polyethylene glycol 3350 microcrystals 
XXXI 0.2 M potassium sodium tartrate tetrahydrate, 20% (w/v) polyethylene glycol 3350 microcrystals 
XXXII 0.2 M ammonium phosphate dibasic, 20% (w/v) polyethylene glycol 3350 small crystals 
XXXIII 0.2 M lithium citrate tribasic tetrahydrate, 20% (w/v) polyethylene glycol 3350 small crystals 
XXXIV 0.2 M sodium citrate tribasic dihydrate, 20% (w/v) polyethylene glycol 3350 small crystals 
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Table 4.3. List of AIP56 crystals measured  
Crystal Diffraction Crystallization solution 
I 4.3 Å 
0.2 M ammonium phosphate dibasic, 15% (w/v) polyethylene glycol 8000, 0.1 M Tris-HCl 
pH 7.9  II 4.3 Å 
III 4.5 Å 
IV 4 Å 0.2 M ammonium phosphate dibasic, 15% (w/v) polyethylene glycol 8000, 0.1 M Tris-HCl 
pH 7.9, 0.2% (v/v) glycerol  V 3.5 Å 
VI 3.8 Å (anisotropic) 
0.2 M ammonium phosphate dibasic, 15% (w/v) polyethylene glycol 8000, 0.1 M Tris-HCl 
pH 7.9, 1% (v/v) glycerol 
VII 3 Å (anisotropic) 0.2 M ammonium phosphate dibasic, 15% (w/v) polyethylene glycol 6000, 0.1 M Tris-HCl 
pH 7.9 VIII 4 Å (anisotropic) 
IX 4 Å (anisotropic) 0.2 M ammonium phosphate dibasic, 15% (w/v) polyethylene glycol 6000, 0.1 M Tris-HCl 
pH 7.9, 0.5% (v/v) glycerol  X 7 Å 
XI No diffraction 0.2 M ammonium phosphate dibasic, 15% (w/v) polyethylene glycol 6000, 0.1 M Tris-HCl 
pH 7.9, 1% (v/v) glycerol XII No diffraction 
XIII 3 Å 0.2 M potassium thiocyanate, 15% (w/v) polyethylene glycol 2000, 0.1 M HEPES pH 7.0 
XIV 3.1 Å 0.2 M potassium thiocyanate, 15% (w/v) polyethylene glycol 2000, 0.1 M HEPES pH 7.0, 
0.2% (v/v) glycerol  XV 4 Å 
XVI 4 Å 
0.2 M potassium thiocyanate, 15% (w/v) polyethylene glycol 2000, 0.1 M HEPES pH 7.0, 
0.5% glycerol  
XVII 3.5 Å (anisotropic) 
XVIII 
3.0 Å 
(anisotropic) 
XIX 8 Å 
0.2 M potassium thiocyanate, 25% (w/v) polyethylene glycol 2000, 0.1 M HEPES pH 7.9 
XX 3.5 Å (anisotropic) 
XXI 5 Å 
XXII No diffraction 
XXIII No diffraction 
XXIV 5 Å 
0.2 M potassium thiocyanate, 20% (w/v) polyethylene glycol 6000, 0.1 M HEPES pH 7.9 
XXV 4 Å 
XVI 8 Å 
XVII No diffraction 
XVIII No diffraction 
XXIX No diffraction 
XXX No diffraction 
XXXI No diffraction 
XXXII 3 Å (anisotropic) 
0.2 M potassium thiocyanate, 15% (w/v) polyethylene glycol 8000, 0.1 M HEPES pH 7.9 
XXXIII 3 Å (anisotropic) 
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1. AIP56: a zinc metalloprotease targeting NF-κB p65 
Photobacterium damselae piscicida (Phdp) is a successful bacterial pathogen whose 
virulence strategy relies on the induction of apoptosis of the host professional phagocytes 
through the secretion of an exotoxin named AIP56 (Costa-Ramos et al, 2011; do Vale et al, 
2007a; do Vale et al, 2005). By inducing apoptosis of both macrophages and neutrophils, 
AIP56 also causes a severe impairment of the host phagocytic defences, allowing the 
establishment of a septicaemic infection (do Vale et al, 2007a; do Vale et al, 2003; do Vale et 
al, 2005). Another consequence of the lack of functional phagocytes is an insufficient 
clearance of apoptotic cells and apoptotic bodies that eventually lyse by secondary necrosis 
(do Vale et al, 2007a). This AIP56-induced phagocyte apoptosis proves to be a very effective 
mechanism of amplification of the etiopathogenicity, because it results in two concerted 
effects against the host: evasion of the pathogen from phagocytosis, a fundamental defence 
mechanism, and release of tissue harmful molecules by secondary necrosis of the apoptotic 
phagocytes (do Vale et al, 2007a). Although the pathology of the disease and the toxic 
effects of AIP56 are well characterized (Costa-Ramos et al, 2011; do Vale et al, 2002; do 
Vale et al, 2007a; do Vale et al, 2007b; do Vale et al, 2003; do Vale et al, 2005), at the 
beginning of this work the molecular mechanisms beyond AIP56 toxicity were still unknown. 
Identification of host proteins targeted by bacterial virulence factors and 
characterization of their processing sites under relevant physiological conditions are 
essential for understanding the biological function of those factors in the context of an 
infection. Here, by showing that AIP56 is a zinc-dependent metalloprotease that cleaves the 
p65 subunit of the nuclear factor-κB (NF-κB) we extend the functional characterization of 
AIP56 and provide valuable information regarding the molecular mechanisms beyond the 
toxin’s activity.  
Several other bacterial toxins such as tetanus toxin (TeNT), botulinum toxin (BoNT) 
and anthrax lethal factor (LF) are zinc-dependent metalloproteases with a crucial role for the 
virulence of their producing bacteria (Moayeri & Leppla, 2004; Schiavo et al, 1994; 
Swaminathan, 2011; Tonello & Montecucco, 2009). The clostridial neurotoxins (TeNT and 
BoNT) cleave the SNARE proteins (soluble NSF-attachment protein receptors) (Schiavo et 
al, 1992a; Schiavo et al, 1992b; Schiavo et al, 1994), a group of proteins involved in the 
fusion of synaptic vesicles with the plasma membrane (Ramakrishnan et al, 2012), causing 
blockage of neurotransmitter release and leading to flaccid paralysis (Swaminathan, 2011). 
The anthrax LF cleaves the N-terminal tail of mitogen-activated protein kinase (MAPK) 
kinases, blocking MAPK signalling and thus causing an impairment of the host immune 
responses (Chopra et al, 2003; Duesbery et al, 1998; Klimpel et al, 1994; Tonello & 
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Montecucco, 2009; Vitale et al, 1998). One of the most prominent effects of the LF-mediated 
blocking of MAPK signalling pathways is the induction of apoptosis on macrophages (Park et 
al, 2002; Popov et al, 2002). By inducing macrophage apoptosis, LF prevents the release of 
chemokines and cytokines that would alert the immune system to the presence of infecting 
Bacillus anthracis, thereby facilitating the septicaemic spread of the infection (Park et al, 
2002; Tournier et al, 2009). The described anthrax LF virulence mechanism resembles the 
one employed by AIP56 during Phdp infections (do Vale et al, 2007a; do Vale et al, 2003; do 
Vale et al, 2005; Silva et al, 2010).  
Our data show that AIP56 cleaves the p65 subunit of NF-κB within its Rel homology 
domain. Cleavage was observed upon incubation of sea bass cell lysates or recombinant 
p65 Rel homology domain with AIP56 and was dependent on the metalloprotease signature 
of the toxin. This proteolytic activity against p65 was found to play a relevant role in the 
intoxication of target cells with AIP56, since an AIP56 metalloprotease mutant lacking p65 
cleaving activity did not induce apoptosis.  
The NF-κB transcription factors consist of homo- or heterodimeric assemblies of the 
Rel/NF-κB proteins (NF-κB 1 (p50), NF-κB 2 (p52), RelA (p65), RelB and c-Rel) of which the 
p50/p65 heterodimer is the most abundant (Gilmore, 1999). These factors regulate the 
expression of hundreds of genes involved in the immunological response including several 
cytokines (such as IL-8, IL-6, IL-10, IL1-α, IL-1β, TNF-α, IFN-γ) and their modulators, 
immune receptors, proteins involved in antigen presentation and cell adhesion molecules 
(Baeuerle & Henkel, 1994; Ghosh et al, 1998; Vallabhapurapu & Karin, 2009). In addition to 
immune related genes, the expression of several proteins involved in cell survival and 
proliferation are also regulated by NF-κB (Burstein & Duckett, 2003; Gerondakis et al, 2012; 
Shishodia & Aggarwal, 2002). These proteins include regulators of apoptosis, both anti-
apoptotic genes (such as cIAP-1 and cIAP-2, Bcl-2, Bcl-xL and Bfl-1), which are up-regulated 
upon NF-κB activation, and pro-apoptotic genes (such as p53, TRAIL and Fas), which are 
down-regulated upon NF-κB activation (Burstein & Duckett, 2003; Shishodia & Aggarwal, 
2002), stress response genes, growth factors, growth factor ligands and their modulators 
(Baldwin, 2012; Gerondakis et al, 2012), among others. The expression of NF-κB-regulated 
genes is signal-induced and highly regulated. Under normal physiological conditions, the NF-
κB complexes remain inactive in the cytosol through association with IκB (inhibitors of NF-
κB) proteins that mask the nuclear localization signals on NF-κB subunits. A variety of 
stimuli, including bacterial and viral products and cytokines acting via cellular receptors 
trigger signalling cascades that leads to degradation of the inhibitory IκB proteins with rapid 
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activation and transport of the NF-κB complexes to the nucleus (Oeckinghaus & Ghosh, 
2009). 
Conservation of the NF-κB transcription factors from Drosophila to humans and the 
presence of a functional NF-κB signalling cascade in the horseshoe crab Carcinoscorpius 
rotundicauda (known as a living fossil) suggest that the proteins involved and their 
mechanisms of action are evolutionarily conserved, underlining their pivotal role in biological 
responses (Gilmore & Wolenski, 2012; Wang et al, 2006). Although the knowledge about NF-
κB biological functions, transcriptional activity and regulation mechanisms in early 
vertebrates is still scarce, evidences point to preservation of function and activation 
mechanisms in fish. A number of NF-κB/I-κB family proteins, with a significant level of 
sequence homology and function conservation to their mammalian orthologues, have been 
identified in several fish species (Correa et al, 2004; Kong et al, 2011; Schlezinger et al, 
2000; Tacchi et al, 2011; Wang et al, 2009). Noteworthy, in zebrafish, a fully conserved NF-
κB/I-κB pathway activated by established NF-κB inducers (such as LPS and UV-light) and 
cross compatible with mammalian orthologues was found (Correa et al, 2004). Moreover, 
indirect evidences also suggest that in carp, NF-κB is involved in induction of expression of 
the inflammatory cytokines tumour necrosis factor-α (TNF-α) and interleukin-1β (IL-1β) (Saeij 
et al, 2003), and in rainbow trout, in the interferon signalling pathway (Collet et al, 2004). 
Furthermore, over-expression of olive flounder p65 in HINAE cells (olive flounder embryonic 
cell line) resulted in increased expression of TNF-α and IκB-α mRNA, suggesting 
transcriptional control of immune-related genes and conservation of auto-regulative feedback 
pathways (Kong et al, 2011). 
N-terminal sequencing of the p65 cleavage fragment, obtained upon incubation of 
recombinant sea bass p65 Rel homology domain with AIP56, revealed that the toxin cleaves 
NF-κB p65 at the Cys39-Glu40 peptide bond. The identified AIP56 cleavage site within p65 is 
evolutionarily conserved and is similar to the cleavage site of the type III secreted effector 
NleC reported by Baruch and colleagues (Baruch et al, 2010). In addition to p65, NleC was 
also described to target c-Rel (Pearson et al, 2011) and the acetyltransferase p300 (Shames 
et al, 2011), and there are contradictory reports regarding its ability to cleave p50 (Muhlen et 
al, 2011; Pearson et al, 2011; Yen et al, 2010). The conservation of the identified AIP56 
cleavage site (within p65) among the Rel/NF-κB proteins together with the degree of 
homology between NleC and the N-terminal region of AIP56 suggest that other members of 
the NF-κB family or the acetyltransferase p300 may also be targeted by AIP56. However, 
whether this hypothesis holds truth remains to be investigated. 
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Several key residues of p65 known to be involved in its interaction with DNA are 
located near the start of the Rel homology domain (Chen et al, 1998a; Chen et al, 1998b; 
Hoffmann et al, 2006) and, in the last decade, several reports revealed a key importance of 
Cys38 of human p65 (Cys39 in sea bass p65) for this interaction. This residue was shown to 
interact with the phosphate backbone of NF-κB binding sites (Chen et al, 1998a) and its 
oxidation and nitrosylation were found to inhibit DNA binding (Kelleher et al, 2007). 
Furthermore, this particular cysteine is also the target of several NF-κB inhibitors with 
reported anti-inflammatory and/or anticancer properties (Garcia-Pineres et al, 2001; Garcia-
Pineres et al, 2004; Ha et al, 2009; Han et al, 2005; Harikumar et al, 2009; Laga et al, 2007; 
Liang et al, 2006; Sandur et al, 2006; Sethi et al, 2008; Straus et al, 2000; Watanabe et al, 
2008) and more recently, Sen and colleagues showed that Cys38 of human p65 plays a key 
role in regulating the anti-apoptotic actions of NF-κB (Sen et al, 2012). These authors 
demonstrated that following TNF-α stimulation, Cys38 of human p65 undergoes hydrogen 
sulphide-linked sulfhydration, enhancing the interaction with its co-activator, the ribosomal 
protein S3 (RPS3), and resulting in an increased binding to the promoters of several anti-
apoptotic genes. They further showed that impairment of Cys38 sulfhydration leads to the 
inability of p65 to bind to DNA and prevents the NF-κB-mediated expression of anti-apoptotic 
genes, thereby sensitizing cells to TNF-α induced cell death (Sen et al, 2012). Therefore, 
cleavage of p65 by AIP56 at the Cys39-Glu40 peptide bond results in the removal of several 
crucial residues involved in DNA interaction. Considering that the proteolytic activity of AIP56 
towards p65 is similar to the one previously described for NleC (both proteases cleave p65 at 
the same peptide bond) and based on the observation that p65 cleavage by NleC 
compromises NF-κB dependent transcription (Baruch et al, 2010; Muhlen et al, 2011; Yen et 
al, 2010), it is likely that AIP56 also affects NF-κB transcriptional activity. Therefore, and 
considering the anti-apoptotic functions of NF-κB, and in particular, of its p65 subunit 
(Bachmeyer et al, 2001; Beg & Baltimore, 1996; Beg et al, 1995; Sen et al, 2012), the AIP56-
mediated depletion of NF-κB p65 is likely involved in the disseminated phagocyte apoptosis 
observed in Phdp infections that contributes to subvert the host immune response and 
determines the outcome of the infection. This adds to a general theme of host-pathogen 
interaction that has recently emerged, consisting in the induction of apoptosis of the host 
immune cells to the pathogen advantage (DeLeo, 2004; Lamkanfi & Dixit, 2010; Weinrauch & 
Zychlinsky, 1999). 
Activation of NF-κB is considered to be the central initiating event of host responses 
to invasion by microbial pathogens (Neish & Naumann, 2011; Rahman & McFadden, 2011) 
and therefore, it is not surprising that successful microbial pathogens have evolved complex 
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strategies to interfere with the NF-κB signalling pathways. In the last years, a growing 
number of pathogenic bacteria were found to target the NF-κB using different proteins that 
affect near all aspects of the NF-κB signalling pathway (reviewed in detail in (Le Negrate, 
2012; Neish & Naumann, 2011; Rahman & McFadden, 2011). These pathogen-derived 
countermeasures have been selected to maintain a delicate balance between activation and 
inhibition of the NF-κB pathway as a survival strategy (Rahman & McFadden, 2011). In the 
context of bacterial infections, inhibition of NF-κB function usually leads to impairment of the 
inflammatory responses (Le Negrate, 2012; Rahman & McFadden, 2011). Findings made to 
date indicate that most bacterial effectors known to interfere with NF-κB signalling target the 
IKK complex, some impair TLR- and MyD88-mediated activation of NF-κB, while a few 
others interfere with NF-κB-dependent transcription (Table 5.1). In addition to NleC, only the 
Vibrio parahaemolyticus VP1686, the Chlamydia protease-like activity factor (CPAF) and the 
Chlamydia trachomatis effector CT441 were reported to directly target NF-κB p65. The 
VP1686 was found to physically interact with p65 and suppress NF-κB activity (Bhattacharjee 
et al, 2006) whereas CPAF and CT441 were reported to cleave p65 at its C-terminal region 
(Christian et al, 2010; Lad et al, 2007a; Lad et al, 2007b). CT441 cleavage of p65 originates 
the C-terminal fragment p22 and an N-terminus-derived p40 fragment that, despite 
containing an intact Rel homology domain for IκBα interaction and DNA binding, was found 
act as a dominant negative regulator of NF-κB activation (Lad et al, 2007a; Lad et al, 2007b). 
Although in many cell types, down-regulation of NF-κB is not sufficient to trigger 
apoptosis, it is widely recognized that cells with inactivated NF-κB are more prone to commit 
suicide in response to different stimuli including TNF-α and TLRs ligands (Beg & Baltimore, 
1996; Haase et al, 2003; Hsu et al, 2004; Park et al, 2005; Van Antwerp et al, 1996; Wang et 
al, 1996). The induction of apoptosis by bacterial effectors through interference with NF-κB 
activity has been described but, this is a fairly uncommon scenario. Examples are the 
Yersinia YopP/J (Monack et al, 1998; Ruckdeschel et al, 1998; Ruckdeschel et al, 2001) and 
its orthologue AopP from Aeromonas salmonicida (Jones et al, 2012), both inhibiting the 
degradation of the inhibitory IκB proteins causing NF-κB to remain inactive in the cytoplasm 
(Fehr et al, 2006; Mukherjee et al, 2006; Ruckdeschel et al, 1998; Zhang et al, 2005; Zhou et 
al, 2005), and the V. parahaemolyticus protein VP1686 (Bhattacharjee et al, 2006) that has 
been described to interact with and suppress DNA binding activity of NF-κB (Bhattacharjee et 
al, 2006). In the case of Yersina YopP/YopJ, the induction of apoptosis in macrophages was 
shown to require stimulation of TLR4 (Haase et al, 2003; Zhang & Bliska, 2003). Whether 
AIP56-mediated depletion of p65 is sufficient to induce apoptosis, in resemblance to what 
has been suggested for macrophage apoptosis induced by the V. parahaemolyticus type III  
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secreted effector VP1686 (Bhattacharjee et al, 2006), or if it requires a second stimulus 
remains to be investigated. 
Almost all bacterial effectors known to modulate NF-κB activity are injected directly 
into the host cell cytosol by type III or type IV secretion systems (see reviews by (Bhavsar et 
al, 2007; Neish & Naumann, 2011; Rahman & McFadden, 2011)) with the only reported 
exceptions being the proteases CT441 and CPAF of the obligatory intracellular Chlamydia,  
that contain predicted signal peptides for sec-dependent secretion (Chen et al, 2010a; 
Christian et al, 2010; Lad et al, 2007b), the Bordetella pertussis cell associated and secreted 
adhesin FHA (Abramson et al, 2008) and the E. coli membrane protein OmpA (Selvaraj & 
Prasadarao, 2005) (table 5.1). AIP56 is also an exotoxin likely secreted by a sec-dependent 
mechanism (do Vale et al, 2005) and acts at distance, without requiring contact of the 
bacteria with the host cell and, therefore, must have a mechanism to enter cells in order to 
cleave the cytosolic located NF-κB p65. 
 
2. AIP56 belongs to the AB toxin family 
Bacterial protein toxins acting in the cell cytosol enter cells through multistep 
processes involving specific binding of the toxin to cell-membrane receptors followed by 
internalization via endocytic mechanism(s) and membrane translocation, with the release of 
the catalytic domain into the cytoplasmic compartment (Falnes & Sandvig, 2000; Montecucco 
et al, 1994). The structure of those toxins is adapted to their entry mechanisms and, to this 
end, these toxins are organized in a so-called AB-type structure consisting of a catalytic A 
subunit bound to a cell interacting B subunit(s) that mediate toxin binding to a cell receptor 
and delivery of the A subunit into the cytosol (Falnes & Sandvig, 2000; Montecucco et al, 
1994). As discussed in chapter I, toxins belonging to the AB toxin family can be synthesized 
and assembled in different ways and the differences in the toxin architectures translate in 
differences in the molecular processes of toxin biogenesis and intoxication pathways 
(Montecucco & Papini, 1995). Diphtheria toxin (DT), Pseudomonas exotoxin A (PE) and the 
clostridial tetanus and botulinum neurotoxins (TeNT and BoNT, respectively) typify those AB 
toxins secreted as a single polypeptide chain composed of three functional domains: a 
catalytic domain, a receptor binding domain and an intermediate membrane translocation 
domain (Collier, 2001; Turton et al, 2002; Wolf & Elsasser-Beile, 2009). 
The work herein presented shows that similarly to DT, PE, TeNT and BoNT, AIP56 
belongs to the AB toxin family, being composed of a single polypeptide chain with an N-
terminal catalytic domain and a C-terminal domain involved in the toxin binding and entry into 
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target cells. The boundaries of the putative membrane translocation domain were not yet 
identified, but our data suggest that the linker region between the two cysteine residues is 
involved in toxin translocation into the cell cytosol. 
AIP56 is synthesized and secreted by Phdp as a single polypeptide and analysis of 
AIP56 primary structure using bioinformatics tools provided the first evidences of a two-
domain/subunit structural organization (Silva et al, 2010). Prediction of secondary structures 
together with limited proteolysis assays confirmed that AIP56 is organized into two structural 
protease-resistant domains linked by a disulphide bond. Truncated versions of the toxin 
produced based on the chymotrypsin cleavage site were used to disclose the role of the two 
identified structural domains. The recombinant AIP56 N-terminal portion (Asn1-Phe285) 
exhibited proteolytic activity in vitro towards NF-κB p65 and delivery of this region into the 
cell cytosol using the Bacillus anthracis PA/LF system (Arora & Leppla, 1993; Arora & 
Leppla, 1994; Milne et al, 1995) reproduced both the proteolytic and the apoptogenic 
activities of the full length toxin, while no toxic effects were observed upon delivery of AIP56 
C-terminal portion. This not only attributes to the N-terminal region the catalytic role, but also 
reinforces the assumption discussed above that the cleavage of NF-κB p65 is a determining 
event for the AIP56 induced-apoptotic cell death. The C-terminal portion of AIP56 exhibited 
no proteolytic activity in vivo or in vitro but, when used as a competitor, it efficiently prevented 
AIP56 toxic effects, demonstrating the involvement of this region in toxin binding/entry into 
target cells. 
Nonetheless, despite sharing the same overal architecture, AIP56 diverges from DT, 
PE, TeNT and BoNT in some specific requirements of the intoxication process which may 
traduce relevant differences in the molecular mechanisms of intoxication. Upon secretion and 
at initial steps of cell intoxication, DT, TeNT and BoNT are cleaved by bacterial or host cell 
proteases(Ahnert-Hilger et al, 1990; DasGupta, 1971; Gill & Dinius, 1971; Tsuneoka et al, 
1993; Weller et al, 1989). Cleavage occurs at an exposed region between two cysteine 
residues yielding a catalytic A chain disulphide-bounded to a binding/translocation B chain 
(Collier, 2001; Turton et al, 2002). In those toxins, proteolysis is required for toxicity and in 
toxin preparations were nicking by endogenous proteases was incomplete or inexistent, mild 
treatment with proteases resulted either in toxin activation or in increased toxin potency 
(Collier & Kandel, 1971; Drazin et al, 1971; Knust et al, 2009; Krieglstein et al, 1991; Rupnik 
et al, 2005; Sandvig & Olsnes, 1981). Furthermore, proteolytic activation was found not only 
to be needed for cell intoxication but also required for enzymatic activity in vitro (Collier & 
Kandel, 1971; Gill & Pappenheimer, 1971; Weller et al, 1988). Proteolytic processing of PE 
by host cell furin or cathepsin proteases, was also reported (El Hage et al, 2010; Inocencio et 
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al, 1994; Ogata et al, 1990), although recent findings indicate that it is not essential for 
toxicity (Morlon-Guyot et al, 2009). PE cleavage by these proteases is low pH-dependent 
and is presumed to take place at the endosomal compartment (El Hage et al, 2010; 
Inocencio et al, 1994). Cleavage occurs within the domain II (translocation domain) of PE (El 
Hage et al, 2010; Inocencio et al, 1994) and structural data reveals the furin cleavage site is 
not protease-accessible at neutral pH (Wedekind et al, 2001). Similarly to DT, TeNT and 
BoNT, PE is synthesized as a holotoxin and requires activation to display enzymatic activity. 
PE conversion into a catalytically active form in vitro requires toxin unfolding and disulphide-
bond reduction (Leppla et al, 1978). By contrast, no evidences of proteolytic processed 
AIP56 in the bacterial culture supernatants or in the serum of infected fish were ever found 
(do Vale et al, 2005) and despite several attempts, including the use of 125I-labelled AIP56 
(not shown), we were unable to detect proteolytic processing of AIP56 upon its interaction 
with host cells. The lack of detection of processed AIP56 may result from the fact that a very 
small amount (not detectable in our experiments) of processed toxin is sufficient to intoxicate 
the cells, similarly to what has been described for other toxins (Falnes et al, 2000), or it may 
indicate that AIP56 is not proteolytically processed upon interaction with target cells. 
Furthermore, AIP56 does not requires proteolytic activation nor unfolding or reduction to 
display enzymatic activity in vitro, as shown by its ability to cleave p65 when incubated either 
with cell lysates or with recombinant sea bass p65 Rel homology domain (see chapter IV 
section 2.2). Another dissonant structural/functional aspect of AIP56 is that integrity of the 
region between the two cysteine residues linking the two functional subunits appears to be a 
requirement for toxicity. Chymotrypsin nicking of AIP56 (at the exposed flexible region linking 
Cys278 and Cys314) rendered the toxin inactive, abolishing its ability to cleave p65 and to 
induce apoptosis upon incubation with sea bass cells. However, nicking did not affect the 
toxin’s proteolytic activity in vitro, as demonstrated by the ability of nicked AIP56 to 
cleave 35S-labelled sea bass p65Rel domain, nor did affect its capacity to interact with the 
host cell membrane, as deduced from the ability of nicked AIP56 to inhibit AIP56-mediated 
p65 cleavage and apoptosis in competition experiments. These findings suggest that the 
AIP56 linker region plays a role in the translocation of the toxin into the cell’s cytosol and 
thus possibly be part of the yet unidentified translocation domain. Unpublished data from our 
laboratory show that similarly to DT, TeNT and BoNT, endosomal trafficking and pH-driven 
structural rearrangements play a crucial role in the AIP56 intoxication mechanisms. AIP56 is 
internalized by a process that requires endosome acidification since drugs that interfere with 
this process protected cells from intoxication. Accordingly, at low pH, AIP56 suffers a 
reversible conformational change with exposure of hydrophobic residues/regions that allows 
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interaction of the toxin with artificial lipid membranes and an external acidic pulse is sufficient 
to trigger translocation of cell-bound AIP56 across the host cell membrane. Within the linker 
region, the two phenylalanine residues constituting the chymotrypsin cleavage site (F285 and 
F286) are highly hydrophobic residues and are flanked N-terminally by an alanine (A284) and 
C-terminally by a leucine (L287), a proline (P288) and a serine (S289). This series of amino acid 
residues form an hydrophobic strech which may be involved, or at least contribute, to 
membrane insertion and toxin translocation. Nonetheless, in silico secondary structure 
analysis suggests that this region does not share the α-helical folding typical of the 
translocation domains of DT, TeNT or BoNT (Montal, 2010; Murphy, 2011) and is predicted 
to be a random coil region (see figure 4.8). Additional data are required to identify the 
boundaries of the AIP56 translocation domain and to determine the precise role played by 
the linker region in the intoxication process. 
Several studies have stated the importance of the conserved inter-chain disulphide 
bridge linking the A and B subunits in the toxicity of DT (Falnes & Olsnes, 1995; Papini et al, 
1993), PE (Madshus & Collier, 1989), TeNT (Kistner et al, 1993; Schiavo et al, 1990) and 
BoNT (Fischer & Montal, 2007; Pirazzini et al, 2011; Simpson et al, 2004). Studies with 
BoNT have suggested that the disulphide bridge must remain intact during membrane 
translocation of the catalytic domain, being required during the low pH-driven structural 
change and for membrane insertion (Cai & Singh, 2001; Fischer & Montal, 2007; Pirazzini et 
al, 2011). In the case of AIP56, disruption of the disulphide bridge linking the two structural 
domains only partially compromised AIP56’s toxicity, suggesting that the integrity of the 
disulphide bond is important, although not essential for intoxication. This disulphide bond 
may be involved in stabilizing the spatial relationship between the domains and/or be 
implicated in membrane insertion as reported for BoNT (Pirazzini et al, 2011). 
Whether AIP56 suffers proteolytic processing during cell intoxication is still unknown. 
Considering the above mentioned structural requirements for AIP56 toxicity, either 
processing occurs at later steps of intoxication, possibly as the result of the action of a 
cytosolic protease, to promote the release of the catalytic domain after membrane 
translocation, or, similarly to what has been described for PE (Alami et al, 1998; Mere et al, 
2005; Morlon-Guyot et al, 2009), AIP56 reaches the cytosol as an unprocessed protein. PE 
was shown to be able to translocate from the endosomal membrane to the cytosol in its 
unprocessed form through a process involving ATP hydrolysis (Alami et al, 1998; Mere et al, 
2005; Morlon-Guyot et al, 2009). Alternatively, AIP56 may localize in an endomembrane with 
the catalytic domain facing the cytosolic compartment where it can interact with and cleave 
p65 similarly to what was described for anthrax edema factor (EF) (Guidi-Rontani et al, 
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2000). Studies from Guidi-Rontani and colleagues revealed that when EF or iodinated EF 
were incubated with RAW 264.7 macrophages in the presence of PA, catalytically active EF 
was found exclusively associated with the cell membrane fraction, in contrast with LF whose 
activity was mainly associated with the cytosolic fraction (Guidi-Rontani et al, 2000). These 
authors suggested that EF plays an active role in its own translocation, being associated with 
the endosomal membrane and exposing the catalytic domain to the cytosol. Also, 
membrane-bound EF is postulated to be responsible for the increase in cAMP in intoxicated 
cells (Guidi-Rontani et al, 2000). Additional studies are required to elucidate the structural 
determinants and the exact mechanism for AIP56 translocation. In this context, solving 
AIP56 crystal structure would provide valuable knowledge. However, and despite our efforts, 
we were unable to obtain crystals suitable for X-ray diffraction studies (see chapter IV section 
5). Nevertheless, our crystallization studies allowed the identification of promising 
crystallization conditions and provided the foundations for future AIP56 crystallization 
projects. 
The different homologies and the structural architecture of AIP56 suggest that the 
toxin has a chimeric structure. This mosaic structure is not an uncommon feature in the 
bacterial world and there are several examples of bacterial genes composed of diverse 
segments with different origins (Baldo et al, 2005; Davies et al, 2002; Haake et al, 2004; 
Krzywinska et al, 2004; Mirold et al, 2001; Stavrinides et al, 2006). It is now recognized that 
acquisition of entire genes or portion of genes by horizontal gene transfer has a key role in 
generating diversity in pathogens by allowing them to acquire novel phenotypic 
characteristics (Haake et al, 2004; Krzywinska et al, 2004). Nevertheless, the actual transfer 
events that gave rise to AIP56 remain undisclosed and deserve further study. 
Even though AIP56 and NleC share functional homology, these virulence factors use 
different mechanisms to intoxicate cells. While NleC is directly injected into the cell 
cytoplasm by its producing bacteria through a type III secretion machinery (Galan & Wolf-
Watz, 2006), AIP56 has an intrinsic ability to reach the cytosol due to the presence of a 
“delivery module” in its C-terminal region. Notwithstanding the molecular effects of NleC 
injection into cells and its contribution to the dampening the host inflammatory response have 
been characterized, little is known about its structural features. Here we have extended NleC 
structural characterization and compared it with the one of the AIP56 catalytic region. 
Circular dichroism (CD) analysis revealed that the secondary structure content of NleC and 
AIP56 N-terminal portion is indistinguishable and in silico secondary structure prediction 
indicates conservation of the relative position of α-helices and β-sheets, suggesting that in 
addition to sharing functional homology, NleC and AIP56 catalytic region are structurally 
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similar. Nevertheless, these proteins were found not to be cross-compatible, since 
substitution of AIP56’s N-terminus by NleC resulted in a non-toxic chimera. Still, it should be 
noted that the exact boundaries of the AIP56 binding/translocation domain were not yet 
established and, therefore, the lack of toxicity of the NleC1-270∙AIP56251-497 chimera may be 
related either with an incorrect AIP56 portion or to an inability of NleC1-270 to translocate. 
Moreover, the PA/LF delivery system, successfully used to deliver the catalytic domains of 
several AB toxins (Arora & Leppla, 1993; Blanke et al, 1996; Milne et al, 1995), including the 
AIP56’s catalytic portion into the cell cytosol, failed to deliver NleC. We postulate that the 
distinct behaviour of AIP56 catalytic region and NleC is a consequence of their different 
unfolding dynamics in response to pH (AIP56 catalytic region was found to be more prone to 
unfold in response to acidification than NleC), because it is known that translocation of 
protein cargos across the PA pores requires pH-driven unfolding of the passenger proteins 
(Collier, 2009). These differences may have implications and should be taken into account 
when considering the use of these molecules as therapeutic agents.  
 
3. AIP56 as a potential therapeutic agent 
In recent years, the focus of medical research in the therapy field has shifted to new 
molecular therapeutics that target specific signalling pathways associated with a given 
disease with the intent of greater specificity coupled with reduced systemic toxicity. The 
major challenges in the development of such therapies concern not only the specificity and 
selectivity of the therapeutic agent, but also the efficiency of its delivery into the target cells. 
In this context, AB toxins, due to their intrinsic ability to translocate into the cytosol of 
eukaryotic cells and deliver protein cargos as well as to their high potency and specificity in 
modifying intracellular targets, have been emerging as attractive tools in pharmacology 
(Barth & Stiles, 2008; Odumosu et al, 2010). Strategies that are used to generate toxin-
based therapeutics involve mixing A and B domains of various toxins to generate chimeras 
with newly desirable properties (Arora & Leppla, 1993; Arora & Leppla, 1994; Blanke et al, 
1996; Krautz-Peterson et al, 2012; Liu et al, 2001; Madshus et al, 1991; Milne et al, 1995; 
Stenmark et al, 1991) or deleting toxin domains and substituting them with eukaryotic 
proteins such as specific antibodies (creating immunotoxins) (Pastan et al, 2007; Weldon & 
Pastan, 2011) or cytotoxic compounds (El Alaoui et al, 2007; Tarrago-Trani et al, 2006). 
Toxins such as cholera toxin (CT), shiga toxin (Stx) and heat labile toxin (LT) have been 
used as vectors to bring into cells proteins or epitopes that are then presented at the cell 
surface by MHC molecules (Haicheur et al, 2000; Lippolis et al, 2000; Loregian et al, 1999), 
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thus functioning as immunomodulators and antigen delivery systems in vaccination (Chen et 
al, 2010b; Facciabene et al, 2007; Zhou et al, 2009). In addition, DT- and PE-based 
immunotoxins are currently in clinical trials for the treatment of hematological malignancies 
and brain tumours (Chandramohan et al, 2012; Debinski, 2002; FitzGerald et al, 2011; 
Weldon & Pastan, 2011), and the B subunit of Stx associated with a topoisomerase I inhibitor 
(used in the treatment of colorectal carcinomas) or other cytotoxic compounds are also being 
presented as promising tools in anti-cancer therapy (Johannes & Romer, 2010).  
Apart from their promising potential in pharmacology, over the last years AB toxins 
have also revealed themselves as extremely interesting tools in cell biology. Studies on the 
intracellular trafficking pathways of CT, Stx and PE have allowed the characterization of 
vesicular and protein transport pathways (Sandvig & van Deurs, 2000; Sandvig & van Deurs, 
2002; Schiavo & van der Goot, 2001; Smith et al, 2006). Indeed, Stx was the first molecule 
observed to be transported from the cell membrane to the ER (Sandvig et al, 1992), 
revealing the existence of a yet undiscovered intracellular trafficking route (retrograde 
transport). Since then, studies on the intracellular trafficking of Stx and other retrogradely 
transported toxins, have been greatly contributing to the fine dissection of the molecular 
mechanisms underlying the fundamental steps of intracellular retrograde protein trafficking 
(Feng et al, 2004; Mallard et al, 1998; Mallard & Johannes, 2003; Mallard et al, 2002; Smith 
et al, 2006). 
As discussed earlier, NF-κB is one of the pivotal regulators of immune responses 
particularly involved in the regulation of the transcription of pro-inflammatory genes (Hayden 
et al, 2006; Vallabhapurapu & Karin, 2009). These include genes encoding several cytokines 
and chemokines, receptors involved in immune recognition and antigen presentation, 
receptors required for neutrophil adhesion and migration and also enzymes associated with 
the inflammatory response such as the inducible form of nitric oxide synthase (iNOS) and the 
inducible cyclooxygenase (COX-2) (Hayden et al, 2006; Vallabhapurapu & Karin, 2009). In 
addition, cytokines that are stimulated by NF-κB, such as IL-1β and TNF-α, can also 
establish a positive autoregulatory loop (through direct activation of the NF-κB pathway) that 
amplify the inflammatory response and increase the duration of inflammation (Hayden et al, 
2006; Vallabhapurapu & Karin, 2009). Therefore, it is not surprising that aberrant NF-κB 
regulation is associated with several inflammatory diseases including atherosclerosis, 
asthma, arthritis, inflammatory bowel disease, muscular dystrophy and multiple sclerosis 
(Tak & Firestein, 2001; Yamamoto & Gaynor, 2001), with NF-κB being an obvious target for 
the treatment/control of such diseases (DiDonato et al, 2012; Yamamoto & Gaynor, 2001). In 
addition to the association between NF-κB and inflammatory pathologies, uncontrolled NF-κB 
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activation has also been associated with cancer disease (DiDonato et al, 2012; Rayet & 
Gelinas, 1999; Staudt, 2010). Constitutive NF-κB activation was found in many lymphoid or 
myeloid tumours (Lim et al, 2012) and in various solid tumours (Carbone & Melisi, 2012; 
Chen et al, 2011; Zubair & Frieri, 2012), with several well-characterized oncogenes, such as 
Ras, Rac and Bcr-Abl, known inducers of NF-κB activity, being often implicated in the NF-κB 
constitutive activation (DiDonato et al, 2012; Rayet & Gelinas, 1999; Staudt, 2010). The roles 
for NF-κB in cancer appear to be complex but, given the importance of this transcription 
factor in controlling apoptosis, cell proliferation and angiogenesis, it is likely implicated in 
facilitating oncogenesis as well as metastasis (Baldwin, 2001; Shen & Tergaonkar, 2009; 
Staudt, 2010). Additionally, it has been reported that NF-κB is activated in cancer cells by 
several chemotherapies and radiation, and that, in many cases, this response inhibits the 
ability of the cancer therapy to induce cell death (Baldwin, 2001; Wang et al, 1999a; Wang et 
al, 1999b).  
A variety of drugs such as corticosteroids, acetylsalicylic acid and other non-steroidal 
anti-inflammatory drugs used in the treatment of several inflammatory conditions have an 
NF-κB inhibitory effect (Olivier et al, 2006; Yamamoto & Gaynor, 2001). However, these 
drugs are nonspecific NF-κB inhibitors, and the use of relatively high concentrations is 
needed to achieve effective inhibition (Olivier et al, 2006; Yamamoto & Gaynor, 2001). Some 
of the above mentioned anti-inflammatory drugs known to inhibit NF-κB also function as 
cancer therapeutics and chemo-preventive agents (Olivier et al, 2006) and, in the last years, 
major efforts were put in the identification/development of NF-κB inhibitors to be used as 
cancer therapeutics (Miller et al, 2010; Shen & Tergaonkar, 2009; Tsang et al, 2012). So far, 
only Bortezomib, a proteasome inhibitor capable of suppressing NF-κB activation, has 
obtained FDA approval for treatment of multiple myeloma (Richardson et al, 2008). Although 
NF-κB inhibitors alone hold great potential as cancer therapeutics, the combined use of NF-
κB inhibitors with cytotoxic chemotherapeutic drugs have been emerging as attractive new 
anti-cancer therapeutic strategies. Chemo-resistance is one of the major issues in cancer 
chemotherapy, and the development and use of new “combination therapies” offer the 
promise of enhancing treatment efficacy (Chen et al, 2011; Madonna et al, 2012; Olivier et al, 
2006; Shen & Tergaonkar, 2009; Zubair & Frieri, 2012).  
Given the indispensable role played by NF-κB pathways in many important biological 
processes, the major concerns regarding NF-κB-targeted therapies relate with the non-
specificity of the utilized drugs and with the adverse effects of long-term global inhibition of 
NF-κB pathways (Baud & Karin, 2009; Chen et al, 2011; Lim et al, 2012). Hence, 
development/discovery of new drugs/compounds that selectively target specific molecules of 
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the NF-κB pathway and the development of new approaches that increase the specificity and 
efficiency of delivery of these molecules have great pharmacological interest.  
In this context, by being an AB toxin targeting NF-κB, AIP56 presents itself as a 
potential therapeutic agent to be used in the treatment of diseases associated with 
uncontrolled NF-κB activation (such as cancer and inflammatory diseases). In addition, 
AIP56 might also be a valuable tool in cell biology studies, particularly in the study of the 
molecular details of the NF-κB-mediated regulation of apoptosis and inflammation processes. 
When compared with NleC, AIP56 has an increased potential to be used as therapeutic tool, 
not only due to the intrinsic ability of AIP56 to reach the cytosol of target cells, but also 
because of the dissimilar unfolding characteristics of AIP56 and NleC proteins (discussed 
above), which might impact on their mechanism of cell delivery. The use of a given 
toxin/effector as a therapeutic agent requires a detailed knowledge of its molecular 
mechanism(s). In the case of AIP56, a complete understanding of the toxin structure/function 
relationships and interaction with cells is still missing. Hence, solving AIP56 three-
dimensional structure, identifying the cell membrane receptor for the toxin and gaining in 
depth knowledge onto the toxin’s intracellular pathways are crucial before considering the 
use of AIP56 as a therapeutic agent. 
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AIP56 was identified as an apoptogenic exotoxin and a key virulence factor of 
Photobacterium damselae piscicida in 2005 by do Vale and colleagues (do Vale et al, 2005). 
At that time, studies on the AIP56 toxin were mainly focused in understanding the 
consequences of the toxin’s apoptogenic activity for the pathology of the disease. It was 
shown that AIP56 induces apoptosis of the host macrophages and neutrophils leading to a 
severe dampening of the host immune response, thus contributing the septicaemic spread of 
the infectious agent (do Vale et al, 2005). Furthermore, the inefficient clearing of the 
apoptosing cells due to phagocyte depletion leads to post-apoptotic secondary necrosis, with 
cell lysis and consequent tissue damage contributing to the necrotic lesions found in the 
diseased animals (do Vale et al, 2007a; do Vale et al, 2007b; do Vale et al, 2003). Later, in 
2011, it was shown that AIP56-induced phagocyte cell death is caspase-dependent, 
involving activation of caspase-8,-9 and -3 and the mitochondria, with loss of mitochondrial 
membrane potential, release of cytochrome c and over-production of ROS (Costa-Ramos et 
al, 2011).  
Nevertheless, a detailed structural and functional characterization of AIP56 was still 
missing and, until the beginning of this work in 2008, very little was known about AIP56 
structure and the mechanisms used by the toxin to reach its targets and kill the cells. With 
this study, by disclosing structural and functional features of AIP56, we gained a mechanistic 
insight into the toxin’s mode of action. We report AIP56 as a zinc-metalloprotease that 
cleaves, and thus inactivates, the host cell NF-κB p65. Taking into account the anti-apoptotic 
functions of NF-κB, and in particular of its p65 subunit, the severe depletion of NF-κB p65 
found in AIP56 intoxicated cells likely explains the disseminated phagocyte apoptosis 
observed in Phdp infections (Costa-Ramos et al, 2011; do Vale et al, 2007a; do Vale et al, 
2005).  
The described AIP56 NF-κB cleaving activity is similar to the one recently reported for 
the AIP56 N-terminal homologue NleC, a type III secreted effector produced by several 
enteropathogenic bacteria (Baruch et al, 2010; Muhlen et al, 2011; Pearson et al, 2011; 
Sham et al, 2011; Yen et al, 2010). Nevertheless, AIP56 differs from NleC by being an AB 
type toxin that is able to enter and reach the cytosol of host cells in an autonomous manner. 
We showed that while the N-terminal region of AIP56 is necessary and sufficient to cleave 
NF-κB p65 and induce apoptosis once at the cell cytosol, the C-terminal region functions as 
a delivery module being involved in host cell binding and toxin internalisation. The 
boundaries of the A and B domains of AIP56 were not yet defined, and despite sharing the 
same overall architecture with known AB toxins secreted as a single polypeptide chain, our 
data revealed that AIP56 diverges from these toxins in some structural details of the 
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intoxication process. AIP56 does not require proteolytic, or any other kind of activation to 
display enzymatic activity in vitro. Furthermore, integrity of the region between the two 
cysteine residues linking the two putative AIP56 functional domains appears to be needed for 
toxicity. These data suggest that this region is involved in the translocation of the toxin into 
the cell’s cytosol and may be part of a yet unidentified translocation domain and raises the 
hypothesis that proteolytic processing might not be required for cell intoxication. 
Nevertheless, the exact mechanism involved in AIP56 translocation across the lipid bilayer 
and the occurrence of proteolytic processing at the cytosol remain to be investigated. 
NF-κB is one of the pivotal regulators involved in a multitude of important cellular 
processes such as cell survival, differentiation and immune responses (Hayden et al, 2006; 
Vallabhapurapu & Karin, 2009). The extensive involvement of NF-κB transcription factors in 
inflammation and cancer establishes them as targets for the treatment of such diseases 
(Kumar et al, 2004; Staudt, 2010; Tak & Firestein, 2001; Yamamoto & Gaynor, 2001). Thus, 
the results obtained during this work, open doors to the use of AIP56 as a therapeutic tool in 
several human pathologies associated to the uncontrolled activation of NF-κB. Because the 
delivery of proteins into the cytosol of eukaryotic cells has a huge biotechnological interest, 
AB toxins such as AIP56, possessing intrinsic abilities to enter target cells, also have an 
increased potential to be used, not only as a tool in cell biology to study cellular processes 
such as endocytosis and intracellular transport, but also as a system to deliver different 
cargos inside target cells (Barth & Stiles, 2008; Pastan et al, 2007; Sandvig et al, 2010b). 
Therefore, the understanding of the intoxication mechanism of AIP56 transcends the context 
of a virulence factor operating in an economically important fish disease and represents a 
new prospect to the understanding and manipulation of a key transcription factor associated 
with several important biological processes often associated with severe human pathologies. 
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